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Abstract 
Foot-and-mouth disease virus (FMDV) causes a highly infectious disease of cloven-hoofed livestock 
with economically devastating consequences. The political and technical problems associated with the 
use of FMDV vaccines make drug-based disease control an attractive alternative. The FMDV genome 
is translated as a single polypeptide precursor that is cleaved into functional proteins by virally-
encoded proteases. Ten of the thirteen cleavages are performed by the highly conserved 3C protease 
(3Cpro), making this enzyme an obvious target for anti-viral drugs.  
This thesis details an attempt to develop 3C protease inhibitor with efficacy against FMDV. 
This includes both rational drug design based on the peptide substrate of the protease, and also the 
high throughput screening of small molecules. 
Chapter 1 provides an introduction to the economic effects of FMD and discusses the various 
ways of control— highlighting the possibility of designing an antiviral drug targeting the 3C protease. 
Discussion then turns to factors involved in the development of antiviral protease inhibitors and 
illustrates the process with some examples of protease inhibitors in clinical use. 
Chapter 2 describes the fluorescence assay used to monitor FMDV 3Cpro activity and the 
further development of this assay into high throughput screen (HTS) format. By this means, a small 
molecule inhibitor (16) of moderate potency (IC50 = 13.2 µM) was discovered. 
Chapter 3 describes the resynthesis of 16 and the elucidation of its mode of action. It is found 
that the inhibition involves the rapid acylation of the protease to form an acyl-enzyme of unusual 
stability. 
Chapter 4 discusses this mode of action in detail, providing an extensive background of 
previous instances of its use in different aspects of biochemistry and drug design. Structure-activity 
relationship (SAR) studies are then carried out, probing the features of the inhibitor class necessary 
for activity. The inhibitors are then tested against the virus in a cell-based assay and found to be 
ineffective. The potential reasons behind this inactivity are then discussed. 
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Chapter 5 attempts to channel the potency of the inhibitors towards an alternative mode of 
action. The eventual strategy is the use of the small molecule binding-elements discovered from the 
HTS coupled with a covalent-modifying warhead. When the HTS-derived compounds prove 
ineffective, focus moves onto adapting compounds developed for use against the closely-related 
human rhinovirus (HRV). By this strategy, a moderately potent (IC50 =32 µM) irreversible inhibitor 
(183) of FMDV 3Cpro was identified. 
Chapter 6 switches focus to substrate-based inhibitor design. The potential problems with 
previously developed peptide inhibitors are discussed and potential solutions worked towards. 
Eventually a compound (227) which demonstrates antiviral activity (EC50=27 µM) is developed. 
Chapter 7 summarizes the project and discusses the direction further investigations might 
take. 
Chapter 8 provides the experimental details of the practical work carried out. 
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Chapter 1: Introduction 
This chapter describes the effects of foot-and-mouth disease (FMD) on the agricultural community 
and discusses the various possible methods of control, highlighting the possibility of treatment with 
antiviral drugs. The focus moves onto the replication cycle of the foot-and-mouth disease virus 
(FMDV) and the strategies that could be used to disrupt it, with the inhibition of the viral 3C protease 
being identified as an attractive strategy. The biochemistry of protease mechanism is briefly discussed 
together with the common methods of protease inhibition. The remainder of the chapter focusses on 
the development of clinically effective protease inhibitors with the aim of designing 3Cpro inhibitors 
which demonstrate anti-FMD activity. 
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1.1 Foot and Mouth Disease 
 
Foot and Mouth Disease (FMD) is a highly infectious viral disease affecting cloven-hoofed animals, 
and is widely seen as a serious threat to livestock. The disease is characterised by the blistering of soft 
tissue inside the mouth and on the feet, resulting in lameness and excessive drooling. Moreover, the 
infected animal experiences prolonged weight-loss and either testicular swelling or a decline in milk 
production. In spite of the relatively low fatality, this loss in productivity, coupled with the highly 
contagious nature of the disease make outbreaks of FMD particularly economically devastating.1 
 
 
Figure 1: Examples of the characteristic lesions and drooling caused by Foot and Mouth Disease.2 
  
19 
 
1.1.1 History 
 
The first appearance of FMD in the historical record occurs in the writings of a monk, describing an 
outbreak near Verona in 1546.3 Over the centuries, the disease became notorious as a particular threat 
to cattle farming, and in the late nineteenth century the German government commissioned a group of 
scientists to discover the cause. Working in isolation on an island in the Baltic, Friedrich Loeffler and 
Paul Frosch took lymph fluid from the lesion of an infected animal and passed it through a bacteria-
proof filter. They had hoped to remove the infectious agent to leave an immunising anti-toxin, and so 
were duly surprised when inoculated calves developed the disease as usual.3-4 They eventually 
concluded that the agent of disease was smaller than “the tiniest known bacteria, so small, that even 
the best modern immersion system renders the agent unidentifiable under our microscope.” This was 
the second ever description of a virus (Ivanovski having recently discovered the tobacco mosaic virus 
in the same way5) and the first ever of an animal virus. 
From here, FMD research progressed as the scientific tools became available. The invention 
of the electron microscope revealed the appearance of a single virion in 1969, and in 1989 the three-
dimensional structure of this infectious agent was completely described using X-ray crystallography.6 
 
1.1.2 Distribution and Serotypes 
 
FMDV is divided into seven distinct serotypes, based on the lack of cross-immunity observed during 
vaccination.7 The Euroasiatic serotypes are A, O, C and Asia1, and the South African Territories 
serotypes SAT1, SAT2 and SAT3.8 
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Figure 2: FMD outbreaks as reported to the OIE from 2008-2012. The OIE is responsible for granting FMD-free status, 
and all member states are required to report the event of an outbreak (OIE 2012).9 
 
Today, FMD is largely confined to the developing world and is prevalent in the poorer areas of South 
America, Asia and Africa (Figure 2). Western Europe, North America and Australasia are largely 
free, though sporadic outbreaks do occur. With the increasing globalisation of markets, such 
outbreaks and the economic devastation they bring are a cause for major concern. Only disease-free 
countries are permitted to trade in livestock and meat, with the result that many poor countries are 
excluded from a potentially lucrative market. Since disease-free countries still run a significant risk of 
infection, eradication or control of the disease is in the interests of all.10 
1.1.3 Infection and Control 
 
The single most dangerous feature of FMD is its highly infectious nature. The virus itself is very 
robust, reportedly surviving for 12 years in soil and up to a year in cell culture.3 It spreads mostly as 
an aerosol; in one instance, the virus from infected cattle in Brittany travelled over 250 km to infect 
cattle on the Isle of Wight.3 
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1.1.3.1 Vaccination 
As with many viral diseases, the initially preferred method of control was vaccination. The first FMD 
vaccine was developed in 1937, based on formalin-inactivated virus obtained from the tongue 
epithelium of infected animals. These vaccines were steadily improved and a workable vaccine was 
launched in 1975.11 By using such vaccines, FMD was wiped out in Europe by 1991.3, 12 
At this point, vaccination ceased. This was mainly for political reasons: disease-free countries did not 
permit imports from countries which vaccinate, meaning that the newly disease-free (yet still at risk) 
European countries were missing out on a vast area of international trade. Although the decision to 
stop vaccinating can be described as political; the difficulties arose from the problematic nature of 
FMD vaccination.4 
FMD is caused by a notoriously diverse set of viruses and there is little cross-immunisation; animals 
vaccinated with one serotype are still at risk from the other six.13,14 Indeed there is occasionally 
sufficient diversity within a single serotype that that one vaccine cannot confer immunity to all its 
members. Other problems include the relatively long time period (seven days) between vaccination 
and immunity, during which the animal is still vulnerable and, as a direct result of the vaccination, 
impossible to diagnose.15 Furthermore the vaccine is only effective for six months, after which the 
animal must be treated again. As a result, for there to be any point in vaccination, animals must be 
vaccinated often with multiple vaccines.16 To make matters worse, FMD vaccines require an 
extensive production of the active virus, an agent which is notoriously hard to contain. 
1.1.3.2 “Stamping Out” 
In short, FMD vaccination is sufficiently difficult that other policies are preferred. The current 
strategy, therefore, is based around non-vaccination, coupled with swift and drastic action in the event 
of an outbreak.4 The advantages of such a policy are numerous. Animal products can be freely sold on 
the international markets and the expensive and hazardous process of vaccine production can be kept 
to a bare minimum. In the event of an outbreak, a process known as “stamping out” is pursued. This is 
based around the control of animal movement and the isolation of infected areas, together with the 
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immediate disposal of at-risk or infected animals. It was most famously used by the UK government 
in response to the FMD outbreaks of the early 2000s. As will be seen, such an approach can be very 
expensive and traumatic for the agricultural community. 
 
 
Figure 3: “Stamping out” in process during the 2001 UK outbreak. This generally involves the pre-emptive culling of 
vast numbers of at-risk animals and the immediate disposal of carcasses by burial or by burning.17 
 
1.1.4 UK Outbreaks 2001-2007 
 
In February 2001, it was confirmed that pigs in South East England were infected with FMD of the 
viral strain Type O Pan Asia. The infection had occurred during fattening in Northumberland where 
the pigs had ingested contaminated meat imported from abroad.18 It was deduced that the infection 
had occurred three weeks prior to detection and it was also known that sheep infected by the Pan Asia 
strain did not display symptoms. In light of this and of the huge amount of animal movement that had 
been occurring, control was attempted by mass slaughter of infected or susceptible animals. Over 4 
million animals19 were culled, and, taking into account the effect of temporary trade restrictions, the 
loss to the UK economy has been estimated at £8 billion.20 In light of this tragedy, it was recognised 
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that policy could be improved in a number of areas: specifically, the rapid diagnosis of disease and the 
control of animal movement.21 
 In August 2007, an outbreak was confirmed in Surrey. The improved emergency measures 
were implemented immediately, including a complete animal movement ban, the relevant culling, and 
extensive surveillance and protection zones. Although it took many months for the outbreak to be 
eradicated, the disease was controlled with no widespread infection.22,23 
 Ironically it was found that the particular strain of the outbreak virus was very similar to a 
strain used by researchers at the Animal Health Facility at Pirbright, a mere 5 km away from the site 
of diagnosis.24 Although the link between Pirbright and the outbreak remains unproven, the very 
possibility highlights the risk of maintaining large populations of the active virus and the need for 
methods of vaccination or other kinds of control that do not rely on it. 
 
1.1.5 Alternative Strategies 
 
1.1.5.1 Superior Vaccines 
An obvious way forward is developing the ability to produce vaccines without the active virus being 
involved in any way. This is very possible: a large number of vaccines are based on the inactivated 
pathogen, or else subunits of the microbes that can be recognised by white blood cells and so 
stimulate the desired immune response. According to this theory, an empty FMDV capsid (see section 
1.2.1) would provoke the same immune response as the live virus, but without the infectious RNA 
aspect. In 2013, researchers used insect cells to produce empty protein shells analogous to the FMDV 
capsid.25 A preclinical study of the technology involving four animals revealed that cows vaccinated 
with the empty virus capsids were protected from infection with the normal FMD virus for up to nine 
months.26 
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 While this is evidently enormous progress, it is far from clear that the synthetic method will 
allow large-scale production of the new vaccines. Also such a vaccine would not solve the other 
difficulties involved in vaccination, namely, the huge number of separate vaccines required and the 
inability to distinguish between newly vaccinated and infected animals. Other methods of control 
might prove more effective at combatting these. 
1.1.5.2 Antivirals 
One such method is the development of antiviral drugs. An antiviral is a substance which treats an 
occurring viral infection by inhibiting the viral replication inside the host. In order to discuss the 
factors involved in the design of an FMDV antiviral, it is necessary to describe the virus and its 
replication cycle in some detail. 
1.2 The Virus Itself 
 
Viruses consist of either two or three parts. All have a genetic element contained in a protein capsid 
and some are further protected by a lipid envelope. Viruses can be classified according to their 
morphology and the nature of their genetics. FMDV belongs to the Aphtovirus genus of the 
Picornaviridae (or picornavirus) family. The picornavirus label refers to the small size of the capsid 
(pico) and the characteristic genetic element, in this case a single strand of positive sense RNA (+ 
ssRNA). Other picornaviruses include Human Rhinovirus (HRV), Hepatitis A (HAV) and poliovirus 
(PV). A diagram showing the main viral RNA and DNA families is shown in Figure 4. 
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Figure 4: A schematic representation of the main viral families. Picornaviridae are comparatively simpler compared to 
the larger DNA and RNA families, consisting only of a protein shell containg naked RNA. Also of relevance in this project 
are the coronaviridae and calicivirdae families 27. 
 
1.2.1 Structure of FMD Capsid 
 
A single particle of FMDV is very simple in comparison with to cellular life forms. The only 
complexity arises in the structure of the capsid. It comprises of 60 copies each of four proteins, VP 1-
4 which self-assemble into protomer. Five protomers constitute into a pentamer and twelve pentamers 
form the icosahedral capsid.28,29 This arrangement is shown in Figure 5. 
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Figure 5: The arrangement of structural proteins in a mature type O1BFS FMDV capsid A) Organisation of the capsid 
proteins. B) A pentamer positioned on the virion looking down the fivefold axis. C) The complete capsid.30 
 
Inside the capsid is the strand of RNA. Clearly the mature virus is, in fact, a reasonably inert 
arrangement of molecules which presents little opportunity for selective attack compared to, say, the 
large number of life processes carried out by the average bacterium. The viral replication cycle on the 
other hand, does at least involve a handful of enzymatic processes that can be exploited. 
 
1.2.2 FMDV Replication Cycle 
 
Viruses replicate themselves by invading cells and using the metabolic machinery of that cell to create 
multiple copies of themselves. The new virions assemble inside the cell and then burst out and begin 
the cycle anew. In this process the host cell is destroyed, and it is this that causes the symptoms of a 
viral disease, up to and including the death of the whole organism.31 A schematic diagram of the 
process for picornaviruses is shown in Figure 6. 
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Figure 6: A representation of a typical picornaviral replication cycle. The virion binds to a cellular receptor which 
enables entry into the host cell. The viral genome uncoats and enters the host cell cytoplasm. After this, the viral RNA is 
translated, and the translation is directed by the internal ribosome entry site (IRES). The resulting polyprotein is then cleaved 
into mature viral proteins which affect the host cell in a number of ways, e.g. they shut off host cell transcription. In the early 
stages of infection, the newly made RNA is translated into additional viral proteins. Finally, the new RNA genomes are 
packaged and the newly formed viral particles exit the host cell by lysis.32 
 
As a virion approaches a target cell, the viral structural proteins interact with receptors on the cellular 
surface. The penetration and uncoating of the RNA is poorly understood, but by whatever mechanism, 
the RNA is released into the cytoplasm. The RNA then proceeds to translate the polyprotein 
precursor, which contains all structural and catalytic FMDV proteins. The proteases rapidly 
autocleave from the polyprotein and process the remaining sequences. At some stage, translation 
ceases and RNA replication begins. With the synthesis of RNA and structural proteins, the assembly 
of new virions can commence. As the viral proteases attack key cell enzymes to bring about cell 
death, the multitude of new virions exit the stricken host. Each of these can invade new cells and 
repeat this process. 
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1.2.3 FMDV Genome 
 
The infectious element of FMDV is its positive sense RNA. The positive sense aspect means it can be 
immediately translated by the cell, much like messenger RNA. Another feature of this replication is 
the high mutation rate. This is due to the viral RNA polymerases lacking a proof-reading ability,7 with 
the result that mistakes are more frequently made during replication. This is the origin of the multiple 
serotypes of FMDV and the root cause of the difficulties involved with vaccination as a control 
strategy against RNA viruses. 
The RNA itself is 8500 bases long and, like mRNA, consists of an open reading fragment (ORF) 
between two untranslated regions (UTRs), termed the 5’ UTR and the 3’ UTR.31,33 
 
Figure 7: Schematic representation of the FMDV RNA. The unusually extensive 5’ UTR is also covalently bonded to the 
VPg. The precise function of the following structural elements is unknown. The S fragment is likely to be responsible for 
genome stability. The Poly C track is possibly involved in the switch from translation to replication. The function of the 
pseudo-knots (PKs) is unknown. The cis-acting replication element (CRE) and internal ribosome entry site (IRES) follow. 
The open reading frame (ORF) is examined in more detail in figure 8. The 3’UTR folds into two stem-loop (SL) structures 
and a poly A tract, the precise functions of which remain unknown.34 
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The ORF is the part of the RNA which encodes the viral proteins. The 5’ UTR encodes no 
information but instead has a role in translation and replication. The large S fragment is responsible 
for the genome stability and the adjacent Poly Cs are involved in the switch from translation to 
replication. During replication the 5’ terminus is bonded to the VPg. Much of the function of the 5’ 
UTR remains a mystery. The 3’ UTR is thought to be involved in replication and translation, though 
its exact function is unknown.31 
 
1.2.4 FMDV Proteins 
 
The ORF translates a polyprotein which contains all structural and catalytic viral proteins. The 
polyprotein and cleavage sites are represented in Figure 8: 
 
Figure 8: Translation of ORF to polyprotein and subsequent cleavage by proteases. A) ORF from the viral +RNA 
directly translates to polyprotein; B) Partial cleavage intermediates generated during processing of the polyprotein; C) 
Mature viral proteins. As can be seen, 3Cpro is responsible for the vast majority of cleavages.30 
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The polyprotein cleavages occur both during and after translation. The Lpro initiates the process by 
autocleaving and the P1/2A fragment is completely freed by cleavage of the 2A/2B junction by the 
2Apro. All but one of the remaining cleavages are known to be carried out by the 3Cpro.35,31 
 With this basic understanding of viral replication in general and the FMDV cycle in 
particular, we are in a position to discuss the strategy behind the design of antiviral drugs. 
 
1.3 Antiviral Drug Design 
 
The design of antiviral drugs is considerably more difficult than the corresponding design of other 
antipathogen drugs for two main reasons.36,37 The first is the relative simplicity of viral biochemistry. 
The individual virus particle is merely a means of delivering genetic material to the next host cell and 
so carries out no life processes. Clearly viral replication involves a number of biochemical processes 
but still vastly fewer than cellular life forms. The other, related, reason is that these processes take 
place inside a host cell and often employ the host’s biochemical apparatus. It is thus difficult to 
selectively impede the virus without causiung corresponding damage to the host.38 
To use an example; in the 1980s it was discovered that certain viral structural proteins contained a 
novel post-translational modification— an amino-terminal myristyl (tetradecanoyl) amide. 
Myristoylation was (and still is) of great interest as a drug target and so investigations into 
myristoylation inhibitors as antivirals began. Eventually it was realised that all such myristoylations 
are carried out by the host enzymes and so it would be impossible to develop an antiviral in this 
manner.39,40 
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1.3.1 General Strategy 
 
Antivirals have been designed to impede every stage of viral replication. Below is a very basic 
summary of these strategies, with a few examples of antiviral drugs in clinical use. 
 Attachment and Entry 
The virus attaches itself to the host cell by the interaction of its structural proteins with 
receptors on the cell surface. In theory, this recognition could be blocked by the use of 
analogues to bind to either participant. 
A practical example is the use of entry inhibitors to combat HIV. The first drug of this class is 
Enfuvirtide, a peptide which is designed to mimic elements of the HIV fusion mechanism. 
HIV binds to the host CD4+ cell receptor via the viral protein gp120; gp41, a viral 
transmembrane protein, then undergoes a conformational change that assists in the fusion of 
the viral membrane to the host cell membrane. Enfuvirtide binds to gp41 preventing the 
creation of an entry pore for the capsid of the virus, keeping it out of the cell.41 
 Uncoating of Genetic Element 
If the genetic element of the virus remains inside the virion capsid, no translation or 
replication can occur. Pleconaril (Figure 9) is an anti-picornaviral drug which prevents the 
exposure of RNA by enteroviruses.42,43 This is achieved by binding to a hydrophobic pocket 
in the VP1 protein. 
 
Figure 9: Structure of pleconaril. Pleconaril binds to the hydrophobic pocket of the VP1 protein of picornaviruses. In the 
case of enteroviruses, this prevents the uncoating of the RNA.42 
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 DNA/RNA Synthesis 
There are a number of ways of inhibiting synthesis of new RNA or DNA. Nucleoside and 
nucleotide analogues achieve this by deactivating the synthetic enzymes as they are 
incorporated. Acyclovir (Figure 10), the first successful antiviral, acts against herpes virus in 
exactly this way.44 
 
Figure 10: The development of acyclovir, an analogue of guanosine. The anti-herpesvirus activity of acyclovir is due to 
its affinity viral enzymes which convert it to acyclovir monophosphate, a nucleotide analogue. The monophosphate is further 
converted into di and triphosphates by cellular enzymes. Acyclovir triphosphate stops replication of herpes viral DNA in 
three ways: 1) competitive inhibition of viral DNA polymerase, 2) incorporation into and termination of the growing viral 
DNA chain, and 3) inactivation of the viral DNA polymerase.44 
 
 Polyprotein Processing 
Inhibition of key proteases will prevent processing of the viral proteases and also limit the 
attack by these proteases on the host cell functions. There a number of protease inhibitors in 
clinical use against HIV45 and also hepatitis C virus (HCV).46 This subject will be covered in 
more detail in section 1.5. 
 Virion Assembly 
If the viral structural proteins are prevented from forming new capsids, the new viral genetic 
material will be unable to exit the cell and infect new hosts. The antibiotic Rifampicin 
possesses some activity against the vaccinia virus and this is thought to be via the prevention 
of virion assembly.47,48 In addition, certain peptide sequences have been found to disrupt 
assembly by competitive interaction with capsid proteins.49 
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 Release 
Even if new virions have been assembled, preventing their release is still an effective antiviral 
strategy. The drug oseltamivir (Tamiflu) acts against the influenza virus by blocking enzymes 
on the viral surface that are crucial to release.50 
 
 
Figure 11: Oseltamivir, an influenza antiviral which works by preventing viral exit. This is achieved by inhibition of 
the viral neuraminidase enzyme upon the sugar chains on the surface of host cells. Oseltamivir itself is a prodrug which is 
metabolised in the liver to release the active species (the free carboxylate).50 
 
1.3.2 Antiviral Strategies Against FMDV 
 
In light of the previously discussed problems with FMD vaccination, there have been a number of 
attempts to develop a specific FMD antiviral. These have focussed mainly on obstructing the 
replication of RNA. 
 Nucleoside Analogues 
2′-C-Methylcytidine is a nucleoside analogue based on Ribavirin which was found to have 
activity against all FMDV serotypes.51 It is suspected that the mode of action involves 
incorporation into nascent RNA chains resulting in the premature termination of RNA 
synthesis. Another strategy involving nucleoside analogues involves the extinction of the 
virus by means of catastrophic levels of mutagenesis. A number of mutagenic analogues have 
been shown to have an effect on viral mutation levels up to extinction.52,53 
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 Oligonucleotides 
One strategy is based on the synthesis of negative sense oligonucleotides complementary to 
the segments of the +ssRNA (sense) which potentially block access to the RNA and so inhibit 
replication. Analogues targeting regions of the FMDV genome have indeed shown some 
antiviral activity.54,55,56,34 Another method is the use of small interfering RNAs (siRNA). 
These are small double-stranded RNAs that serve as a guide sequence that instructs the 
multicomponent RNA-interfering silencing complex to destroy specific mRNAs. This has 
been attempted with regard to the genes coding key FMDV proteins.57,58 
 Protease Inhibition 
Cell permeable analogues of the cysteine protease inhibitor E-64 have demonstrated antiviral 
activity against FMDV, reducing viral yields by a factor of 1000.59 Inhibition of the Lpro by E-
64 in vitro had already been demonstrated and in cell-based assays, generation of unprocessed 
L/P1/2A polyprotein was observed. Since the viral structural proteins are released from this 
sequence it was clear that the inhibitor was acting on target and as a result assembly of 
complete virions could not take place. 
 
 
Figure 12: Two compounds with anti-FMDV activity: 2’-C-methylcytidine (1) is a nucleoside analogue which terminates 
RNA synthesis when incorporated in the developing sequence.51 E64d (2) is a cell-permeable analogue of the well-known 
cysteine protease inhibitor E-64. The epoxide reacts irreversibly with the thiol nucleophile of cysteine proteases, including 
the FMDV Lpro it is presumed.59 
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1.3.3 3Cpro as a Drug Target 
 
This thesis is concerned with the inhibition of 3Cpro as a means for the design of antiviral drugs acting 
against FMD. 3Cpro is an attractive drug target for three main reasons: 
1. It is highly likely to be crucial to viral replication since it is responsible for 10 of the 13 
cleavages during polyprotein processing.60 As we have just seen, Lpro is responsible for only 
one, and yet its inhibition is detrimental to virus growth. 
2. The 3Cpro gene is one of the most highly conserved in the FMDV genome. It has been shown 
that across all seven serotypes, the amino acid sequences of the respective 3Cpro are 76% 
similar.61 This compares favourably to the other viral proteins, most notably the structural 
proteins whose variation is the source of the difficulties involved in vaccination. 
3. There are no equivalent enzymes in mammalian cells. 
Before detailing the strategy involved in designing such an inhibitor, it is necessary to put FMDV 
3Cpro in its context as a member of a large and important family of enzymes. 
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1.4 FMDV 3Cpro 
1.4.1 Proteases 
  
Proteases (also called proteinases or peptidases) catalyse proteolysis, the hydrolysis of peptide bonds 
that link amino acids into proteins. 
 
 
Figure 13: The process of proteolysis. 
 
Proteases are found in all organisms and are involved in a multitude of different roles. The pancreatic 
enzymes trypsin and chymotrypsin play a role in digestion; thrombin is involved in blood clotting; 
and as we have seen, proteases play a crucial role in viral replication. 
The specificity of proteases, that is the number of sequences they will cleave, varies widely. Digestive 
proteases and proteases involved in bone reabsorption will generally hydrolyse any peptide sequence 
in a number of places. Other proteases, such as viral proteases, whose role is to liberate specific 
sequences from a larger polyprotein, show considerably more specificity. 
The specificity of a protease can be represented using the Schechter and Berger notation (Figure 14).62 
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Figure 14: Schechter and Berger notation for a protease with a bound substrate. P1 – Pn denote the amino acid residues 
on the N-terminus side of the peptide substrate, whereas P1’ – Pn’ denote the residues on the side of the C-terminus. S1 – Sn 
and S1’ – Sn’ are the corresponding enzyme binding sites. The scissile bond is indicated.62 
 
1.4.2 Protease Classification 
 
Proteases can be classified in a number of ways. The most commonly used method involves the 
designation of the key residue/species in the active site. There are six main groups: 
 Serine proteases 
 Cysteine proteases 
 Threonine proteases 
 Aspartate proteases 
 Glutamic acid proteases 
 Metalloproteases 
Other methods of classification include by optimal pH (into acid, neutral and basic proteases) or by 
evolutionary origin. In the latter case, proteases are divided into “clans”, each of which is thought to 
reflect a separate evolutionary origin. The clans can be further divided into families, based on 
sequence similarity. The MEROPS database lists proteases in this fashion.63 
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1.4.3 Protease Mechanisms 
 
The catalytic activity of proteases is ultimately achieved by the conversion of a moderate nucleophile 
into a powerful one. This nucleophile can either be a water molecule (in the case of aspartate, metallo- 
and glutamic acid proteases), or an amino acid side chain (serine, threonine and cysteine proteases).  
 
 
Figure 15: Comparison of two types of protease mechanism. The aspartate-type protease (A) acitvates a water molecule 
nucleophile, whereas the serine/cysteine-type protease (B) relies on an intrinsic nucleophile activated by the catalytic triad 
charge relay system. 
 
1.4.3.1 Catalytic triad 
 
As can be seen in Figure 15, the nucleophilic side chain is most commonly activated by the charge 
relay system of a catalytic triad. The three components of the triad are the acid, the base and the 
nucleophile. The acid residue polarises the base which activates the nucleophile, lowering its pKa and 
thus increasing its reactivity towards the electrophilic carbon of the scissile bond. 
The nucleophile is always a hydroxyl or thiol belonging to a serine, threonine or cysteine residue. As 
shown here, the base is generally a histidine. In rare cases, lysine or serine act as the base 64. The acid 
is commonly an aspartate or glutamate residue, although in some instances it is something else (for 
example, histidine) or, as we shall see, is not required at all. A special case is the threonine protease 
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arrangement, in which the catalytic threonine is the N-terminus residue.65 The threonine hydroxyl acts 
as the nucleophile and the N-terminal amine as the base.66 This self-activating arrangement has also 
be observed for proteases with N-terminal catalytic serines and cysteines.66 
1.4.3.2 Chymtrypsin-like Proteases 
 
The classic example of a catalytic triad is found in chymotrypsin. The mechanism is shown in Figure 
16. 
 
Figure 16: Catalytic mechanism of chymotrypsin. (i) Activation of serine by charge relay of His and Asp. (ii) Tetrahedral 
intermediate. (iii) Acyl-enzyme. (iv) Charge relay activates water molecule for attack. (v) Second tetrahedral intermediate. 
(vi) Release of carboxylic acid side of scissile bond.67 
 
The cleavage process is best considered as the displacement of the C-terminal side of the scissile bond 
to form an intermediate with the serine hydroxyl acylated with the N-terminal side. Water in turn 
displaces the enzyme to release the N-terminal side with a free carboxylate as its C-terminus. These 
displacements occur in a two-step process involving the formation of a tetrahedral transition state 
stabilised by the oxyanion hole of the protease. 
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1.4.3.3 Serine vs Cysteine Proteases 
This is in contrast to the mechanism of papain (Figure 17), the most widely studied cysteine protease. 
Papain occurs naturally in the papaya fruit and is commonly used as a meat tenderizer and digestive 
aid. 
 
Figure 17: Catalytic mechanism of papain. i) Attack of deprotonated cysteine on scissile bond. (ii) Tetrahedral 
intermediate. (iii) Acyl-enzyme. (iv) Histidine activates water molecule for attack. (v) Second tetrahedral intermediate. (vi) 
Release of carboxylic acid side of scissile bond.67 
 
Though there are clear similarities between the two mechanisms, the differences are instructive.67 
Compared to oxygen, sulfur’s extra d orbital makes it a softer electrophile and gives the SH group of 
cysteine a lower pKa
 compared to the OH group of serine. In fact the pKa of cysteine is sufficiently 
low that papain can exist as the thiolate anion in the ground state enzyme. In contrast, serine is 
dependent on other residues to reduce its pKa. The low pKa of cysteine works to the protease’s 
disadvantage in the resolution of the first tetrahedral intermediate as unproductive reversal of the 
cysteine’s attack is the more favourable breakdown product. The triad base is therefore oriented to 
protonate the leaving group amine to ensure that it is ejected to leave the cysteine sulfur covalently 
bound to the carbonyl carbon. Finally, resolution of the acyl-enzyme (to release the other half of the 
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substrate) requires serine to be re-protonated, whereas cysteine can leave as the thiolate anion. 
Sterically, the sulfur of cysteine also has longer bonds and a bulkier van der Waals radius to fit in the 
active site and a mutated nucleophile can be trapped in unproductive orientations. For example the 
crystal structure of thio-trypsin indicates that cysteine points away from the substrate, instead forming 
interactions with the oxyanion hole.68 
1.4.4 Protease Inhibitors 
 
Protease inhibitors are molecules which block the activity of proteases. This can be achieved in many 
different ways and protease inhibitors vary enormously in size and chemical behaviour, ranging from 
large proteins to tiny molecules. Naturally occurring protease inhibitors are generally proteins or long 
peptides,69 whereas synthetic inhibitors are shorter peptides or non-peptidic small molecules. Protease 
inhibitors can be classed according to their target proteases, or their mechanism of action. The 
MEROPS protease database also lists protease inhibitors.63 The most common inhibitory mechanisms 
are as follows. 
 
1.4.4.1 Reversible Inhibition 
Reversible inhibitors bind to the enzyme using only non-covalent interactions and no formal chemical 
reactions. These can be removed from the enzyme by dilution or dialysis. Reversible inhibitors can 
further be classed as competitive, uncompetitive and non-competitive.70,71 
 Competitive inhibitors are by far the most common. These bind to the active site, directly 
competing with the substrate. 
 Uncompetitive inhibitors bind to the enzyme-substrate complex and prevent further catalysis 
at this stage. 
 Non-competitive inhibitors bind with similar efficacy to the enzyme with or without the 
substrate. This generally occurs through an allosteric mechanism. 
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Benzamidine (3), a reversible competitive inhibitor of trypsin, is shown (Figure 18).72 
 
Figure 18: Benzamidine, a reversible competitive trypsin inhibitor.72 
 
1.4.4.2 Irreversible Inhibition 
Irreversible inhibitors function by specifically altering the active site of its specific target through 
covalent bond formation.73 These modifications alter the active site to the extent that it can no longer 
perform peptide bond hydrolysis. Irreversible inhibitors can be divided into two classes, affinity labels 
and mechanism-based inhibitors.74 
 Affinity labels employ a chemically reactive structure to modify the catalytically important 
residues in the active site. They can be further divided into classical and quiescent based on 
their reactivity. Classical affinity labels are highly reactive— examples include halomethyl 
ketones, epoxides and sulfonyl fluorides— and would be expected to react with many 
nucleophilic species in a biochemical system. Quiescent affinity labels are significantly less 
reactive and generally exploit the binding of the enzyme in order to inactivate it through an 
“aberrant” (i.e. distinct from the enzyme’s catalytic role) pathway. In this way, quiescent 
affinity labels have more specific enzyme targets than classical labels. Examples include 
Michael acceptors and acyloxymethyl ketones.73 
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Figure 19: Examples of affinity label mechanisms. A) Inactivation of a serine protease by sarin (nerve gas) which contains 
a phosphoryl fluoride classical affinity label. B) Inactivation of a cysteine protease by an acyloxymethyl ketone, a quiescent 
affinity label.73 
 
 Mechanism-based inhibitors are compounds which are not initially enzyme inhibitors, but are 
modified by the catalytic pathway of the enzyme to become so. An example of this concept, 
the isocoumarin class of serine protease inhibitor,75 is shown in Figure 20. 
 
 
Figure 20: Mechanism-based inhibition of serine protease. The initial structure is cleaved by the protease to form the 
protease-inhibitor acyl-enzyme. Deacylation can then occur, freeing the enzyme to effect more cleavages. Alternatively the 
inhibitor can alkylate the active site histidine, irreversibly inhibiting the protease.76 
 
As can be seen, what makes mechanism-based inhibition different to other kinds of 
irreversible inhibition is that the covalent modification cannot occur until the inhibitor enters 
the catalytic cycle of the enzyme. 
1.4.4.3 Reversible Covalent Inhibition 
Like irreversible inhibition, reversible covalent inhibition involves the formation of a covalent bond. 
However in this case the bond formation is reversible. This type of inhibitor is often a transition-state 
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analogue, molecules which mimic the high-energy substrate intermediates bound most tightly by the 
enzyme. Stable, tetrahedral intermediate- resembling structures have been proved to be formed by 
proteases with peptide aldehydes, peptide methylketone derivatives, peptide boronic acids (Figure 
21)77,78 and peptide phosphonic acids.79 
 
Figure 21: Reversible covalent inhibition of serine protease by boronic acid transition state analogue. 
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1.4.5 Viral Cysteine Proteases 
 
Viral proteins come in many forms and often have very little in common beyond their purpose. 
Human immunodeficiency virus (HIV) has an aspartate protease and hepatitis C virus (HCV) a 
serine.80 There are various viruses with cysteine proteases, most notably Tobacco Etch Virus (TEV), 
the protease of which is widely used as a tool in biochemistry. There are three viral families whose 
cysteine protease is of interest in drug development: 
 Coronaviruses 
Large RNA viruses with a spikey crown-like capsid. The most famous is the cause of Severe 
acute respiratory syndrome (SARS). This family uses two proteases, the Papain-like protease 
(PLpro)81 and the 3C-like protease (3CLpro)82, both of which have a papain-like catalytic dyad 
based mechanism. 
 Caliciviruses 
Simple non-enveloped RNA viruses with cup-shaped depressions on their capsids, 
caliciviruses are relatively poorly studied due to the difficulties involved in growing them on 
culture. A group member, noroviruses are notorious as an infectious cause of gastroenteritis. 
They appear to have a 3CL similar to coronaviruses.83 
 Picornaviruses 
These have been discussed as the family to which FMDV belongs. They can use up to three 
proteases, the leader protease (Lpro) (a papain-like protease), the 2Apro (a chymotrypsin-like 
cysteine protease) and the 3Cpro. 
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1.4.6 FMDV 3Cpro Structure and Mechanism 
 
3Cpro is found in all picornaviruses and so various versions of this enzyme have been extensively 
studied in recent years. The structures of the 3Cpros of HAV84, HRV85, PV86 and E-7187 have all been 
solved and found, as expected, to have much in common. They belong to the unusual class of cysteine 
proteases which possess an overall fold similar to that of chymotrypsin. Moreover, they also possess a 
conserved Cys-His-Asp/Glu catalytic triad at the active site, analogous to the Ser-His-Asp triad found 
chymotrypsin-type protease. It remains unclear as to whether this triad functions in precisely the same 
way as the chymotrypsin triad. The Asp residue in HAV 3Cpro appears to be oriented away from the 
active site, presumably indicating a lack of involvement in the catalytic process. Meanwhile in HRV 
and PV, the catalytic Asp residue is replaced by a Glu. This substitution is highly unusual in serine 
proteases and perhaps indicates that there are important differences between viral proteases and better 
understood proteases such as chymotrypsin. 
More recently, a similar study has been taken with regard to FMDV.88 It was found that FMDV 3Cpro 
adopts a fold similar to that of chymotrypsin with a double β-barrel structure characteristic of that 
enzyme. Moreover the active site possessed a Cys-His-Asp catalytic triad in a conformation very 
similar to the triad in serine proteases. So far, FMDV has the only picornaviral 3Cpro in which the triad 
is truly analogous to chymotrypsin, and it was hypothesized that it could in fact possess a more 
efficient catalytic mechanism.89,90 
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Figure 22: Crystal structure of FMDV 3Cpro and a closeup of the active site. The three amino acid residues of the 
catalytic triad in the active site of the enzyme – Cys, His and Asp – are highlighted in pink. Red atoms represent oxygen, 
whereas the blue atoms correspond to nitrogen. Ser-182 is also shown as it forms a hydrogen bond with Asp-84, and the 
equivalent Ser in chymotrypsin is of great importance. In the actual crystal structure Cys-163 is replaced with an alanine but 
the cysteine has been restored here by modelling.91,92 
 
It was thought that, in spite of the thiol nucleophile, FMDV 3Cpro might have more in common with 
chymotrypsin than with papain. Eventually when the enzyme was tested against some well-known 
protease inhibitors, this was indeed found to be the case.93 E-64, a cysteine protease inhibitor highly 
effective against papain, proved completely ineffective. At the same concentrations, TPCK (4), 
designed for chymotrypsin, inhibited the protease completely. 
 
Figure 23: Protease inhibitors tested for activity against FMDV 3Cpro. E-64 is designed to act against cysteine protease, 
with the epoxide alkylating the active-site thiol.94 TPCK is specifically designed for activity against chymotrypsin, with the 
benzene ring mimicking the phenylalanine P1 preference of chymotrypsin.95 IC50 values from Jaulent et al..
93 
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1.5 FMDV 3Cpro as an Antiviral Drug Target 
 
1.5.1 Protease Inhibitors in Clinical Use 
 
The act of inhibiting a protease can be trivially easy. The two compounds mentioned above, E6494 and 
TPCK95, are very effective at inhibiting their target proteases. However, being reactive affinity labels, 
they are also highly toxic and unsuited for any drug development. In order to design a protease 
inhibitor with potential to be of clinical use, it is necessary to develop an inhibitor which is 
considerably more inert and selective towards the target, as well as possessing a large number of other 
“druglike” qualities. The structures of two protease inhibitors in clinical use are shown below. The 
Cathepsin K (an enzyme involved in bone reabsorption) inhibitor is intended as a treatment for 
osteoporosis.96 In contrast to TPCK and E-64, it is reversibly covalent (i.e. the nitrile binds covalently 
but reversibly to the enzyme active site). K777 inhibits cruzain, a key protease required for the 
survival of the parasite T. cruzi, responsible for Chagas disease.97 Although K777 could be classed as 
an affinity label, its vinyl sulfone warhead is sufficiently inert (i.e. a quiescent affinity label) that this 
compound is non-toxic. 
 
Figure 24: Two protease inhibitors in clinical use. The Cathepsin K inhibitor is based around a reversible interaction 
between the nitrile group and the active site thiol of the enzyme.96 K777 contains a vinyl sulfone as a Michael acceptor 
which irreversibly alkylates the active-site thiol of cruzain.97 
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1.5.2 Design of Anti-FMDV Protease Inhibitors 
The purpose of this project is to develop a 3Cpro inhibitor capable of stopping viral replication in a 
cell-based assay. To achieve this, the inhibitor would have to meet (at least) the following criteria: 
1. Potency 
Clearly the inhibitor requires significant potency against the enzyme if such potency is likely 
to translate to the complexities of the cellular system. 
 
2. Selectivity 
As mentioned, proteases are vital to all biological systems and any host cell is bound to have 
vital proteases with structural similarities to 3Cpro. It is crucial that activity is kept as specific 
as possible otherwise the inhibitor could simply kill the host rather than selectively preventing 
viral replication. 
 
3. Druglikeness 
Molecular structures can be analysed for comparisons with known drugs, in order to predict 
their likely suitability for development as orally available drugs. This assessment is 
traditionally carried out by checking compliance with Lipinski’s Rule of Five.98 The aim of 
this project is the development of inhibitors with cellular activity, and so druglike qualities 
relating to such things as metabolism by the liver are clearly not relevant. Nonetheless, other 
factors relating to molecular size and hydrogen bonding are highly relevant for cell 
permeability and so must be considered during the design process. 
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1.5.3 General Strategies 
In order to develop such an inhibitor, it is necessary to pursue one of several general strategies. A 
representation of these strategies is shown in Figure 25. 
 
 
Figure 25: Schematic representation of the general process of early-stage protease inhibitor design. The three factors 
under consideration are starting point (HTS or substrate-based), basic structure (small molecule or peptide) and mode of 
action (the various types of covalent/non-covalent mechanisms discussed in section 1.4.4). 
 
1.5.3.1 Finding a Starting Point 
The initial challenge, therefore, is the discovery of a starting point. There are two main ways to 
achieve this.71,70 
 Substrate-based Design 
This involves using the substrate of the protease as a starting point. Clearly the substrate has 
an affinity for the enzyme, and if modified in some way, this affinity can be channelled 
towards inhibition instead of proteolysis. 
 High Throughput Screening 
The other method of identifying a starting point is via high throughput screening (HTS). In 
this approach, a vast number of compounds are screened against the enzyme in the hopes of 
identifying compounds with at least moderate activity which can be further developed. 
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1.5.3.2 Basic Structure 
Protease inhibitors can, generally speaking, be divided into those with peptidic structure and small 
molecules: 
 Peptides 
Given the natural substrates of proteases are peptides, it follows that peptidic compounds can 
be designed to form inhibitory interactions against specific proteases. The advantage of 
peptides is that they form very tight interactions with their target receptor, and are therefore 
highly potent and selective. Another advantage is that, having natural occurring structural 
elements, they are safely degraded and excreted by the host’s mechanisms, as opposed 
accumulating in bodily tissue. The disadvantages of peptides are related to this property: they 
have a very short half-life in the body and cannot be taken orally due to degradation by host 
digestive processes.99 An additional factor is poor cell permeability due to the polar nature of 
amide bonds.100 
 
 Small molecules 
The term “small molecule” refers to non-peptidic, organic compounds. The advantage of 
small molecules is that, being synthetic compounds, they can be designed to be potent, 
selective, water soluble or cell permeable. As a result, most drugs are small molecules.101,102 
 
1.5.3.3 Mode of Action 
 
As discussed in section 1.4.4, protease inhibitors can act on their target in various different ways. The 
main issue is whether the inhibitor forms a covalent bond with the protease. Covalent modification of 
this kind is generally regarded as a disadvantage in drug design for two main reasons. The first is 
because such reactivity will often be promiscuous enough to result in toxicity.103 The other reason is 
that covalently modified proteins will often provoke immune responses.104 For these reasons, 
reversible non-covalent inhibitors are generally preferred by the pharmaceutical industry. However 
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covalent protease inhibitors in clinical use do exist as mentioned in section 1.5.1, and so these 
disadvantages are not insurmountable. In fact covalent mechanisms may have certain advantages, for 
example lower drug concentrations required for efficacy,105 and covalent drugs are a highly profitable 
class of drugs for the pharmaceutical industry.104 
The term “warhead” refers to the use of electrophiles to covalently bind the nucleophiles of the target 
enzyme.106 They generally consist of either reversible covalent species (such as aldehydes or boronic 
acids), or quiescent affinity labels (such as Michael acceptors). An advantage of reversible covalent 
warheads is that they are likely to dissociate from the enzyme active site if the enzyme is denatured or 
degrades, and so will not provoke an immune response. 
 
1.5.3.4 The Design Process 
 
These factors are not completely independents of each other. For example, a substrate-based approach 
for designing a protease inhibitor will generally lead to a peptide-based structure and HTSs are 
generally focussed on the discovery of small molecules. Reversible non-covalent inhibitors rely on a 
multitude of unpredictable non-covalent interactions and so are difficult to design and must be 
discovered empirically; whereas warheads are generally used as a modification of the substrate. There 
are exceptions to these trends: small molecule binding elements have been designed based on 
mimicking the substrate,107 and peptides can be screened against enzymes in the hopes of finding 
unnatural interactions.108 
The process of antiviral protease inhibitor development can be best illustrated by the design of anti-
HIV compounds. 
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1.5.4 Anti-HIV Protease Inhibitors 
 
There are 25 approved anti-HIV protease inhibitors,109 discovered and developed by various different 
companies. Two which illustrate the differing design features highlighted above are saquinavir and 
tipranivir.110 
 
1.5.4.1 Saquinavir 
Saquinavir111 was the first antiretroviral protease inhibitor to be approved by the FDA,109 and a 
representation of its design process is shown (Figure 26). 
 
Figure 26: Early-stage protease inhibitor design schematic for saquinavir. The strategy was to modify the peptidic 
substrate to create a reversible non-covalent inhibitor. The peptide was then modified to improve druglike qualities, a 
process called “depeptidisation”. 
 
“Depeptidisation” refers to the process of chemically altering the structure of a peptide to improve cell 
permeability and half-life. The development of saquinavir is shown in Figure 27. 
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Figure 27: The development of saquinavir. A cleavage site suitable for development into an inhibitor was identified, 5. 
This site was then modified to create a transition state mimics of type 6, which functioned as inhibitors. This basic structure 
was then modified and depeptidised, eventually to produce saquinavir (7).110 
 
It was found that three of the cleavages catalysed by the HIV protease occurred between 
phenylalanine and proline. Since cleavage at the N-terminus of proline does not occur in mammalian 
biochemistry, this was an ideal starting point to develop potency and selectivity. This substrate (5) 
was converted into an inhibitor (6) by substituting the scissile amide bond for a secondary alcohol in 
order to imitate the transition state of proteolytic cleavage. The enzyme has a high affinity for this 
transition state (since it catalyses the process) and the result is a highly potent inhibitor. This inhibitor 
was further developed in order to optimise in vivo activity, and the result was a highly effective 
antiretroviral drug (7). 
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1.5.4.2 Tipranavir 
 
The other method of identifying a starting point is via HTS. Tipranavir is an antiretroviral protease 
inhibitor that was developed in this way (Figure 28). 
 
Figure 28: Early-stage protease inhibitor design schematic for tipranavir. HTS was used to identify reversible non-
covalent small molecule compounds which could be further developed. 
 
The advantage of this approach is that resulting small molecules generally have better “druglike” 
qualities than the peptidic compounds which result from the structure-based approach, and so the 
lengthy process of depeptidisation carried out for the saquinavir development is not needed. The 
disadvantage is that the starting small molecule is generally of modest potency, and so the activity 
must be built up by extensive SAR studies. The development of tipranavir112,113 is shown (Figure 29). 
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Figure 29: Development of tipranavir. Warfarin 8 (an anti-coagulant) was found to possess modest activity against the 
HIV protease. An analogue, phenprocoumon (9), was found to improve upon this potency and possess antiviral activity. This 
core structure was enhanced via 10 to produce tipranavir (11).110 
 
An HTS identified warfarin (itself an anticoagulant) as a weak inhibitor of the HIV protease. 
Synthesis and testing of various analogues of warfarin identified phenprocoumon (9) as a significantly 
more potent inhibitor; sufficiently potent, in fact, to allow both anti-HIV activity in a cell-based assay, 
and also a co-crystal structure of the phenprocoumon/HIV-1 protease complex. This crystallographic 
information allowed extensive structure-based design, and tipranavir (11) was the eventual result. 
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1.5.5 Cysteine Protease Inhibitors as Antivirals 
Both of these protease inhibitors are reversible non-covalent inhibitors. Since the HIV protease is an 
aspartate protease, at no point during the catalytic cycle does it form a covalent bond with its substrate 
(see section 1.4.3). As a result it is significantly easier to develop non-covalent reversible inhibitors 
for this type of protease than it is for proteases which form covalent bonds during the catalytic 
process. The intrinsic nucleophilicity of these proteases generally requires a form of covalent action in 
order to produce a potent inhibitor.114 
This is best demonstrated by the development of anti-HCV serine protease inhibitors. 
 
1.5.5.1 Development of HCV Protease Inhibitors 
The replication of HCV involves the NS3 serine protease. As mentioned in section 1.3.1, two anti-
HCV protease inhibitors have entered clinical use. In both cases the initial HTS-based approach did 
not provide any starting points, and so a substrate-based design approach was pursued.115,116 A 
schematic for the design of boceprevir is shown in Figure 30. 
 
 
Figure 30: Early-stage protease inhibitor design schematic for boceprevir. The strategy was to modify the peptidic 
substrate with a warhead. The peptide was then modified to improve druglike qualities. 
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The development of boceprevir is shown in Figure 31. Consideration of the polyprotein substrate led 
to the discovery of undecapeptide α-ketoamide inhibitors.117 The α-ketoamide is a transition-state 
analogue-type reversible covalent warhead which binds the active-site serine with its electrophilic 
ketone (as discussed in section 1.4.4.3). These compounds had structures with 11 amino acid residues 
that spanned from P6 to P5′ and exhibited excellent inhibition (Ki =1.9 nM). The large molecular 
weight necessitated extensive development and depeptidisation. Boceprevir (Ki =1.9 nM, EC90 = 0.4 
µM) was the eventual result.118 
 
 
Figure 31: Development of boceprevir. Examination the native cleavage sites of the polyprotein allowed the design of a 
series of undecapeptides with α-ketoamide warheads. These compounds were highly potent yet too large for oral use. 
Reductions in size and extensive SAR studies lead to boceprivir— an orally-active and clinically effective protease 
inhibitor.118 
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1.5.5.2 Development of HRV 3Cpro Inhibitors. 
Although no antiviral cysteine protease inhibitors have entered clinical use, rupintrivir reached 
clinical trials before development was ceased.119 Rupintrivir was developed using a structure-based 
design approach similar to boceprevir, but with the use of an irreversible-acting covalent warhead 
(Figure 30). 
The optimal substrate for the HRV 3Cpro was first established as being H2N-Thr-Leu-Phe-Gln-Gly-
Pro-CO2H with cleavage occurring between the Gln and Gly residues.
120 The concept was that a 
truncated sequence with a reactive warhead replacing the scissile amide bond might function as an 
irreversible inhibitor (Figure 32).121,122 The C-terminal side of the cleavage site was known to be far 
more important for protease recognition and a Michael acceptor (in this case a trans-α,β-unsaturated 
ethyl ester) was incorporated as a good warhead for cysteine nucleophiles (Figure 33). 
 
Figure 32: Development of rupintrivir. With the optimal sequence (12) identified, the C-terminal side of the scissile bond 
was replaced with an unsaturated ethyl ester Michael acceptor to act as a warhead. This compound (13) had a decent potency 
against the enzyme (EC50 = 0.54 µM). The peptide specificity sequence was then modified to increase potency and enhance 
“druglike” qualities. Rupintrivir (14) was the result.123 
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Figure 33: Reaction of a cysteine thiol with a Michael acceptor. 
 
The resulting compound was a potent inhibitor of HRV 3Cpro and also displayed moderate antiviral 
activity. Further development to enhance the potency and depeptidise the compound eventually 
resulted in rupintrivir (14).124,123 
Though rupintrivir is an excellent anti-HRV agent, it has not entered clinical use. In a human 
experimental HRV challenge trial rupintrivir reduced the severity of illness and viral load, providing 
proof of concept for the mechanism of 3C protease inhibition.125 In a subsequent natural infection 
study in patients, rupintrivir was not able to significantly affect virus reduction or moderate disease 
severity and thus was halted from further clinical development.119 
 
1.5.5.3 Development of FMDV 3Cpro Inhibitors 
Since HRV and FMDV are closely related viruses and since the HRV study had met with reasonably 
good success, a similar approach was used by N. Roqué-Rosell126,92 to develop an anti-FMDV agent.  
 
 
Figure 34: Development of FMDV 3Cpro inhibitors by rational design based on the optimal substrate, mirroring the 
rupintrivir development.92 
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With the optimal substrate sequence determined, a Michael acceptor was attached to the C-terminus 
of the P1-4 tetrapeptide to provide a potent inhibitor.127 Unfortunately, this compound displayed no 
antiviral activity, possibly because of the positive charge of the P2 lysine (charged groups generally 
prevent cell entry). This residue was vital for potent inhibition and although various ways (discussed 
in section 6.1.2) around this problem were tried, no compounds derived from this approach 
demonstrated any antiviral activity.92 
1.6 Aims 
 
The purpose of this project is to continue this development of anti-FMDV agents. With the difficulties 
experienced in the structure- based approach, it was decided, in the first instance, to focus on 
developing small molecule inhibitors. The aims can be summarized: 
1. By use of HTS, find a “hit” compound i.e. a molecule with at least moderate potency against 
the enzyme. 
2. Determine precisely how this compound is acting to inhibit the enzyme. 
3. By the synthesis of analogues, attempt to improve enzyme potency. 
4. Channel this potency against the enzyme into antiviral activity in a cell-based assay. 
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Chapter 2: Enzyme, Assays and Screens 
In order to carry out the high throughput screening necessary to discover small molecule inhibitors, a 
means of monitoring enzyme activity must first be developed. This chapter outlines the fluorescence 
assay previously designed to monitor FMDV 3Cpro activity in parallel with the current author’s efforts 
to reproduce this assay. This involves the expression and purification of an active mutant of FMDV 
3Cpro and also the synthesis of a version of the peptide substrate modified with fluorescent labels. 
Also described, is the further development of this assay into HTS format and the screening of a large 
library of compounds by the Dundee Drug Discovery Unit. The “hit” compounds obtained from this 
screen are then evaluated to confirm their activity. 
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2.1 Assay Concept 
 
There are various ways to monitor enzyme activity. Initial investigations into the cleavage specificity 
of FMDV 3Cpro employed an HPLC based assay.88 This was not practical for the screening of 
compounds however because the process was time consuming and the level of inhibition difficult to 
quantify. The most effective assays combine sensitivity, specificity and the ability to monitor activity 
continuously. Fluorescence is one of the methods of choice for these reasons and also due to a lack of 
interference with biological components that are themselves typically non-fluorescent.128 
Fluorescence assays have been developed to monitor the activity of PV 3Cpro129,130, HRV 3Cpro131,132 
and SARS 3CLpro.133,134,135 
What then is required is a version of the enzyme substrate, the fluorescent behaviour of which is 
altered upon exposure to the enzyme. For proteases, a widely used route is to attach two groups, a 
fluorescence donor (fluorophore) and a fluorescence acceptor (quencher), on either side of the scissile 
bond. In the unprocessed substrate, the fluorescence of the donor is quenched intramolecularly by 
non-radiative resonance-energy transfer. For this to occur, the fluorescence emission spectrum of the 
donor must overlap the absorption spectrum of the acceptor and it is necessary that they are in close 
proximity, since the distance between a donor- acceptor pair will influence quenching. The minimum 
distance recommended is the Förster distance R0 which is specific for a given donor-acceptor pair. 
After cleavage, the donor and acceptor are physically separated and the fluorescence of the donor 
group is thereby restored. In other words, the proteolytic activity will be correlated an increasing 
intensity of radiation at the characteristic emission wavelengths of the donor. Any inhibition of the 
protease will manifest itself in a lower rate of increase in fluorescence. Complete inhibition will 
prevent any such increase. These concepts are illustrated schematically in Figure 35. This concept was 
first achieved practically for HIV protease substrates.136,137 
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Figure 35: Concept behind fluorescent peptide cleavage assay. The fluorophore is excited by radiation of a particular 
wavelength and emits radiation with a different wavelength. When the peptide is intact, this is absorbed by the quencher. 
After peptide cleavage, this radiation is no longer quenched and so can be monitored. The growth in intensity of this 
radiation is related to the level of enzyme activity and thus the level of enzyme inhibition. 
 
2.2 Fluorogenic Substrate 
 
2.2.2 Design 
 
The fluorescent substrate used in this thesis was designed by Jaulent et al.93 When designing a 
substrate such as this there are basically three points to consider: 
1. Peptide sequence 
A peptide sequence with a high turnover rate by the enzyme will provide the assay with 
greater sensitivity and allow lower concentrations of enzyme to be used. 
An examination of the cleavage sites on the viral polyprotein provides an insight into 3Cpro 
specificity. All of them possess a glutamine or glutamic acid in the P1 position. There is also 
a strong preference for lysine in the P2 position when there is a glutamine P1 (see Figure 36). 
Using this as a basis, Knox et al.138 screened a number of sequences using an HPLC based 
assay and found that the VP1/2A junction was particularly susceptible to cleavage. 
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Figure 36: FMDV 3Cpro substrate sequences and residue conservation. The table shows the sequences of the natural 
substrates of 3Cpro in FMDV A1061. The sequence logos, generated using Weblogo139, are the result of the alignment of the 
sequences from over 100 strains of FMDV split into two groups (P1-Gln and P1-Glu)61. The overall height of each stack 
indicates the sequence conservation at that position (expressed in bits), whereas the height of symbols within the stack 
reflects the relative frequency of the corresponding amino or nucleic acid at that position. 
 
2. Fluorescent groups 
 
The requirement is for two compounds with an emission/absorption overlap and whose 
structures allow attachment to the peptide chain. The EDANS/DABCYL pairing is commonly 
used136 because of the excellent energy overlap of the donor and quencher 
emission/absorption spectra. EDANS absorbs at 341 nm and emits fluorescent radiation at 
471 nm whilst DABCYL absorbs at 453 nm without emitting fluorescence. 
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Figure 37: Structures of fluorescent groups EDANS (5-((2-Aminoethyl)amino)naphthalene-1-sulfonic acid) and 
DABCYL (4-([4-(Dimethylamino)phenyl]-azo)-benzoic acid). Highlights indicate functionality used to attach to peptide 
chain. 
 
3. Attachment of groups. 
As indicated in Figure 37, both groups possess useful functionality that allows easy 
attachment to a peptide chain without affecting the fluorescent behaviour of either group. The 
acid group of the DABCYL allows easy attachment to the N-terminus of the peptide and the 
primary amine of the EDANS can couple to the C-terminus, or else to a carboxylic acid of an 
amino acid side chain. Since the peptide is too long to allow effective resonance transfer from 
end to end, and also possesses no acidic side chains, it was necessary to insert an aspartic acid 
residue into the sequence. 
 
The best performing substrate that was tested corresponded to the P5–P8′ peptide with DABCYL on 
the N-terminus and EDANS on the P3′ position: DABCYL-APAKQ↓LLD(EDANS)FDLLK. This 
compound, which is the substrate used throughout this thesis, will hence be referred to as FRET 4. 
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Figure 38: Structure of FRET 4 fluorogenic substrate. The APAKQLLDFDLLK sequence mimics the VP1/2A cleavage 
site of the natural substrate. This is augmented by an EDANS fluorophore attached to an Asp side chain acid, and a 
DABCYL quenched attached to the N-terminus.92 
 
2.2.3 Synthesis of FRET 4 
 
Solid phase peptide synthesis (SPPS) is the preferred method the synthetic production of peptides. It 
involves the use of a solid resin support composed of a polymer that is insoluble, with a linker 
attached that is able to couple to the C-terminal of an amino acid. The peptide is then built up by 
adding amino acids to the N-terminus of the developing chain. The advantage of SPPS is that all 
excess reagents and solvents are easily removed by simply washing the resin. This negates the need to 
separate the developing peptide chain from the reaction after every reaction stage. As will be seen 
later on in this thesis (section 6.7), techniques such as aqueous/organic extraction and silica 
chromatography become impractical once the peptide chain reaches a certain length. A diagram of 
Fmoc SPPS is shown in Figure 39.140 
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Figure 39: A schematic diagram of Fmoc SPPS. The peptide chain is grown from the C-terminus to the N-terminus. The 
C-terminus of the first residue is typically attached to the resin. The next residue is required with the amine protected with an 
Fmoc group and the acid free. The acid is activated using coupling reagents (typically HBTU) and then reacted with the free 
amine of the first residue. The Fmoc group protecting the N-terminus of the new dipeptide can be removed and the cycle 
repeated again with the third residue. After the chain is completed, it can be cleaved from the resin, and its side chains 
deprotected, in one step.140 
 
SPPS was successfully used to synthesize the FRET4 substrate. The process was made easier by the 
commercial availability of Fmoc-protected aspartic acid with the EDANS group attached to the side 
chain.141 This compound could simply be incorporated into the SPPS process as with any other Fmoc 
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amino acid. Once the peptide chain was completed, the deprotected N-terminus could be reacted with 
Dabcyl-OSu.141 
 
2.3 Expression and Purification of FMDV 3Cpro 
 
With the ability to monitor FMDV 3Cpro activity in hand, it was now a case of producing the enzyme 
itself. This was achieved using a previously developed method88 the basic concepts of which are 
shown in Figure 40. The 3Cpro in question corresponded to the A1061 viral strain, with several 
alterations. Two mutations (C95K and C142A) had been introduced to enhance solubility and storage 
lifetime, and a histidine tag had been introduced at the C-terminus to facilitate purification. 
 
 
 
Figure 40: Protein expression and purification. The plasmid containing a FMDV 3Cpro producing gene is introduced to an 
appropriate bacterial cell line. The resulting 3Cpro producing bacteria are allowed to multiply in a large volume of culture. 
After sufficient growth, IPTG is added in order to induce the bacteria to over-express 3Cpro. The cell is lysed and the 3Cpro is 
captured from the resulting mixture by means of affinity resin. The resin is washed and the protein displaced from the resin 
to afford sufficiently pure protease. 
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A plasmid produced by P. Zunszain (Imperial College London) was introduced into the cell line. The 
cells were then plated onto agar, and a resulting colony of bacteria was progressively grown up into 
large volumes of LB broth. After several hours of growth, the cells were induced to over express 3Cpro 
by addition of IPTG. After a few more hours of over-expression, the cells were harvested from the 
mixture and lysed by means of sonication. After removal of the cell debris and nucleic acids, affinity 
resin was introduced in order to capture the His-tagged protease. After thorough washing, the protease 
was displaced from the resin by an excess of imidazole. Full details of this process are in the 
experimental (section 8.1). 
2.4 Fluorescence Assay 
2.4.1 Hydrolysis of FRET4 by FMDV 3Cpro 
 
With the production of both protease and substrate, the next task was simply to mix them together in 
order to demonstrate the hydrolysis of the FRET 4 by 3Cpro by observation of the resulting increase in 
fluorescence at the emission wavelength of EDANS. This was achieved and is demonstrated in Figure 
41. 
.  
Figure 41: Hydrolysis of FRET 4 by FMDV 3Cpro. The presence of 3Cpro (0.5 µM) causes an increase in fluorescence due 
to the hydrolysis of FRET4 (50 µM) by the protease. 
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2.4.2 Enzyme Kinetics 
 
Further analysis of the enzyme/substrate/inhibition kinetics is now required in order to be able to 
quantify exact levels of inhibition. 
2.4.2.1 Michaelis Menten kinetics 
The hydrolysis of a peptide by a protease is best modelled using Michaelis Menten kinetics.142 This 
simplification views the catalytic pathway as an enzyme E binding to a substrate S to form a complex 
ES, which in turn is converted into a product P with the regeneration of the enzyme. This can be 
expressed as the following equation. 
 
 
The Michelis Menten equation can be derived from this. As hydrolysis proceeds, the enzyme, the 
substrate and the product concentrations vary. However, if the substrate concentration is significantly 
larger than the enzyme concentration, substrate consumption can be neglected and [S] ≈ [S]0. 
Moreover, at any given time the enzyme concentration can be expressed in terms of the known initial 
concentration and the concentration of the intermediate, thus [E] = [E]0 –[ES]. The rate of formation 
of ES can be expressed as below. Assuming a steady state is reached this will also be equal to zero. 
 
     
  
    (         )                     
 
This equation can be rearranged to express [ES] as a function of the rate constants, [E]0 and [S]. 
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If we consider that the rate of the reaction (v) is determined by the limiting rate constant (k2) then v = 
k2[ES.] 
  
         
      
  
    
 
Then if we refine k2 as kcat and (k-1 + k2)/k1 as KM, we obtain the Michaelis-Menten equation. 
  
           
      
 
kcat is the catalytic constant, also known as the turnover number, and has the properties of a first order 
rate constant. KM is known as the Michaelis constant. Another expression of the Michaelis-Menten 
equation can be derived by substituting kcat[E]0 with Vmax which is the limiting rate for a particular 
system and is dependent on the initial enzyme concentration. 
  
       
      
 
Thus a graph of v against [S] will resemble Figure 42. In this way a plot of initial rate, v, against [S] 
can be used to determine Vmax and Km. These constants can be used to evaluate a particular substrate 
for an enzyme. kcat (= Vmax/E0)describes the catalytic rate and Km the affinity of the enzyme for a 
substrate. The kcat/KM increases with the enzymes ability to hydrolyse the substrate and so is a 
measure of how good a substrate is for a particular enzyme. 
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Figure 42: Plot of rate (v) against substrate concentration ([S]) for a typical substrate. As can be seen the rate is 
initially proportional to [S] but levels of a Vmax. Thus Vmax/KM can be determined by measuring the initial gradient. Vmax can 
then be determined by increasing [S] until the saturation point is reached.142 
 
2.4.2.2 FRET 4 and FMDV 3Cpro 
In the case of 3Cpro acting on FRET 4, kcat/KM is found to be 58 M
-1s-1.93 In this case saturation could 
not be achieved due to the relatively high KM meaning that sufficiently high concentrations of the 
substrate could not be obtained. Thus the actual values of kcat and KM cannot be determined. 
2.4.2.3 Inhibition Kinetics 
Once an inhibitor is added in the situation becomes more complicated. The enzymology is very 
different depending on the mode of inhibition. The kinetics of irreversible inhibition are very different 
to those of reversible inhibition, and the latter itself has a number of different varieties (competitive, 
uncompetitive, non-competitive). 
Thus the kinetics of inhibition will be confronted whenever any particular mode is encountered and 
identified. 
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2.4.2.4 IC50 determination 
The IC50 of an inhibitor is the concentration required to decrease the activity of the enzyme by 50% 
under particular assay conditions i.e. the lower the IC50 the more potent the inhibitor. IC50 values can 
give a comparison between different inhibitors for a given assay that does not depend on knowing the 
exact inhibition mechanism. As such it is a useful measure for the early stages of drug discovery. 
In order to determine IC50 values, the initial rate of reaction is measured for different inhibitor 
concentration. The relative rate is then plotted against inhibitor concentration using a logarithmic 
scale and the inhibitor concentration corresponding to 50% inhibition can be accurately estimated. 
This process is best illustrated with an example. TPCK (Figure 43) is a serine protease inhibitor which 
also inhibits 3Cpro.93 The mode of inactivation is irreversible covalent modification with the active site 
cysteine being alkylated by the inhibitor (a classical affinity label as discussed in section 1.4.4) 
(Figure 44) 
 
Figure 43: TPCK, a chloromethyl ketone chymotrypsin inhibitor with efficacy against FMDV 3Cpro. 
  
Figure 44: Inhibition of a cysteine protease by a chloromethyl ketone. 
 
The IC50 of TPCK against FMDV 3C
pro has been determined on several separate occasions using the 
FRET4 assay.93,143 Therefore it is the obvious choice to use as a control to ensure the assay is 
calibrated and working correctly. 
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Different concentrations of TPCK were incubated with the enzyme for 30 minutes at 37 °C, after 
which time the residual enzyme activity was measured upon addition of the FRET 4 substrate. The 
IC50 curves are then obtained using GraFit.
144 The resulting IC50 curve is shown in Figure 45. 
 
              
Figure 45: Representative IC50 curve for TPCK. Readings were obtained after 30 minutes of incubation of the inhibitor 
(different concentrations obtained by triple dilution from 100 µM) with the enzyme (0.5 μM) upon the addition of the FRET 
substrate (50 μM). The error bars show the standard deviation from the main value from duplicates. The IC50 of this 
compound is 2.85 ± 0.31 μM as determined with GraFit computer package. 
 
Which is to say an IC50 value of 2.85 ± 0.31 µM. This value is in excellent agreement with previous 
values of 2.92 and 3.21 µM and suggests the assay is working effectively. 
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2.4.2.5 IC50 and Irreversible Inhibition 
An important point here is the relationship between incubation time and irreversible inhibition; a 
longer incubation time is reflected in a lower IC50 value. Therefore, an IC50 alone is only an 
appropriate measure for reversible inhibition, which is unaffected by incubation time. However, so 
long as the incubation time is kept constant, the “apparent” IC50 of an irreversible inhibitor is still a 
valid means of estimating and comparing the potencies of a compound series. This thesis encounters 
irreversible inhibition on several occasions, and the IC50 measure is used. Under these circumstances 
“IC50” is used as shorthand for “apparent IC50” and the incubation time is 30 minutes unless specified 
otherwise. 
2.5 High Throughput Screen 
 
The FRET 4 assay was adapted for HTS format by the Drug Discovery Unit at the University of 
Dundee. The modified assay used to screen the Drug Discovery Unit’s General Diversity Set (GDS, 
n=63740), Diverse MiniSet (DMS, n=15667), and Protease Focussed Set (PFS, n=3317). 
Initial single point screening of the GDS identified 88 compounds (PI ≥46%), yielding an initial hit 
rate of 0.14 %. On retesting of these compounds (30 μM), 71 of the 88 compounds were confirmed as 
hits (PI ≥40%, 80.7 % confirmation rate, 0.11 % confirmed hit rate). 
Initial single point screening of the DMS and PFS identified 34 compounds and 2 compounds 
respectively (PI ≥ 40), yielding an initial hit rate of 0.22% and 0.06%. On retesting these compounds 
(30 μM), 33 of the 36 compounds tested were confirmed as hits (PI ≥40%, 91.7 % confirmation rate, 
0.21 % confirmed hit rate). 
False positives were identified using an umbelliferone quenching assay. Of 124 compounds tested, a 
total of 6 compounds were shown to be non-quenching at the concentrations tested. 
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2.5.1 Results 
The structures of the six compounds are shown below together with their IC50 values as determined by 
DDU. 
 
Figure 46: Hit compounds from HTS. Subsequently obtained commercially for retesting at Imperial College London. 16 
was obtained from 145. 17 and 18 from 146. 19 from 147. 20 and 21 from 148. 
 
2.5.2 Confirmation of Results 
The first task was to obtain samples of the compounds and confirm their activity. The compounds 
were purchased from commercial screening companies (Figure 46), however the confirmation of 
activity, in most cases, confirmed precisely the opposite. Compounds 18-21 demonstrated no activity 
up to 100 µM. Compound 17 affected the enzyme to an extent, but far less so than expected. 
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Compound 16 alone demonstrated potency consummate with what was expected. These results are 
shown in Table 1. 
Table 1: Comparison of IC50s from HTS and confirmation testing. 
Compound 
Dundee 
IC50 
(µM) 
Imperial 
IC50 
(µM) 
16 9.05 13.1 
17 13.8 
41% @ 
100µM 
18 7.2 >100 
19 15.9 >100 
20 18.8 >100 
21 4.1 >100 
The large number of false positives was disappointing, however the identification and confirmation of 
a reasonably potent small molecule inhibitor in 16 was nevertheless a breakthrough. 
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Chapter 3: 2-Quinolone Inhibitors 
This chapter describes the resynthesis of compound 16 and a series of analogues of that compound 
which enabled initial structure-activity relationship studies. It then documents the surprising way the 
inhibitor’s mode of action was determined. 
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3.1 Resynthesis of 16 
 
The synthesis of 16 could be approached in various ways. Due to the commercial availability of 4-
hydroxyquinolone 23,149 an initial route was chosen involving the esterification of 23 followed by a 
Fries rearrangement. 
 
 
Figure 47: Retrosynthesis for compound 16 leading to commerically available 23. The 3-toluoyl-4-hydroxyquinolone 
(16) is derived from the toluoyl ester 22 by a Fries-type rearrangement. The ester would easily be obtained from the 
commercially available 4-hydroxyquinolone 23. 
 
A classic Fries rearrangement, involving an ionic melt with aluminium trichloride, was partially 
successful. However, following the approach of Kappe et al.150 a more unusual approach proved to be 
far more effective. This method involved the gentle isomerisation of 22 with potassium cyanide at 
room temperature.151 The reaction took three days to complete, but was ultimately far milder and 
easier than the traditional aluminium trichloride method. 
 
Figure 48: Synthesis of 16. Reagents and Conditions: (a) o-toluoyl chloride, triethylamine, DCM, rt, 16 h, 89%; (b) 
Potassium cyanide, triethylamine, DCM, rt, 72 h, 94%. 
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Thus compound 16 was obtained in good yield. The spectra obtained were all identical to those 
obtained from the commercially bought material and an IC50 of 14.5 µM was obtained which is close 
to previous values (section 2.5.2). 
 
3.2 Determining the Mode of Action 
 
Having established the activity of compound 16, it was now necessary to determine precisely how it 
was working to inhibit the enzyme. The initial question is whether inhibition is covalent or non-
covalent. There are a number of ways of determining this, but the best is probably by means of a rapid 
dilution assay.70,152 
 
3.2.1 Rapid Dilution Assay 
 
A rapid dilution assay is used to distinguish between covalent and non-covalent modes of action. The 
basic principle is that non-covalent reversible inhibition is always a function of the current level of 
concentration of inhibitor and enzyme, whereas covalent inhibition is affected by previous levels. To 
put it another way, if an enzyme is exposed to a covalent inhibitor at high concentrations, a large 
proportion of the enzyme will be inhibited. If the mixture is diluted, the enzyme will not regain 
activity because an irreversible covalent bond has been formed. However in the same situation, an 
enzyme that is reversibly inhibited will regain activity upon dilution because no covalent bonds have 
been formed. The non-covalent interactions of a reversible inhibitor are “washed away” by the 
dilution in a way in which covalent interactions are not. 
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Thus one can run two parallel experiments, the first of which involves incubation with a low volume 
of assay buffer (and thus high concentrations of inhibitor) and the other with a higher volume of 
buffer. Prior to measurement, the first mixture is diluted to the same volume as the second, so that the 
final concentrations of all assay components are the same. 
For the case of reversible non-covalent inhibition, both experiments will give the same result. 
However for covalent inhibition, the first experiment will demonstrate greater inhibition. 
This experiment was performed on compound 16 and the result is shown below. 
 
Figure 49: Rapid dilution experiment for 16. In the rapid dilution experiment the inhibitor and protease are incubated at 
high concentration before dilution, addition of the substrate and measurement. The constant dilution experiment uses the 
same final concentrations as the rapid dilution experiment, however incubation is carried out at lower concentration. Full 
details are in the experimental (section 8.3.3). Comparison of rapid and constant dilutions shows an increased activity for 
rapid dilution, indicating covalent modification as inhibitory mode. 
 
As can be seen, the inhibitor proves more effective in the rapid dilution experiment than the constant 
dilution experiment. This is consistent with irreversible inhibition of the protease. 
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3.3 Structure-activity Relationships of 3-Acyl Group 
 
With resynthesis successfully achieved and the hit validated, it was decided to use this chemistry to 
vary the 3-acyl group of the compound in order to begin the process of obtaining structure activity 
relationships (SAR). It was also important to ensure that at least some similar compounds retained 
activity to ensure there was a possibility of increasing the potency by the synthesis of analogues. 
A series of analogues was synthesized by adapting the above pathway (where indicated, compounds 
were prepared and tested by J.K. Chen153, T. K. Lok154 and G. Sooranna155 (in each case, Imperial 
College London)). Fortunately, the potassium cyanide-catalysed isomerisation proved equally 
effective towards other acyl groups. 
 
Table 2: Comparison of different acyl groups in 3-position. 
Compound -R 
IC50 
(µM) 
24153 
 
33 
25 
 
>100 
26 
 
>100 
84 
 
27153 
 
33 
28153 
 
23 
29 
 
47 
30 
 
39 
 
The activities of these compounds are shown in Table 2. As can be seen switching the aromatic group 
for an aliphatic compound killed off all activity, whereas the compounds containing aromatic 
elements retained activity to some extent. 
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3.4 Activity of the Intermediate 
 
During this process the O-acyl intermediate (22) was tested for activity. To our surprise, this 
compound demonstrated inhibition of the protease. In fact, on further testing the compound proved to 
have an IC50 of 0.14 µM: 100 times more potent than the original compound. There seemed to be 
three possible explanations: 
a)  Both compounds (16 and 22) were, independently, inhibitors of FMDV 3Cpro. 
b) The mild isomerisation of 22 to 16 was discussed (Figure 48). It is possible that 16 itself can 
be rearranged back to 22 either by the active site of the enzyme. 
c) The samples of 16 retain small impurities of 22. A 1% impurity of 22 with an IC50 of in 0.1 
µM in a sample of 16 would manifest itself as having an IC50 of around 10 µM— exactly 
what was observed. 
 
3.4.1 Testing the Hypothesis 
 
In order to test these hypotheses it was decided to resynthesize 16 by a route which avoided the 
intermediate 22. The eventual synthesis, developed from literature procedures,156 is shown in Figure 
50. 
 
Figure 50: Alternative synthesis of 16(aka 34 by this route). Reagents and conditions: (a) Diphenyl ether, 150ºC. (b) 4M 
NaOH (aq), 67%. 
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The compounds shown (Table 3) were made, and the crystal structure (Figure 51) of 35 was obtained 
to settle any concerns about the true structures of the compounds concerned. 
 
 
Figure 51: Crystal structure of 35. Crystals of 35 were obtained from ethyl acetate in an evaporation chamber. The 
structure was solved by the Crystallography Service, Imperial College London. 
 
3.4.2 Results 
 
Table 3: Comparison of 3-acyl groups synthesized via different routes and ester intermediates. 
Compound -R Synthetic Route IC50 (µM) 
16 
 
A 14.5 
34 
 
B > 100   
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22 
 
_ 0.20 
24153 
 
A 38 
35 
 
B >100 
36153 
 
_ 0.32 
37153 
 
B >100 
38153 
 
_ 0.16 
 
As can be seen, the 3-aryl-type compounds made via route B have a drastically reduced activity 
compared to those made via route A, while the intermediate esters (22, 36 and 38) are vastly more 
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potent. This appeared to rule out hypotheses a and b— if 16 was an inhibitor, either in itself or by 
catalytic rearrangement to 22, one would expect it to demonstrate inhibition regardless of its synthetic 
pathway. In fact, this evidence indicated that hypothesis c is correct, and the true inhibitor had always 
been the ester intermediate 22, present in samples of 16 as an impurity.  
An additional hypothesis was that an isomerisation of 16 to 22 was carried out by the solvents used to 
assay the compounds. Since the final compounds are dissolved in DMSO prior to assaying, the 
DMSO could act as a nucleophilic catalyst in a manner similar to the cyanide anion (Figure 48). The 
O-acyl (22) to C-acyl (16) isomerisation is presumably favoured due to the hydrogen bond 
interactions of the hydroxyl group and the extra conjugation of the C-acyl system. However it is 
possible that the DMSO could slowly facilitate the reverse reaction, providing an ever present 
impurity of 22 in DMSO solutions of 16. 
This last hypothesis could not be ruled out by the above tests (Table 3) as the DMSO stock solutions 
of the inhibitors concerned had been in existence for differing periods of time prior to assaying. In 
order to investigate this hypothesis, DMSO solutions of 16 could be tested by LCMS over long 
periods of time in order to monitor any appearance of 22 in the solution mixture. 
In any case, it seemed clear that 22 was the true inhibitor and so the investigation was to focus on it. 
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3.5 Mode of True Inhibitor 
  
With the identification of the true inhibitor, the next question was precisely how these compounds 
were inhibiting the protease so potently. It is highly unusual for such a small molecule, obtained from 
a random screen, to demonstrate such efficacy. Based on the incubation and dilution assays, we knew 
that the compounds were acting to covalently modify the enzyme. The precise nature of this 
modification, however, was impossible to deduce from the structure of the inhibitor. 
  
3.5.1 Evidence for Mode of Inhibition 
 
On examination of the raw data from the assays, something unusual was spotted (Figure 52). The 1 
µM demonstrated a clear upward inflexion. 
 
Figure 52: Raw data obtained from IC50 determination for compound 24. Concentrations refer to the concentration of 
inhibitor. PC refers to positive control (i.e. no inhibitor) and NC refers to negative control (i.e. no inhibitor or enzyme). The 
feature of interest is the clear “concavity” for the 1 µM experiment. This signifies an increase in the rate of fluorescence 
increase, perhaps indicating enzyme regeneration.   
 
Curves which show an upward inflexion such as this are unusual and indicate an accelerating 
substrate hydrolysis, which in turn can only be caused by the reactivation of the enzyme. 
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A longer assay, run over 4 hours, confirmed this phenomenon. In some cases, the enzyme achieved 
complete reactivation over the 4 hours. 
 
Figure 53: 4 hour assay for different ester intermediate compounds. Inhibitors (1 µM) and protease (0.5 µM) incubated 
for 30 minutes before addition of substrate (50 µM) and measurement. Implications of this assay explored more fully in the 
next chapter (section 4.5.2). 
 
It was also observed that the reactivation changed drastically with different acyl groups. 
There were four pieces of evidence as to the mode of inhibition: 
1. The structure of the inhibitors. 
2. Covalent modification. 
3. Enzyme reactivation observed at longer times/lower concentrations of inhibitor. 
4. Enzyme reactivation appeared to vary with the acyl group. 
91 
 
3.5.2 Hypothetical Mode of Action 
 
This evidence enabled us to formulate a hypothetical mode of action, which would explain the above 
phenomena (Figure 53). 
   
Figure 54: Hypothetical mode of action. The active site thiol cleaves the ester to form a stable acyl-enzyme. The slow 
hydrolysis of this complex allows regeneration of the active protease. 
  
In this mode of action, the protease attacks the central ester bond as it would attack the scissile amide 
bond. However the resulting acyl enzyme is so stable that the catalytic pathway is stuck here. In other 
words, the inhibitor is a substrate of the enzyme, but the hydrolysis of the acyl-enzyme intermediate is 
sufficiently slow that the enzyme is effectively trapped, and the “substrate” can manifest itself as an 
“inhibitor”. This certainly explains the curiosities surrounding these inhibitors. The inhibition 
involves the formation of a covalent bond as opposed to the binding of an inert ligand. Enzyme 
reactivation is explained by the eventual hydrolysis of the inhibitors and the rate of this reactivation is 
dependent on the structure of the acyl portion of the inhibitor. For example the benzoyl group appears 
to form a relatively unstable acyl-enzyme (that is to say, this compound is a better substrate). Those 
inhibitors with a para substituent demonstrate a lower rate of enzyme reactivation, which would 
indicate a more stable acyl-enzyme. 
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The ramifications of this mode of inhibition will be explored in the next chapter. For now it was a 
case of proving it was indeed taking place. 
3.5.3 Testing the Hypothesis 
The best way of achieving this was to obtain evidence of the existence of the acyl-enzyme 
intermediate by mass spectrometry. 
Measuring the mass of entire macromolecules such as proteins is a considerable challenge.157,158 This 
is for two main reasons. Firstly, proteins are fairly fragile with respect to most spectroscopic 
techniques and are liable to fragment. Secondly, proteins are mostly obtained as solutions in buffer— 
aqueous mixtures of various salts and other agents intended to mimic the protein’s natural 
environment. The noise of these species will likely drown out the protein’s less robust signal. 
Therefore, prior to measurement, it is generally necessary to “desalt” the buffered enzyme solution, in 
an effort to obtain as near as possible the enzyme as a solution in pure water. 
In spite of extensive efforts, it proved impossible to obtain the 3Cpro acyl-enzyme mass spectrum. 
Parallel investigating had shown that these inhibitors also demonstrated activity against chymotrypsin 
(discussed in section 4.5). Obtaining a chymotrypsin acyl-enzyme is considerably easier for two 
reasons. Chymotrypsin is a significantly more robust protease and can be commercially obtained in 
crystalline form and dissolved in ultrapure water, negating the need for extensive desalting. Also, 
because chymotrypsin is a serine protease, the acyl-enzyme would in this case be an ester rather than 
a thioester and so correspondingly more stable. 
In the event, a mass spectrum of the chymotrypsin acyl-enzyme was obtained and clearly 
demonstrated the expected mass increase. Modified chymotrypsin with a mass of 25567 Da was 
observed, as opposed to 25449 Da for the free enzyme. This mass difference of +118 corresponds to 
the addition of a toluoyl group and so indicates that this mode of action is indeed taking place. 
This proved the existence of the chymotrypsin acyl-enzyme intermediate and heavily suggested the 
similar existence of a 3Cpro version. 
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Chapter 4: Pseudo-irreversible 
Inhibition of 3Cpro 
Since the mode of action (called “pseudo-irreversible” inhibition) is relatively unusual, this chapter 
begins by discussing the significant uses of it in biochemistry and medicinal chemistry. SAR 
investigations were then conducted looking at both halves of the compound, the acyl group and the 
leaving group in an attempt to increase the potency and stability of the acyl enzyme complex. The 
inhibitors developed are then tested against FMDV itself. 
 
 
Figure 55: Early-stage protease inhibitor design schematic for pseudo-irreversible inhibitors. 
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4.1 Pseudo-irreversible Inhibition: Naming Convention 
As described in the previous section, the mode of these inhibitors is based on their behaviour as 
substrates of the protease. This kind of inhibition has no generally agreed name and is referred to 
using various terms (for example “acyl-enzyme inhibition”114, “acylating inhibition”79 or “alternate 
substrate inhibitors”74 ). 
The naming convention in this project is to refer to this mode as “pseudo-irreversible” inhibition. This 
a term used in regard to a class of acetylcholinesterase inhibitors.159,160,161 Acetylcholinesterase 
(AChE) is a serine hydrolase that cleaves the neurotransmitter acetylcholine. 
 
Figure 56: The hydrolysis of acetylcholine by AChE. 
Carbamate-based AChE inhibitors, of which neostigmine 39 (Figure 57) is an example, typically use a 
mode of action in which they undergo hydrolysis by AChE but form an unusually stable carbamate 
with the oxygen of the AChE serine. 
 
Figure 57: The AChE inhibitor Neostigmine, a typical inhibitor of the carbamate class. 
 
Figure 58: Mode of action of neostigmine. AChE hydrolyses the carbamate bond of neostigmine resulting in the formation 
of a new carbamate with the AChE serine. The subsequent hydrolysis is sufficiently slow that the effect is to inhibit the 
cleavage of acetylcholine itself.159 
As can be seen, although the enzymes concerned differ in role and catalytic pathway, the mode of 
inhibition is fundamentally the same. 
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PART 1: BACKGROUND 
4.2 Pseudo-irreversible Inhibitors of Serine Proteases 
 
Since the mode of action of the O-acyl ester inhibitors is unusual, and relatively unknown in a 
medicinal chemistry context, the next few sections will look at past instances of pseudo-irreversible 
inhibition of proteases. 
 
4.2.1 The Determination of Serine Protease Mechanism 
 
The two-step mechanism for chymotrypsin-catalyzed hydrolysis of esters and amides was first 
proposed based on the work of Balls and Harley. Having noted that chymotrypsin and trypsin were 
stoichiometrically inactivated by a nerve gas,162 (diisopropyl fluorophosphonate), Balls was able to 
stoichiometrically acylate chymotrypsin at low pHs.163 This enabled the identification of the 
nucleophilic serine residue. Hartley showed that the action of chymotrypsin on p-nitrophenyl acetate 
produced a “burst” of nitrophenol stoichiometric with the quantity of chymotrypsin.164 
These results strongly suggested that the enzyme was being acylated. This was strongly reinforced by 
the work of Bender who used o-nitrophenyl cinnamate (40) to pseudo-irreversibly inhibit 
chymotrypsin.165,166,167 The resulting cinnamoyl chymotrypsin acyl-enzyme was sufficient stable to 
allow detection by spectrometry. 
 
Figure 59: o-Nitrophenol cinnamate, a pseudo-irreversible inhibitor of chymotrypsin. 
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4.2.2 Active Site Titration and the GB Group 
 
Pseudo-irreversible inhibitors were developed as active site titrants, compounds that can be used to 
accurately determine enzyme concentration. Most famously, Shaw developed p-nitrophenol 
guanidinobenzoate (NPGB) (41) as trypsin titrant.168 
This compound’s effectiveness as an active site titrant is due to its extremely high potency. This is in 
turn due to the highly stable nature of the acyl-enzyme— guanidinobenzoyl trypsin. Upon mixing 
with trypsin, a stoichiometric amount of NPGB will immediately react, releasing the same quantity of 
nitrophenol (which can be detected chromogenically). Because of the stability of the acyl-enzyme, 
hydrolysis and regeneration of trypsin is minimal. 
The effectiveness of this guanidinobenzoate (GB) group against trypsin-like enzymes has led to its 
use in clinical drugs. Nafamostat mesilate (42) is a pseudo-irreversible protease inhibitor which is 
widely used as an anticoagulant.169 
 
 
Figure 60: Two pseudo-irreversible inhibitors of trypsin-like enzyme. p-Nitrophenol guanidinobenzoate168 (41) a widely 
used active site titrant for trypsin. Nafamostat mesilate is (42) used as an anti-coagulant.169 
 
As can be seen (Figure 60), nafamostat employs the GB acyl group together with a more soluble 
leaving group. 
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4.2.3 Kinetics of Pseudo-irreversible Inhibition 
 
To reiterate, the reaction between a protease and a pseudo-irreversible inhibitor is as follows: 
 
 
 
Thus there are three considerations: The initial binding of the pseudo-irreversible inhibitor, the 
reaction to form the acyl enzyme, and deacylation to regenerate the enzyme. 
It should be emphasized pseudo-irreversible inhibitors are substrates. The inhibitory nature arises 
from the slowness of the deacylation step, and hence the value of k3. 
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4.2.4 Role of Acyl Group 
4.2.4.2 Guanidinobenzoate Acyl-enzymes 
 
Why are these acyl-enzymes so stable? One possible answer arises from studies performed on the GB-
type inhibitors. Trypsin has a preference for basic residues such as lysine and arginine in the P1 
position. It was believed that GB mimics these amino acids and the difference between the 
lysine/argine side chain and the GB aromatic ring causing the unusual acyl-enzyme stability. The 
structural similarities between the GB acyl group and the non-covalent trypsin inhibitor benzamidine 
(3) discussed in the introduction (section 1.4.4.1) are obvious. This theory was confirmed by co-
crystal structures of the GB-trypsin acyl-enzyme complex.170,171,172 
 
Figure 61: Crystal structure showing GB acyl group bound to the active site serine of trypsin, with the guanidino 
group in the P1 pocket (from Mangel et. al. 171). 
 
As can be seen, the GB group does indeed form an ester with the active site serine. The basic 
guanidine group sits in the P1 position as expected, with the rigidity of the aromatic ring jamming the 
active site in an unfavourable conformation for subsequent attack on the acyl-enzyme. 
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4.2.4.3 Azapeptides and Carbamates 
 
Peptidic versions of pseudo-irreversible inhibition have been achieved be the use of azapeptides and 
peptide carbamates.73 
 
Figure 62: Pseudo-irreversible peptide compounds. In both cases, a c-terminal ester is combined with an α-nitrogen. This 
nitrogen contributes to an unusually stable acyl-enzyme which impedes the catalytic turnover and causes inhibition.73 
 
The stability of the acyl-enzyme here relies mainly on the electronics involved.173,174 The resonance 
effects of the adjacent nitrogen atom make the carbonyl carbon much less electropositive and so much 
less susceptible to the nucleophilic attack by water which is required for deacylation to take place. An 
additional factor for the case of azapeptides is the geometry of the α-nitrogen which orients the acyl-
group in a position which disfavours deacylation. 
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4.2.4.2 β-Lactam-based Inhibitors 
 
A variety of β-lactam-based compounds are inhibitors of serine proteases.73 The exact mode of 
inhibition varies but generally begins with the active-site serine opening the lactam ring and forming 
an acyl-enzyme with the lactam acyl group. After this, the most common mechanism involves the 
alkylation of the active site histidine by electrophilic centres on the opened β-lactam.175 This type of 
mechanism has much in common with the coumarin mechanism-based inhibitors discussed in section 
1.4.4.2. More relevant to this discussion of pseudo-irreversibility are β-lactams which form acyl-
enzyme stabilised by non-covalent interactions. For example, Wilmouth et al. obtained the structure 
of a porcine pancreatic elastase-β-lactam adduct.176 The ring-opened β-lactam acylates the active site 
serine, but the ester carbonyl is rotated by 120° and is not located within the oxyanion hole (Figure 
63). The hydrolytic water is displaced, thus disfavouring hydrolysis of the acyl-enzyme complex. 
 
Figure 63: Schematic of porcine pancreatic elastase complexed with β-lactam. The active serine is acylated by the ring 
opening and the ester carbonyl is oriented away from the oxyanion hole (Gly-193) disfavouring a nucleophilic attack.73,176 
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4.2.5 The Role of the Leaving Group 
 As can be seen there is a fairly wide tolerance of leaving group. In fact, various fluorescence groups 
have been combined with the GB group for use as active site titrants.177,178,179,180 
 
Figure 64: Trypsin active site titrants and inhibitors. Compounds with leaving groups such as fluorescein (43) and 
methylumbelliferone (44) will emit fluorescence after cleavage 
 
All of these compounds deactivate trypsin— 43 and 44 are effective active site titrants. Nonetheless, 
kinetic studies have shown differences in the rates of reaction of trypsin with these compounds. It 
remains unclear precisely what causes the difference in activity. Studies by Bender indicate that the 
pKa of the leaving group is relatively unimportant.
181 For example the thioester analogues of pseudo-
irreversible esters (theoretically a far better leaving group) do not manifest higher rate constants. 
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4.3 Pseudo-irreversible Inhibition of Cysteine Proteases 
 
There has been no equivalent discovery of pseudo-irreversible protease inhibitors for common 
cysteine proteases such as papain. This is unsurprising given the relative instability of thioesters 
compared to esters. Epoxides such as E64 are generally used for the active site titration of papain-like 
proteases.182,183 
However when trypsin is mutated to thiol-trypsin, that is the active serine is altered to cysteine, the 
new protease is still inactivated by NPGB but with an increased rate of deacylation,184 exactly as 
predicted based on thioester instability. 
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4.4 Pseudo-irreversible Inhibitors of Viral Cysteine Proteases 
 
4.4.1 Discoveries 
 
As mentioned in the introduction, the first generation of viral cysteine protease inhibitors were based 
on the substrate and generally consisted of a few amino acids with a warhead on the C-terminus. So 
far this approach has not lead to a clinically useful drug, and so researchers began to examine other 
options. This included the use of HTS and the attempted adaption of anti-HIV protease inhibitors. On 
three separate occasions this has led to the discovery of pseudo-irreversible inhibitors: 
 Zhang et. al. screened a library against the coronavirus SARS 3Clike protease.185 This 
revealed the compound 47 with an IC50 of 0.5 µM. 
 
Figure 65: Pseudo-irreversible SARS 3CLpro inhibitor based on chloropyridyl leaving group. 
Mass spectrometry identified the acyl-enzyme, confirming that the mode was indeed pseudo-
irreversible. 
 
 During the synthesis of analogues of lopinavir (an anti-HIV protease inhibitor), Wu et al. 
discovered that the active component in their SARS CoV 3CLpro assays was an ester of HOBt 
formed during the coupling process (48).186,187 These compounds were highly potent (ki =17.4 
nM). 
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Figure 66: Pseudo-irreversible SARS 3CLpro inhibitor based on hydroxybenzotriazole leaving group. 
Once again, mass spectrometry confirmed the mode of action. 
 The work described in this thesis is the third such occasion. 
 
4.4.2 The Viral Protease Acyl-Enzyme 
 
Versheuren et. al. investigated the action of 48 on SARS CoV 3CLpro more fully.188 They managed to 
obtain a co-crystal structure of the enzyme-48 adduct which did indeed turn out to be the stable acyl-
enzyme. Electron density corresponding to dimethylaminobenzoate was found covalently bonded to 
the thiol of the catalytic cysteine residue. Surprisingly, the catalytic histidine was found to be twisted 
away from its catalytic position and was instead π stacking with the aromatic ring of the inhibitor. In 
contrast to the situation with the GB-trypsin complex, the inhibitor is found to partially occupy the S2 
pocket rather than the S1. 
 
Figure 67: Crystal structure of SARS 3CL acyl-enzyme. p-Dimethylaminobenzoate species is found to be covalently 
bonded to the active site thiol as expected. Acyl group is oriented towards the P2 pocket where it pi stacks with the active 
site histidine. This presumably prevents the histidine activating a water molecule to hydrolyse the thioester. Hydrolysis 
therefore occurs more slowly.188 
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PART 2: RESULTS 
4.5 Investigating the Role of the Acyl Group 
4.5.1 Synthesis of Analogues 
With the discovery of the potent inhibitors and the elucidation of their mode of action, the next task 
was the production of analogues in order to probe the crucial structural elements which give the 
inhibitors their potency. A series had already been made inadvertently. These were the intermediates 
of the synthesis of the 3-aryl-2-quinolones (section 3.3). 
Since the chemistry involved was comparatively simple, a large number of analogues was rapidly 
synthesized. 
 
Table 4: Comparison of different acyl groups 
Compound -R IC50 
(µM) 
36153 
 
0.42 
49 
 
>100 
50 
 
>100 
106 
 
51154 
 
>100 
52153 
 
0.16 
53153 
 
0.38 
54153 
 
0.15 
55 
 
0.76 
56154 
 
5.50 
57153 
 
2.3 
58154 
 
3.99 
59154 
 
4.14 
107 
 
60154 
 
<0.1 
61154 
 
<0.1 
62 
 
0.57 
63 
 
0.78 
64154 
 
<0.1 
65153 
 
1.1 
66 
 
0.33 
67154 
 
<0.1 
 
This confirmed the previously obtained results. An aromatic acyl group is clearly required for 
inhibition. It appears that electron-donating substituents produce more inhibition. 
An attempt was also made to synthesize 68 and 69, in order to determine whether other pi systems 
such as alkenes and alkynes also provided inhibition.  
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Figure 68: Target compounds intended to probe effect of other pi systems on acyl-enzyme stability. 
 
4-hydroxyquinolone (23) was therefore coupled with the relevant carboxylic acids (crotonic acid for 
68, and propiolic acid for 69). On inspection of the 1H NMR spectra, it was deduced that further 
intramolecular Michael reactions had occurred, forming 70 and 71 instead of the desired compounds 
68 and 69. 
 
Figure 69: Actual products from attempted synthesis of 68 and 69. These result from further intramolecular reactions 
after successful coupling of acyl groups to 4-hydroxyquinolone. 
 
The nucleophilic nature of the 3 position of the 4-hydroxyquinolone core has been used already in this 
thesis (section 3.1). The ability of 4-hydroxycoumarins to attack Michael acceptors from this position 
is also well established.189 
In contrast, cinnamate derivatives (72 and73) did not undergo subsequent intramolecular Michael 
attack, suggest the extended conjugation of these compounds disfavour such a reaction. 
These four compounds were tested for activity. 
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Table 5: Comparison of lactone and cinnamate esters. 
Compound -R IC50 
(µM) 
70 
 
>100 
71 
 
>100 
72154 
 
<0.1 
73 
 
0.23 
70 and 71 demonstrated no inhibition, whereas the cinnamate derivatives 72 and 73 proved highly 
potent. 
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4.5.2 Effect of Acyl Structure on Deacylation 
 
Some of the inhibitors were then tested over a longer period of time (4 hours) in order to assess the 
approximate rate of enzyme reactivation, and the effect of different acyl groups. The results mirrored 
the IC50s in that the acyl groups with electron-donating substituents were far better inhibitors than the 
simple benzoyl group (36), which was better than the p-nitrobenzoyl (56). As can be seen (Figure 70), 
the enzyme achieves almost complete reactivation when mixed with approximately 2 equivalents of 
56 whereas the p-methyl (52) and p-methoxy (54) continue to inhibit the enzyme even after 4 hours. 
 
 Figure 70: Reactivation of the enzyme over 4 hours. Inhibitors (1 µM) and protease (0.5 µM) incubated for 30 minutes 
before addition of substrate (50 µM) and measurement. 
 
This sort of timespan would presumably be sufficient to prevent viral replication. 
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4.5.3 Mimicking the P2 Lysine 
 
Based on the structure obtained by Verscheuren et al. and assuming FMDV 3Cpro behaves similarly to 
SARS CoV 3CLpro, it seemed a distinct possibility that the acyl group was binding in the P2 pocket. In 
this case, a comparison of the two active sites (Figure 71) makes it clear that the interactions between 
the P2 Lysine and the S2 pocket could potentially picked up by an inhibitor. For example if the 
compound was modified to include a primary amine (Figure 72). 
 
 
Figure 71: Comparison of SARS 3CLpro acyl-enzyme structure188 (left) with FMDV 3Cpro active site190 (right). The 
diagram in each case shows the P2 position. In the SARS structure, the acyl group (covalently bonded to the active site thiol) 
is oriented in the P2 position and traps the active site histidine in a pi-stacking interaction, preventing the activation of a 
water molecule required for deacylation. The FMDV structure shows a 3Cpro mutant with the active site cysteine replaced 
with an alanine. Assuming stable FMDV 3Cpro acyl-enzymes are formed by similar interactions with the active-site histidine, 
further interactions could be obtained with a positive charge mimicking the P2 lysine. 
 
Figure 72: Compound 74 designed to mimic P2 lysine. 
 
The synthesis was straightforward. Carboxylic acid 75 was coupled to the quinolone and then Boc- 
deprotected to give the desired compound 74. 
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Figure 73: Synthesis of 74. Reagents and conditions: (a) EDCI, HOBt, DIPEA, DMF, 16h, rt, 76%. (b) 10% TFA:DCM, 1h, 
rt, 43 %. 
 
74 gave an IC50 of 1.22 µM, which was less effective than other inhibitors, and suggesting that 
favourable interactions were not being formed. The protected (76) and acetylated (77) versions were 
found to be inactive which could indicate the positive charge of 74 was forming the desired 
interactions, but that other factors offset any gain in activity. 
 
Table 6: Activities of p-methyleneamino-based compounds. 
Compound -R IC50 
(µM) 
74  1.22 
76  >100 
77  >100 
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4.5.4 Investigating the Role of the Leaving Group 
 
Next it was decided to examine the role of the leaving group in inhibition. The question was whether 
the leaving group was just that— i.e. simply a means of activating the ester— or whether it played a 
role in the initial binding of the compound and the attack of the thiol on the carbonyl of the inhibitor. 
The leaving groups that were initially chosen for synthesis are shown in Figure 74. 78, 79, and 80 
gradually simplify the N-methyl-2-quinolone scaffold down to a simple napthyl. 78 would also 
examine the role of the N-methyl group and improve solubility. The 2-pyridone (82) is a single-ring 
version of the 2-quinolone. The coumarin group (81) is an oxygen analogue of 78, and the nitrophenol 
(83) is an excellent leaving group (pKa =7). If 83 is an effective inhibitor it could provide a useful 
active site titrant for FMDV 3Cpro. 
 
Figure 74: Possible leaving groups. 78, 79 and 80 are a sequence simplification of the N-methylquinolone. Another 
simplification is to the single ring version 82. The coumarin 81 is a simple analogue of 78 with NH replaced by O. The 
nitrophenol group 83 is structurally unrelated but is an excellent leaving group (pKa = 7). 
 
4.5.4.1 Synthesis 
Most of these compounds were commercially available, but 78 and 82 would have to be synthesized. 
78 was synthesized by the reaction of aniline 84 with Meldrum’s acid 85 and subsequent cyclisation 
of 86 with Eaton’s reagent.191 
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Figure 75: Synthesis of 78. Reagents and conditions: (a) 80ºC, 1h. (b) Eaton’s reagent (10% P4O10 in MeSO3H), 70ºC, 1h, 
42%. 
The synthesis of 2-pyridone 82 was achieved using selective N-methylation of 2,4-dihydroxypyridine 
87 with DMS. 
 
 
Figure 76: Synthesis of 82. Reagents and conditions: (a) Me2SO2, NaOH, H2O, rt, 12h, 28%. 
 
Both syntheses were achieved, and the new leaving groups could further be reacted with toluoyl 
chloride. 
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4.5.4.2 Results 
The toluoyl esters of these leaving groups were synthesized and tested for activity. The results are 
shown (Table 7). 
 
Table 7: Comparison of different leaving groups. 
Compound -R IC50 (µM) 
88 
 
0.14 
89 
 
8.10 
90 
 
>100 
91 
 
0.31 
92 
 
<1 
116 
 
93 
 
>100 
As expected, the simplification of the 4-quinolone scaffold resulted in a decrease of activity. 88 was 
just as good as the parent compound, 89 displayed inhibition but greatly reduced and 90 was inactive. 
The coumarin analogue 91 is similarly potent, while the single ring 2-pyridone 92 demonstrates a 
reduced activity. The nitrophenol analogue 93 displays no inhibition- indicating that factors besides 
pKa of the leaving group are important. 
 
4.5.4.3 SARS and HRV Pseudo-irreversible Inhibitors 
 
As mentioned in section 4.4.1, various other pseudo-irreversible inhibitors have been discovered for 
other viral cysteine proteases.185,192,193 There appears to be a certain cross-effectiveness, and inhibitors 
developed for SARS have excellent activity against HRV and vice-versa. 
The most widely used scaffolds are shown in Figure 77. 
 
Figure 77: Leaving group with efficacy against SARS 3CLpro and HRV and HAV 3Cpro. X= Cl, Br. 
 
Esters derived from these compounds demonstrated excellent activity against FMDV 3Cpro. This also 
enabled the synthesis of an inhibitor with a crotonic ester acyl-group 97. This alternative pi-system 
appeared to also form a stable acyl-enzyme. 
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Table 8: Activity of compounds with halopyridine leaving groups. 
Compound -R IC50 (µM) 
96 
 
0.37 
97 
 
0.87 
98 
 
0.44 
 
This demonstrates that the cross efficacy of these leaving groups extends to FMDV. 
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4.5.4.4 Fluorescent Leaving Groups 
Further attempts were made to create an active site titrant for FMDV 3Cpro. In this case, 7-
hydroxymethylumbelliferone (99) and fluorescein (101) were used as leaving groups. A version of the 
methylumbelliferone compound was created with an acetyl group (100). The purpose behind this was 
to create a new substrate for 3Cpro. Since the acetyl version of the inhibitor (49) does not exhibit any 
inhibition, it a reasonable assumption that this is because the acyl-enzyme is not stable and the 
catalytic pathway proceeds as normal. In theory then, the hydrolysis of 100 could be followed by 
monitoring the increasing concentration of 7-hydroxymethylcoumarin by fluorimetry. 
 
Figure 78: Efforts to introduce a fluorescent element into inhibitor leaving group. 
 
This approach did not work. 99 and 101 exhibited no inhibition, and 100 did not appear to be 
hydrolysed by the 3Cpro (based on fluorometric monitoring) This further emphasises the difference 
between the behaviour of serine proteases, where any leaving group will do, and 3Cpro. 
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4.5 Activity Against Trypsin and Chymotrypsin 
 
As mentioned previously, a selection of compounds were assayed for activity against trypsin and 
chymotrypsin. Assays were performed using standard protocols and commercially obtained AMC 
fluorogenic substrates (details in the Experimental). In general the inhibitors were inactive against 
trypsin and moderately active against chymotrypsin. Some of the key points were: 
 The thiophene analogue 67 proved an excellent inhibitor of all three proteases. 
 The cinnamate analogue 72, as expected (see section 4.2.1), was an excellent inhibitor of 
chymotrypsin. 
 The leaving group did not have a large effect on the trypsin/chymotrypsin activity, if one 
compares the activities of 22, 91 and 96. This is consistent with the relative unimportance of 
leaving group for digestive serine proteases mentioned previously (section 4.2.5). 
 
Table 9: Activity of compounds against trypsin and chymotrypsin 
Compound Structure 
IC50 (µM) 
FMDV 3Cpro 
IC50 (µM) 
Trypsin 
IC50 (µM) 
Chymotrypsin 
22 
 
0.20 80.3 3.06 
120 
 
67 
 
<0.1 1.41 <0.1 
72 
 
<0.1 >100 0.66 
56 
 
5.5 >100 3.65 
91 
 
0.31 55.7 0.93 
96 
 
0.37 29.4 5.60 
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4.6 Comparison of Pseudo-irreversible Inhibition in Digestive Serine 
and Viral Cysteine Proteases 
 
Clearly pseudo-irreversible inhibition is broadly the same process in both families of enzymes. 
However there is an interesting difference. 
As we saw in section 4.2.5, the leaving group barely plays a role in the serine protease mechanism. It 
does, inevitably, affect the rate constants, but the overall cleavage process remains the same. 
Ultimately guanidinobenzoyl esters will be highly effective inhibitors of trypsin regardless of what 
that leaving group actually is. This can be seen in the array of active site titrants in section 4.2.5. 
The same is not true of the viral proteases mechanism. Here, the structure of the leaving group 
appears to be crucial to inhibition. Compounds such as 93 and 99 possess good leaving groups in 
terms of the pKas involved but demonstrate no inhibition. 
The conclusion to be drawn here is that digestive proteases will cleave any ester, and so once an 
effective acyl group has been found, any ester with this group in it will be an effective inhibitor. As 
we know, viral proteases are necessarily far more specific than digestive proteases and so will not 
cleave every ester. The structure of the leaving group is as vital as the structure of the acyl group. This 
would suggest that the leaving group plays a role in binding to the protease active site. 
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4.7 Antiviral Activity 
 
The primary purpose of this project was to develop 3Cpro inhibitors with potent activity against the 
virus in a cell-based assay. With this in mind, the inhibitors were sent to the Pirbright Institute 
(Pirbright, UK) where a cell-protection assay was developed. 
Viral assays were performed by M. Windsor (Pirbright Institute, UK)— details are in the 
Experimental (section 8.5). 
To ensure that the assay provided accurate data, it was decided to test a known anti-FMDV agent and 
compare the EC50 value obtained with the literature value. 2’-C-Methylcytidine (1), mentioned in the 
introduction, is a commercially available nucleoside analogue which demonstrates EC50 values of 6.4 
± 3.2 µM against FMDV.51 
 
 
Figure 79: 2'-C-Methylcytidine. This compound was discussed in the introduction (section 1.3.3), 
 
Testing at Pirbright gave an EC50 of 5.5 ± 3.2 µM which is in excellent agreement with the literature 
value and suggested the assay was working well. 
Unfortunately, the developed protease inhibitors demonstrated no inhibition even when tested at 1mM 
concentrations. 
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4.7.1 Possible Reasons for the Lack of Antiviral Activity 
 
In spite of the impressive potency against the enzyme the complete lack of any activity against the 
virus suggested there were some major issues regarding the druglikeness of these compounds. The 
potential problems can summed up in four points. 
 Solubility 
The compounds in question are relatively hydrophobic and “crashing out”/crystallisation was 
observed during antiviral assays. Clearly if a significant proportion of the compound remains 
undissolved this could have a serious effect on antiviral activity. 
 
 Cell Permeability 
The compounds possess no obvious barriers to cell permeability such as charged species or 
large molecular weight. They conform to Lipinski’s rules and are predicted to have decent 
druglikeness (using OSIRIS property explorer).194 
 
 Overly Rapid Deacylation 
If the protease is completing the hydrolysis of the inhibitor sufficiently quickly, it can 
subsequently process the polyprotein without viral replication being overly hampered. 
 
 Premature Hydrolysis 
The compounds are relatively activated esters and esters are notorious for their hydrolysis in 
biological systems. This factor was of particular concern and so was investigated next. 
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4.7.2 Hydrolysis of Pseudo-irreversible Inhibitors 
 
It was decided to investigate the stability of compound 22 in water using an HPLC-based assay. An 
aqueous solution of 22 was measured immediately after solution and 30 minutes later. The results are 
shown (Figure 80). 
 
Figure 80: HPLC traces demonstrating the hydrolysis of 22 in water. The comparison is between the level of hydrolysis 
on the addition of water and after 30 minutes. 
 
This demonstrates that a significant proportion of 22 had been hydrolysed after only 30 minutes, 
indicating the poor survivability of these compounds and perhaps accounting for the lack of cellular 
activity.   
Another factor is the interaction of the pseudo-irreversible inhibitor with other hydrolases. In section 
4.5 the compounds were tested against the digestive proteases trypsin and chymotrypsin. In some 
cases the compounds displayed no inhibition against trypsin. This could have been for two reasons: 
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(a) The inhibitor has no interaction with the protease. 
(b) The inhibitor is easily cleaved by the protease. The acyl-enzyme is relatively unstable and 
easily hydrolysed during the catalytic cycle. To put it another way, the inhibitors are excellent 
substrates of trypsin. 
If the latter scenario is the correct one, then the inhibitor does not survive its interaction with trypsin. 
If this occurs with hydrolases in the serum and host cells of the cell-based assay, then the survivability 
of these compounds is likely to be very low. Compound 22 was tested for hydrolysis with trypsin 
using the same LCMS-based assay. 
 
Figure 81: HPLC traces demonstrating the hydrolysis of 22 in presence of trypsin. Comparison with Figure 80 indicates 
levels of hydrolysis enhanced by the presence of trypsin. 
 
The HPLC traces proved difficult to quantify, however a qualitative comparison suggests that the rate 
of hydrolysis of 22 is enhanced by the presence of trypsin. Given the relative lack of inhibition this 
compound demonstrates on trypsin (IC50= 80.3 µM), this is consistent with scenario (b).  
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4.7.3 Antiviral Inhibitors of SARS CoV 3CL 
 
A series of similar compounds display antiviral activity against the SARS coronavirus.193 Clearly for 
them to do this, the potential problems with pseudo-irreversible inhibitors mentioned above are not an 
issue. Therefore these compounds were synthesized and tested against the FMD protease and virus. If 
the inhibitors displayed efficacy against the protease then it was hoped that their cell-based efficacy 
against SARS might translate to anti-FMDV activity. Ultimately, despite displaying potency against 
FMDV 3Cpro, there was once again no effect against the virus. This perhaps indicates that pseudo-
irreversibility is unlikely to be a successful strategy against FMDV. 
 
Figure 82: Examples of SARS pseudo-irreversible inhibitors with proven antiviral activity. 
 
Table 10: Activity of compounds against FMDV and SARS proteases and viruses. SARS-related activities obtained 
from Ghosh et. al.193 
Compound 
IC50 (µM) 
FMDV 3Cpro 
EC50 (µM) 
FMDV 
IC50 (µM) 
SARS 3CLpro 
EC50 (µM) 
SARS 
102 nd >100 0.03 6.9 
103155 <1 >100 0.08 12.1 
104155 <1 >100 0.31 24 
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4.7.4 Inverse Substrates 
 
A potential solution to the problem of off-target/premature hydrolysis of the pseudo-irreversible 
inhibitor ester bond was provided by a consideration of inverse substrates.195 Inverse substrates for 
trypsin-like serine proteases (also called substrate mimetics) were developed from compounds such as 
NPGB by reversing the central ester bond so that the highly specific acyl group of the inhibitor 
becomes a highly specific leaving group for a new compound.196 
 
Figure 83: Development of "inverse" substrates from GB esters. The high specificity of the GB acyl group enables the 
design of highly specific leaving group, allowing the design of substrates which are dependent on the leaving group rather 
than the acyl group. 
 
This is of great interest because protease function is independent of the acyl moiety— an inversion of 
the usual situation in which P1 is the crucial residue 
When viewed like this, it becomes apparent that in many ways the FMDV 3Cpro pseudo-irreversible 
inhibitors can be seen as an inverse substrate, as it appears hydrolysis depends on the leaving group. 
If this analysis is accurate, then an inversion of the ester bond (Figure 84) would produce a compound 
(106) which would also be a substrate of the enzyme. 
128 
 
 
Figure 84: Inversion of compound 22 to form 106. Catalytic hydrolysis of 106 by 3Cpro would form acyl-enzyme 107. 
 
If the resulting acyl-enzyme (107) is stable, then 106 will display inhibition also. From there, a 
replacement of the aromatic leaving group with a simple ethyl group (108) might provide a pseudo-
irreversible inhibitor with more stability in water (pKa of ethoxide leaving group = 16). 
 
Figure 85: Ethyl ester analogue of 106. If 106 proved to inhibit 3Cpro, 108 might provide to be an inhibitor with a longer 
half-life in a biological system since its ester is less activated. 
 
Analogues of 106 and 108 were synthesized using the following synthetic pathway (Figure 86). Isatin 
(109) is refluxed with malonic acid in acetic acid.197 The resulting compound 110 is converted to its 
ethyl ester (111) by simple esterification in ethanol with catalytic sulfuric acid. The cresol analogue 
(113) proved more difficult to synthesize, but was achieved with protection of the quinolone function 
by chlorination to a 2-chloroquinoline (112) and subsequent deprotection with sodium acetate.198 
129 
 
 
Figure 86: Synthesis of inverse substrates 111 and 113. Reagents and conditions: (a) Malonic acid, acetic acid, 110 ºC, 
12h, 82%. (b) H2SO4, EtOH, 80 ºC, 16h, 91%. (c) POCl3, 100 ºC, 3h. (d) SOCl2, 80 ºC, 1h. (e) p-cresol, Et3N, benzene, 80 
ºC, 1h. (f) Sodium acetate, acetic acid, 110 ºC, 1h, 48%. 
The inverse version of the bromopyridine compounds (115) was also synthesized due to the 
commercial availability of 3-bromonicotinic acid (114). 
 
 
Figure 87: Synthesis of inverse substrate 115. Reagents and conditions: (a) EDCI, DIPEA, p-cresol, MeCN, rt, 12h, 23%. 
 
Upon testing against the protease, none of the inverse compounds displayed any inhibition. Further 
investigations are required to determine the following questions: 
1. Are the inverse substrates being hydrolysed? This could be determined with an HPLC-
based assay (as in section 4.7.2). If hydrolysis is not occurring, than the inversion of the ester 
bond has altered the reactivity and the new esters are not substrates of the protease. 
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2. Does the acyl group form a stable acyl-enzyme with the protease? If hydrolysis is 
occurring then it is probable that the resulting acyl-enzyme is insufficiently stable to provide 
an inhibitory effect. This could be further investigated by synthesis of compounds 116 and 
117, which use the successful quinolone leaving group. 
 
 
Figure 88: Compounds designed to probe ability of inverse acyl groups to form stable acyl-enzymes. They consist of 
the standard quinolone leaving group together with the inverse acyl group. 
 
If such compounds demonstrated no inhibition and are being hydrolysed then it suggests that 
the reason for the inactivity of the inverse substrates lies with the instability of the acyl-
enzyme. 
4.8 Conclusions 
The conclusions to be drawn from this investigation can best be divided into three points. 
4.8.1 Pseudo-irreversibility and Viral Cysteine Proteases 
 
While the interaction of serine proteases and pseudo-irreversible inhibitors is reasonably well 
understood, the corresponding behaviour of viral cysteine proteases is poorly characterised. This is for 
several reasons: viral proteases have been discovered far more recently, are far more difficult to 
produce and are far less robust than the digestive proteases. Also they have generally been discovered 
by medicinal chemists who are less concerned with the precise kinetics of the process. 
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4.8.2 Pseudo-irreversibility and Drug Design 
 
There have been various highly potent pseudo-irreversible inhibitors developed against SARS, HRV 
and HAV. Thus far, the previously mentioned SARS inhibitors are the only instance of antiviral 
activity for a pseudo-irreversible inhibitor. The most likely reason of this ineffectiveness is that the 
compounds have a very low survival rate in a biological system due to reactivity of the constituent 
ester. This is a well-known problem with esters, and is generally solved by the replacement of an ester 
with a bioisostere— that is a chemically different group which is nevertheless similarly recognised by 
biological systems. This is clearly not an issue for reversible ligands. However in this case the ester is 
intrinsic to the specific mode of action of the inhibitors and so cannot be replaced. 
 
4.8.3 Reviewing the Screen 
The compounds discovered by the HTS are shown below. 
 
Figure 89: Compounds discovered by HTS. 
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16 has been discussed at length. Previously it was noted that 17-20 all share a common structural 
similarity and possibly the same inhibitory mode. After this extensive study of pseudo-irreversible 
inhibitors, it is fairly apparent what this mode is. Shown (Figure 90) is a pseudo-irreversible 
chymotrypsin inhibitor (118).199 
 
Figure 90: N-trans-Cinnamoylimidazole. A pseudo-irreversible inhibitor of chymotrypsin used as an active-site titrant. 
The leaving group is an imidazole ring- similar to the nitrogen-containing heterocycle-based compounds discovered from the 
HTS. 
 
The structural similarities to 17-20 are obvious. It appears that sp2 hybridized nitrogens are capable of 
performing the same leaving group role as alcohols. The relatively easy hydrolysis of such 
compounds in an aqueous environment perhaps accounts for the lack of inhibitory activity in some 
assays. 
Compound 21 gives no inhibition. The structure of the commercially obtained material was confirmed 
by LCMS, and the compound was resynthesized by G. Sooranna155 but at no point did this structure 
demonstrate inhibition. 
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4.8.4 What Next? 
The HTS had resulted in the development of highly potent inhibitors, the mode of which was of great 
biochemical interest. In spite of this potency, these inhibitors seemed to be unsuitable for use as 
antiviral agents, which was the purpose of this thesis. Therefore it was decided to abandon the 
investigation into the pseudo-irreversible inhibition of VCPs, and instead attempt to alter the mode of 
action into something more conventional. 
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Chapter 5: Changing the Mode of Action 
This chapter details attempts to channel the potency of the pseudo-irreversible inhibitors into an 
alternative mode of action, more suitable to a biological environment. 
 
Figure 91: Early-stage protease inhibitor design schematic for the proposed conversion of pseudo-irreversible 
inhibitor mechanism. 
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5.1 The Binding of Pseudo-irreversible Inhibitors 
 
The evidence appeared to indicate that pseudo-irreversible inhibitors, though highly potent against the 
enzyme, are an unrealistic way of preventing viral replication inside a cell. Nevertheless, as discussed 
in the previous chapter, it seemed highly likely that the leaving group played a role in the initial 
binding of the inhibitor prior to the formation of the stable acyl-enzyme. It followed therefore that this 
affinity for the enzyme active site might be channelled towards alternative inhibitors with different 
modes of action. 
5.2 Pseudo-irreversible to Reversible 
 
 
Figure 92: Early-stage protease inhibitor design schematic for the intended conversion of pseudo-irreversible 
inhibitors to reversible non-covalent inhibitors. The intention is to effect this by means of synthesizing non-hydrolysable 
analogues of the ester-based pseudo-irreversible inhibitors. 
 
A possible way of achieving this is to design analogues of the pseudo-irreversible inhibitors which 
retain the basic structure but resist the initial cleavage by the protease. The simplest alteration is to 
change the ester bond to a ketone. There is some precedence for this as can be seen in Figure 93.200,187 
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Figure 93: The development of a reversible SARS 3CLpro inhibitors from a pseudo-irreversible inhibitors. In both 
cases, the ester bond is substituted for a ketone, making non-hydrolysable analogues. The new compounds (120 and 122) did 
indeed exhibit reversible inhibition of SARS 3CLpro, though at a much reduced level.187,200 
 
As can be seen, these reversible inhibitors display much less activity than the parent pseudo-
irreversible compound. This is presumably because as the competitive reversible binding of a 
substrate to the enzyme active site will provide less inhibition than the irreversible modification of the 
active site nucleophile. However, the resulting moderate inhibitor is still a relatively small, simple 
compound with the potential to be developed into a larger compound with more binding interactions, 
and hence potency. 
The equivalent compound (124) for the FMDV 3Cpro series is shown below (Figure 94), together with 
another possibility. The amide version 123 is obviously cleavable, but since amide bonds are stronger 
than ester bonds and have a significantly different geometry, the binding of the inhibitor to the active 
site and hence the mode of action could potentially be different. 
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Figure 94: Possible non-hydrolysable analogues of 22. The ketone version, 124, follows the same principle as 120 and 122 
(Figure 93). The amide analogue (123) is another possibility.  
 
5.2.1 Synthesis of the Amide Analogue 
 
Instead of 123, the amine analogue of 96 was synthesized instead, due to the commercial 
availability140 of the amino version of the leaving group (125). 
 
Figure 95: Synthesis of 126. Reagents and conditions: (a) o-Toluoyl chloride, triethylamine, DCM, RT, 98%. 
 
This compound showed no inhibition. This is consistent with previous studies192 in which amide 
versions of ester pseudo-irreversible inhibitors are themselves ineffective. 
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5.2.2 Synthetic Approaches Towards Ketone Analogue 
 
There exists no general method for the synthesis of keto-quinolones such as the putative inhibitor 124. 
A retrosynthetic analysis indicating various different disconnections is shown (Figure 96). 
 
 
Figure 96: Retrosynthetic analysis of ketone 124. Three possible disconnections are shown. The blue route leads to a 
reaction involving the acylation of the methyl group of the quinolone. The red route leads to a ketone attacking the 
electrophilic 4-position of the quinolone. The green route leads to a phenyl nucleophile being acylated by a carboxyl 
derivative incorporating the quinolone. 
 
5.2.2.1 Cine Substitution of 3-nitro 
One established procedure201 which could potentially be adapted is shown in Figure 97. In this 
instance, a ketone can be brought onto the 4 position under relatively mild conditions. 
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Figure 97: Literature synthesis of 129. Ketone 128 is reacted with TNQ (X) (trinitroquinolone) under mild conditions. The 
ketone is substituted at the 4 position for a nitro group at the 3 position (cine substitution). 
 
For the synthesis of 124 therefore, 130 (Figure 98) is required which itself can be synthesised easily. 
 
Figure 98: Planned synthesis of 124. This route relies on the cine reaction in Figure 97. The starting material for that 
reaction is the mononitrated quinolone 130, which is itself easily synthesised. 
 
Before attempting this synthesis it was felt prudent to test some of the synthetic pathways. TNQ (127) 
itself is obtained from the nitration of N-methylquinolone (131). There was some concern as to the 
role of the nitro group in the 8 position. 
 
Figure 99: Synthesis of trinitroquinolone (TNQ) 127. Reagents and conditions: (a) 1:1 H2SO4:HNO3, 100 ºC, 12h, 94%. 
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Indeed there is some evidence202 that the steric crowding of the 8-nitro and N-methyl group leads to a 
distortion which activates the 4 position to cine attack.  
 
Figure 100: A crystal structure of 127 illustrating the steric clash between the 8 nitro group and the N-methyl. This 
clash results in a straining of the molecule which further activates the 4 position to attack.202 
 
If this is indeed the case, the planned synthesis is impractical. Therefore was decided to test the 
reaction beforehand to see if it was viable without the 8-nitro group. 3,6-Dinitro-N-methylquinolone 
(132) had been synthesized previously (Figure 101) during an attempted synthesis of TNQ using 
nitration conditions that were too mild (nitric acid without sulfuric acid). 
 
Figure 101: Synthesis of dinitroquinolone (DNQ) 132. Reagents and conditions: (a) HNO3, 80 ºC, 12h, 86%. 
 
As suspected, the reaction with DNQ (132) did not work, with no change to the starting materials 
being observed by TLC or LCMS. This suggests that the target compound cannot be made via this 
route. 
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Figure 102: Attempted cine substitution on 132. 
 
5.2.2.2 Lepidine Approach 
The next approach relied on the well-established chemistry of lepidine (134) (4-methylquinoline). The 
4-methyl group is sufficiently acidic that lepidine can easily be turned into a nucleophile after 
deprotonation with a moderate base.203,204 
 
Figure 103: Synthesis of 135. Reagents and conditions: (a) LDA, THF, -78 ºC, 30 mins. (b) ArCO2Me, THF, -78 ºC to rt, 6 
hours, 53%. 
 
From here, the challenge is to convert the quinoline function of the 135 to the lactam of the quinolone. 
There are various procedures for this205,206 and it was achieved in reasonable yield for a simple model 
using N-methylation and subsequent oxidation with KMnO4.
207 
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Figure 104: Synthesis of 131. Reagents and conditions: (a) MeI, DCM, rt, 16 hours. (b) KMnO4, MeCN, rt, 30 mins. 
This was then applied to the keto-lepidine system but even using several different oxidants (KMnO4, 
potassium ferricyanide), this reaction could not be achieved. 
 
Figure 105: Attempted synthesis of 137. Reagents and conditions: (a) MeI, acetone, rt, 10 hours. (b) attempts made with: 
(i) KMnO4, MeCN, rt, 3 hours. (ii) Potassium ferricyanide, water. 
 
5.2.2.3 4-Methyl Quinolone as a Nucleophile 
While not as effective in this role as lepidine, 4-methylquinolones (such as 138) demonstrate a certain 
amount of nucleophilicity after deprotonation.208,209 The advantage of this approach is that the target 
compound is obtained directly from this step, with no need for the potentially difficult oxidation step. 
 
Figure 106: Intended us of 4-methylquinolone as an electrophile. 
Before this could be tried 4-methyl quinolone 138 had to be synthesized. This was achieved relatively 
easily using a Pechmann condensation.210 
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Figure 107: Synthesis of 138 using Pechmann condensation. Reagents and conditions: (a) AcOH, 110 ºC, 48 hours. (b) 
H2SO4, 130 ºC, 6 hours, 57 %. 
 
The reaction could then be tried. It was not particularly successful; however it did attain a 7% yield of 
the desired compound. 
 
Figure 108: Synthesis of 137. Reagents and conditions: (a) BuLi, THF, 1 hour, -78 ºC. (b) ArCO2Me, THF, -78 ºC to rt, 5 
hours, 7%. 
 
Unfortunately, 137 displayed no activity against FMDV 3Cpro at 100 µM, and therefore no further 
efforts were made to improve the synthetic yields. 
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5.3 Use of Warheads Against Serine and Cysteine Proteases 
 
 
Figure 109: Early-stage protease inhibitor design schematic for the proposed conversion of pseudo-irreversible 
inhibitors to covalent-warhead type inhibitors. 
 
5.3.1 Reversible Inhibition of Cysteine and Serine Proteases 
 
The lack of activity of 137 illustrated an important point about the nature of serine and cysteine 
proteases which was briefly touched on (section 1.5.5). In the introduction (section 1.4.3) we 
distinguished between proteases which employ a water molecule as a nucleophile (aspartate and 
metallo-proteases) and protease with an intrinsic nucleophile (serine, threonine and cysteine). For the 
former, the tetrahedral intermediates formed during catalysis are at no point covalently bonded to the 
protease; rather the protease stabilises these species via non-covalent interactions. As a result, 
successful inhibition of these proteases can be achieved using chemically unreactive structures 
mimicking these interactions. The large number of non-covalent competitive reversible inhibitors of 
the HIV protease is a testament to the success of this strategy against aspartate proteases. 
 In contrast, serine and cysteine proteases themselves form a covalent bond to the tetrahedral 
intermediates and acyl-enzymes during catalysis. It follows that purely non-covalent inhibitors would 
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struggle to demonstrate high levels of potency against these covalent-catalysing proteases. Non-
covalent serine and cysteine protease inhibitors have been discovered but are generally more 
elusive.114 Furthermore, effective non-covalent inhibitors have generally been discovered by means of 
screening211,212 rather than through rational design by the alteration of substrates. 
 
5.3.2 Warheads 
A more common strategy for the development of serine and cysteine protease inhibitors is the 
attachment of an electrophilic bioisostere to the key portions of the natural substrate (section 1.5.5). 
These warheads can be either irreversible affinity labels (Figure 110) or reversible-covalent transition 
state analogues (Figure 111). 
 
Figure 110: Irreversible covalent warheads acting on a cysteine protease. Examples here are methylketones with a 
leaving group (X), for example halomethyl ketones or acyloxymethyl ketones (section 1.4.4.2). Epoxides, as in E-64, and 
Michael acceptors— unsaturated alkenes conjugated to an electron withdrawing group (EWG). 
 
Figure 111: Reversible covalent warheads acting on a cysteine protease. Examples here are aldehydes and electrophilic 
ketones, specifically α-ketoamide and α-ketoheterocycle. 
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5.4 Pseudo-irreversible to Irreversible 
5.4.1 Concept 
Given the failure of the non-hydrolysable analogue and the general difficulties surrounding non-
covalent inhibition of cysteine proteases it was decided to instead channel the activity of the pseudo-
irreversible inhibitors towards a different form of covalent inhibition. Our strategy was to combine the 
presumed binding ability of the leaving group of the pseudo-irreversible inhibitors with the reactivity 
of a warhead. The basic concept is illustrated in Figure 112: 
 
Figure 112: Development of warhead based inhibitor from pseudo-irreversible inhibitor. 
 
 This can be compared with the peptide based inhibitor discussed in section 1.5.5.2 (Figure 113): 
 
Figure 113: Peptide-based inhibitor 15. Although obtained from a substrate-based design, this compound demonstrates the 
principle of attaching an electrophilic warhead to a binding element. 
 
Here the binding element is the C-terminal side of the cleavage site and the warhead is an unsaturated 
ethyl ester Michael acceptor. 
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The novel aspect of this strategy is the use of a small molecule instead of a peptide as the binding 
element. Given the failure of 15 to demonstrate antiviral activity was suspected to be related to the 
peptidic nature of the molecule,92 a replacement small molecule binding element could potentially 
more successful in this regard. 
 
5.4.2 Initial Design 
 
In terms of the specific warhead to use, unsaturated ethyl ester Michael acceptors have a known 
efficacy based on previous work, as in 15. It was therefore decided to test the concept using this 
warhead, before attempting any improvements in this area. Potential inhibitor structures are shown in 
Figure 114. 
 
Figure 114: Hypothetic warhead based inhibitors. Compounds represent two possible positions for the unsaturated ethyl 
ester Michael acceptor warhead. 
 
5.4.3 Synthesis and Results 
 
Compound 147 was comparatively simple to synthesize using literature procedures 213. Selenium 
dioxide was used to introduce an aldehyde at the 4 position of the commercially available starting 
material 144 149. This aldehyde 145 was then easily converted to a Michael acceptor by means of a 
Wittig reaction 146 with a commercially available Wittig reagent. 
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Figure 115: Synthesis of 147. Reagents and conditions: (a) SeO2, xylene, 150 ºC, 48 h. (b) Wittig reagent 146, THF, rt, 24 
h, 64%. 
 
This compound gave demonstrated 57% inhibition at 100 µM. This was felt to be encouraging, given 
the warhead did not entirely mirror the cleavage site of the pseudo-irreversible inhibitors. The longer 
molecule 143 was thought to be better able to mimic the orientation of the pseudo-irreversible 
inhibitor. The synthesis here was more difficult and ultimately required an extra Wittig reaction to 
achieve the desired homologation. 
There arose some difficulties with the 2-quinolone structure (as described below) and so the chemistry 
was first achieved successfully with the bromopyridine leaving group. 
 
Figure 116: Synthesis of compounds 151 and 153. Reagents and conditions (a) H2SO4, EtOH, 78 ºC, 12h, 93%. (b) 
NaBH4, MeOH, rt, 6 hours, 72%. (c) Dess Martin periiodane, DCM, rt, 30 mins, 96 %. (d) Wittig reagent 146, THF, rt, 24 h, 
80%. (e) NaHMDS, THF, -78 ºC, (Methoxymethyl)triphenylphosphonium chloride, 76%. (f) THF, 2M HCl, rt, 6 h, then (d) 
42%. 
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This synthetic route for the 2-quinolone produced a set of isomers which could not be separated by 
chromatography (either conventional silica chromatography or reverse phase HPLC). The suspected 
structures (143 and 156) are shown. 
 
Figure 117: Attempted synthesis of 143. Reagents and conditions (a) SeO2, xylene, 150 ºC, 48h, 69 %. (b) NaHMDS, 
THF, -78 ºC, (Methoxymethyl)triphenylphosphonium chloride, 64 %. (c) THF, 2M HCl, rt, 8 hours. (d) Wittig reagent 146, 
THF, rt, 24h. 
 
Ultimately neither of the bromopyridine-based Michael acceptors (151 and 153) nor the mixture of 
compounds (143 and 156) displayed any inhibition. 
5.5 Assessment of Leaving Group Binding Efficacy 
The attempts at adapting the pseudo-irreversible inhibitors had been largely unsuccessful. Only the 
Michael acceptor 147 had demonstrated any inhibition. This indicated that although our reasoning as 
to the binding role of the leaving group may well be correct, the binding is insufficient to enable the 
use of a warhead. Another possibility is that the aromatic acyl group also plays a role in the initial 
binding. If we adapt inhibitor 147, potentially 157 (Figure 118) would be a more potent inhibitor. 
150 
 
 
Figure 118: Potentially more successful inhibitor. This concept relies on the aromatic acyl group of the pseudo-
irreversible inhibitors also playing a role in the initial binding to the enzyme active site. 
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5.6 Alternative Binding Groups 
Although the leaving group approach proved ineffective, the fundamental idea of adding a warhead to 
a binding element remains reasonable. The peptide derived inhibitor 15 is based around adding a 
warhead to the natural binding element, i.e. the key portion of the viral polypeptide. 
This approach produced a potent inhibitor, but one whose peptide nature precludes antiviral activity. 
The use of a small molecule binding element would hopefully be more successful in this aspect. 
Table 11: Comparison of warhead-based compounds with peptide or small molecule binding components. 
Binding Component Warhead 
Compound IC50 (µM) 
 
 
15 0.68 
 
 147 
54% @ 100 µM 
With the binding of the leaving group having proved insufficient for effective inhibition, it was a 
question of finding a new and more effective small molecule binding element. 
All leads from the HTS had by this point been exhausted and so it was necessary to attempt to adapt 
compounds from similar strategies attempted against different VCPs. 
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5.7 Benzamide HRV Inhibitors 
As discussed in the introduction (section 1.5.3.1), there are two basic methods to obtain such binding 
elements: rational design and random screening. A series of benzamide-based inhibitors have been 
designed to inhibit HRV 3Cpro.107 
 
Figure 119: Early-stage protease inhibitor design schematic for benzamide-type HRV inhibitors. This series is based 
on a small molecule approximation of the P1 glutamine residue with a Michael acceptor warhead. 
 
5.7.1 Design 
The basic concept is illustrated in Figure 120. Initial design was deliberately very simple:  positioning 
a warhead so that it could react with the nucleophilic cysteine and placing a carboxamide group in the 
S1 recognition pocket to mimic the P1 glutamine. A meta-substituted phenyl ring positioned these two 
elements with the appropriate distance and relative orientation leading to 157, which inhibited HRV 
3Cpro (Kobs/[I] = 52 M
-1s-1) and also displayed antiviral activity (EC50=15.9 µM). 
153 
 
 
Figure 120: Design process for benzamide binding element. The meta-substituted ring positions the amide and the 
electrophilic centre in approximately the same positions as the P1 glutamine/scissile bond in the natural substrate.107 
 
These inhibitors were developed further. An extensive SAR study on the 5 position resulted in 159, 
which inhibited the protease with Kobs/[I] = 139 M
-1s-1 and displayed an exceptional EC50 of 600 nM. 
 
Figure 121: Further developments of the meta-benzamide concept. 159 is an improved analogue of 158, with extensive 
augmentation in the 5 position.107 The isatin compound 160 relies on the electrophilic ketone of the cyclic α-ketoamide as a 
warhead.214 
 
There are clear structural similarities between 158 and a well-known isatin class of HRV inhibitor (for 
example 160) which was discovered using a similar rationale.214 In this case, the warhead was an 
isatin (effectively a cyclical α-ketoamide). These compounds demonstrated superb activity against the 
protease, but were generally ineffective against the virus and also highly toxic.215 
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Despite this, meta-substituted benzamides are clearly highly effective against HRV 3Cpro and so have 
potential against the closely related FMDV 3Cpro. 
 
5.7.2 Synthesis and Results 
 
Fortunately, the synthesis of these compounds is described fully in the literature.107 One method starts 
from the commercially available 3-iodobenzoic acid (161).140 The acid is converted to the amide (162) 
by chlorination followed by reaction with ammonia, and then the unsaturated ethyl ester is coupled to 
the ring by Heck reaction. 
 
 
Figure 122: Synthesis of 158. Reagents and conditions: (a) Oxalyl chloride, DCM, DMF, rt, 1 hour. (b) 18% NH3 (aq), 
83%. (c) ethyl acrylate, palladium diacetate, triethylamine, MeCN, 70ºC, 12h, 38 %. 
 
The compound demonstrated inhibition against FMDV 3Cpro (32% inhibition at 100 µM), but not to 
the levels against HRV 3Cpro. This is perhaps an indication that the meta-substituted benzamide does 
not approximate the P1 glutamine as well in FMDV 3Cpro as it does in HRV 3Cpro. 
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5.8 4-Quinolone HRV 3Cpro Inhibitors 
5.8.1 Design 
Another option was based around work done by AstraZeneca in an effort to develop non-covalent 
inhibitors of HRV.216 An NMR-based assay discovered the 2-phenyl-4-quinolone (163) scaffold as a 
weak but non-covalent reversible inhibitor. The more-soluble analogue 164 also displayed inhibition  
 
Figure 123: Compounds discovered during AstraZeneca development. 163 was discovered by an NMR-based HTS, 
while 164 was an analogue designed to improve solubility.216 
 
A crystal structure of 163 bound to HRV 3Cpro which lead to several further developments. 
 
 
Figure 124: X-ray crystal structure of 163 bound to HRV 3Cpro. As can be seen, the active site cysteine nucleophile is 
oriented close to the 6 position allowing the insertion of a warhead in this position to enhance potency.216 
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The crystal structure indicated scope for hydrophobic and pi-stacking interactions with His40 at the 7 
position. The addition of a benzyl group to this position did indeed increase activity while retaining 
the reversible non-covalent mode of action. 
 
Figure 125: 164, a 7-benzyl analogue of 163. The benzyl group enhances potency by allowing further non-covalent 
interactions, specifically pi-stacking with His40.216 
 
As can also be seen, the catalytic cysteine is close to the 6 position. This enabled the SMW approach 
to be taken. The insertion of warheads at this position produced some moderately effective 
irreversible (166, IC50= 10 µM) and covalently reversible (167, IC50= 1 µM) inhibitors. 
 
 
Figure 126: 166 and 167, based on the 4-quinolone core with the addition of a warhead in the 6 position.216 
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5.8.2 Basic Synthesis 
 
 
Figure 127: Early-stage protease inhibitor design schematic for 4-quinolone-type HRV inhibitors. The NMR-based 
assay discovered non-covalent small molecule inhibitors. The potency was low, but could be improved by the addition of a 
warhead. 
 
The synthesis of compound 163 was well documented in the literature, and relatively straightforward. 
Thus it was decided to synthesize this compound and 164 and compare any FMDV 3Cpro activity 
against the literature values for HRV. If the comparison was sufficiently favourable, syntheses of the 
more complex compounds (165, 166 and 167) could be attempted. 
There are various ways to make 2-aryl-4-quinolones. Based on the available materials, the pathway 
shown in Figure 128 was attempted. 2-aminoacetophenone (168) was benzoylated,217 and then 
cyclised with sodium hydroxide.218 The difficulty was in purification, as 4-quinolones are sufficiently 
insoluble that purification by conventional or reverse-phase chromatography is difficult. Ultimately, 
163 could be precipitated out of a biphasic mixture in sufficient purity (>95%). 
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Figure 128: Synthesis of 163. Reagents and conditions: (a) Benzoyl chloride, Et3N, DCM, rt, 12 h, 99%. (b) NaOH, 1,4-
dioxane, 60 ºC, 1 hour, 85 %. 
 
The scaffold of 164 is significantly less well documented than the 4-quinolone. The chosen route 
involves the condensation of ethyl benzoylacetate 171 and 170.219 
 
Figure 129: Synthesis of 164. Reagents and conditions: (a) AcOH, 110 ºC, 12 hours, 55 %. 
 
5.8.3 Initial Results 
The activity of 164 could not be measured using the FRET4 assay as 164 turned out to be a 
fluorophore and so minor changes in fluorescence could not be observed. 
163 on the other hand, could be observed to be inhibiting FMDV 3Cpro (37% at 100µM) at levels 
comparable to the HRV protease. 
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Table 12: Activities of compounds from AstraZeneca HTS. 
Compound Structure 
HRV 3Cpro 
Inhibition (100 µM) 
FMDV 3Cpro 
Inhibition (100 µM) 
163 
 
35% 37% 
164 
 
44% nd 
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5.8.4 Synthesis of Substituted 4-Quinolones 
With this positive confirmation of the molecular recognition of 163 by FMDV 3Cpro, it was decided to 
synthesize the warhead analogues (166 and 167) in an attempt to obtain inhibitors of similar potency 
as was demonstrated against HRV. 
5.8.4.1 Difficulties 
4-Quinolones present a significant synthetic challenge.220 
 Solubility  
As discussed, 4-quinolones are highly insoluble to most solvents, both polar and nonpolar. 
This is probably due to their flat nature and presumed tendency to pi-stack. 
 Reactivity 
The reactivity of 4-quinolones is not well documented in the literature. The corresponding 2-
quinolone, the scaffold of which has been used extensively in this thesis (for example 88), is 
relatively inert. However it is unknown to that extent the quinolone adapts the 4-
hydroxyquinoline tautomer (Figure 130), and to what extent the amine is deactivated by the 4-
carbonyl. 
 
Figure 130: Tautomerism of 4-quinolone to 4-hydroxyquinoline. 
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5.8.4.2 Possible Approaches 
There are a number of approaches to synthesising substituted 2-aryl-4-quinolones. Those of relevance 
here are summarized in Figure 131. 
 
 
Figure 131: Retrosynthetic analysis of substituted 2-aryl-4-quinolone. Route A involves the condensation of 2-
hydroxyacetophenone and an aldehyde. Route B involves the condensation of aniline and a 1,3-ketoester. Route C is via the 
2-amideacetophenone intermediate (as in Figure 128). This can be achieved via acylation of the 2-aminoacetophenone as 
before, or else via amidation of 2-haloacetophenone.  
 Flavylium condensation approach 
This approach221 relies on the rapid condensation of a 2-hydroxyacetophenone with an aryl 
aldehyde. The reaction pathway is shown below: 
 
 
Figure 132: Synthesis of substituted 4-quinolone (173) via flavylium intermediate (179). The flavylium is synthesized 
by condensation of a 2-hydroxyacetophenone (174) with an aldehyde and triethyl orthoformate in the presence of perchloric 
acid. The flavylium is then converted to the quinolone by reaction with ammonia. 
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On appearance, this way is perfect, as it allows the generation of virtually any substituted 2-
aryl-4-quinolne; given that the synthesis of substituted 2-hydroxyacetophenones is 
comparatively simple. 
However this reaction pathway relies on the precipitation of the intermediate 179 and the 
product. As such, altering the structures excessively may prevent this occurring. 
 Aniline condensation 
This involves the reaction of an aniline and a 1,3-keto ester. Enamination of an aniline is 
followed by a rapid cyclisation at high temperature.222 Incidentally this is the opposite of a 
similar reaction carried out previously (Figure 107) in which the amine reacts first with the 
ester to form the 2-quinolone. 
 
Figure 133: Synthesis of compounds of type 173. Reagents and conditions: (a) Cyclohexane, TsOH, 80 ºC, 12 hours. (b) 
Ph2O, 230 ºC. 
 Via 2-amidoacetophenone 
This approach has already been used to generate 163. An alternative route to intermediates of 
type 169 is via the amidation of 2-haloacetophenones.218 
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5.8.4.3 Aniline Plus 1,3-Ketoester Method 
It was then decided to pursue the route shown in Figure 134. In this case, p-bromoaniline (181) is 
reacted with ethylbenzoyl acetate to generate 6- bromoquinolone (182). The Michael acceptor group 
could then be introduced via Heck reaction to obtain 183. 
6-Bromo-2-benzyl-4-quinolne could indeed be easily generated from the corresponding aniline. 
 
Figure 134: Attempted synthesis of 183. Reagents and conditions: (a) Ethyl benzoylacetate, TsOH, cyclohexane, 100ºC, 16 
h. (b) Ph2O, 230 ºC, 30 min, 51 %. 
With this compound made, the subsequent Heck reaction could be attempted. This reaction was 
unsuccessful, indicating to us that 4-quinolones are unsuited to this type of chemistry, perhaps for 
reasons both of solubility and reactivity. 
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5.8.4.4 Protecting Groups 
With the difficulties surrounding the chemistry of 4-quinolones, a new approach was needed. A 
suitable protecting group would convert the 4-quinolone into something more inert and hopefully 
more soluble. Ultimately, the benzyl group was decided upon.223 Refluxing the 182 in DMF with 
benzyl bromide converted to 4-benzyletherquinoline 184. This compound was indeed more soluble 
and also underwent the Heck reaction with good yield to form 185. 
 
Figure 135: Synthesis of 183. Reagents and conditions: (a) K2CO3, benzyl bromide, DMF, 60 ºC, 12 hours, 80%. (b) ethyl 
acrylate, palladium diacetate, triethylamine, MeCN, 80 ºC, 16 h, 93%. (c) TFA, 60 ºC, 12h. 
 
The standard method of benzyl deprotection is hydrogenolysis.224 This reaction has the potential to 
reduce the Michael acceptor warhead however, and so an alternative method is desirable. Strong acids 
such as HBr and TFA have the potential to effect debenzylation.225 A standard TFA Boc deprotection 
(i.e 10% TFA in DCM, stirred for 1 hour) showed a partial effect. In the end, refluxing 185 overnight 
in pure TFA released the 4-quinolone 183 in acceptable yield and moderate purity. 
Using the same principles, aldehyde 190 could also be prepared. The reaction pathway is shown in 
Figure 136. First, 186 with an ester in the 6 position is synthesized. 186 is protected and then reduced 
and oxidised to the aldehyde 189. 189 is deprotected using the TFA method to obtain 190. 
165 
 
 
Figure 136: Synthesis of 190. Reagents and conditions (a) K2CO3, benzyl bromide, DMF, 60 ºC, 12 h, 88 %. (b) LiAlH4, 
THF, 0 ºC, 3 h, 88 %. (c) Dess-Martin periiodane, DCM, rt, 30 mins, 95 %. (d) TFA, 60 ºC, 4 h. 
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5.8.5 Results and Discussion 
 
Compound 183 was found to inhibit FMDV 3Cpro with an IC50 of 32 µM. This was less than the stated 
value for HRV (10 µM) but still an effective inhibitor. 
Surprisingly, aldehyde 190 displayed no inhibition at all. This was at odds with the literature, in which 
the aldehyde analogue is the more potent. 
 
Table 13: Comparison of aldehyde and Michael acceptor warheads for benzamide and 4-quinolone-based inhibitors. 
HRV activities taken from Baxter et al.216 and Reich et al.107 
Compound Structure 
HRV 3Cpro 
IC50 (µM) 
FMDV 3Cpro 
IC50 (µM) 
183 
 
10 32 
190 
 
1 >100 
158 
 
Kobs/[I] = 52 M
-1s-1 32% @ 100 µM 
191 
 
>100 _ 
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However in retrospect this was itself a contentious result. Reich et al. found that the aldehyde version 
of their Michael acceptor (191) displayed very poor inhibition.107 Aldehydes are generally effective 
warheads and so Reich et al. ascribed this to the difference between aryl aldehydes and those beta to 
an amino acid. Since the aldehyde 190 is also an aryl aldehyde, one would expect this compound to be 
significantly less effective than the Michael acceptor version which is what was observed against 
FMDV. 
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5.9 Conclusions 
 
Table 14: Comparison of different binding components with Michael acceptor warhead. 
Binding Component Warhead Compound IC50 (µM) 
 
 
15 0.68 
 
 
147 45% @ 100 µM   
 
 158 
37% @ 100 µM   
 
 
183 32 
 
In any case, compound 183 displayed an IC50 of 32 µM which, though not especially potent, is the 
most effective non-pseudo-irreversible inhibitor developed so far in this study. The structure of this 
compound remains relatively simple thus allowing further modification to increase potency. 
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Chapter 6: Peptides and Warheads 
The small molecule approach had met with a number of setbacks. It was decided to switch focus to 
the substrate based design approach. An analysis of the potential issues with the family of inhibitors 
developed by N. Roqué-Rosell was carried out, and potential solutions were worked towards. 
 
 
Figure 137: Early-stage protease inhibitor design schematic for the peptidyl warhead inhibitors. This strategy mirrors 
the development of rupintrivir as discussed in the introduction (section 1.5.5). 
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6.1 Summary of Previous Work 
 
As mentioned in the introduction a previous attempt to develop anti-FMDV inhibitors was undertaken 
using the rational design approach. The upshot was compound 15 shown in Figure 138 which had 
excellent potency against the enzyme but no antiviral activity.92 
 
Figure 138: Compound 15 based on tetrapeptide with C-terminal Michael acceptor. 
 
6.1.1 Potential Problems 
 
As for the pseudo-irreversible inhibitors, there were a number of potential reasons why this compound 
proved ineffective in a cell assay. 
1. Positive charge. The P2 Lysine was found to be crucial in attaining decent potency against 
the enzyme. However primary amines are notorious for their lack of cell permeability.71 
2. Peptide backbone. Peptides of above a certain length are generally unsuitable as drugs due to 
lack of cell permeability and a vulnerability towards metabolism by host hydrolases 
(discussed in section 1.5.3.2).  
3. Michael acceptor. The irreversible warhead is itself vulnerable to attack by nucleophiles 
other than the target thiol. The rupintrivir development indicates that this unsaturated ethyl 
ester Michael acceptor is unreactive towards DTT,121 however nonspecific reactivity cannot 
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be ruled out— particularly considering the high concentration of free thiols in mammalian 
cells.226 
4. Ester. The warhead also contains an ester- which, as we have seen, is a functional group 
liable to be hydrolysed. The product of this cleavage, an unsaturated carboxylic acid, has been 
found to be relatively ineffective against the HRV protease.121 
 
6.1.2 Previous Attempted Solutions 
 
Of these potential problems, the positively charged lysine residue was thought to be the biggest 
barrier to cellular activity. Several approaches were tried to eliminate the positive charge while 
retaining the affinity of 15 for the enzyme. 
6.1.2.1 Other Basic Residues 
Analogues of 15 were synthesized with different basic P2 residues in the hopes of retaining enzyme 
potency while altering the structure in the hope of obtaining cellular activity. Arginine and histidine 
both retained enzymatic potency, but displayed no antiviral activity.92 
6.1.2.2 The Prodrug Approach 
The basic idea is to “mask” the positive charge such that a neutral version of the compound can enter 
the cell. Once inside the prodrug is metabolised and the true inhibitor released. 
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Figure 139: Prodrug approach. Amidine 192, can be masked as the N-hydroxyl version 193. This species would not be 
protonated under biological conditions and so cell-entry would not be prevented. Once inside the cell, the masked drug is 
metabolised back to the initial amidine, allowing the compound to exhibit its activity. 
 
In this instance, the lysine side chain was switched to homo-arginine which was almost as effective 
enzymatically (IC50 = 1.2 µM). The guanidine group of arginine could be masked as the N-
hydroxylated version. This approach has been successfully used to mask amidine groups (Figure 
140).227, 228 
 
Figure 140: Prodrug compound incorporating the masked guanidine residue 194. The rationale was that after cell entry, 
the N-hydroxyl-guanidine would be metabolised to release the positively-charged homo-arginine residue which could form 
the necessary interactions for potency against the viral protease. 
 
It was found that the hydroxylation did not decrease the enzyme potency by much (IC50 = 2.7 µM). 
Unfortunately, this approach did not produce any success, with no antiviral activity being observed.92 
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6.2 New Approaches 
 
6.2.1 Synthesis 
 
Before new approaches can be discussed, it is necessary to introduce the synthesis of these substrate-
based inhibitors. As discussed (section 2.2.3) SPPS is the preferred method of synthesizing peptides 
of over 3 or 4 residues in length. The difficulty here is that SPPS generally involves the attachment of 
the C-terminus to resin and the growth of the peptide on the N-terminus. The inhibitors have a 
Michael acceptor warhead instead of the usual C-terminus acid, and so this approach is impossible. 
The eventual path pursued by Roqué-Rosell92,122 was to instead anchor the peptide to the resin via the 
P1 side chain. Rink amide resin141 allows an acid group to be coupled and then released as an amide. 
Therefore an Fmoc-protected glutamic acid, with a Michael acceptor instead of a C-terminus can be 
coupled to the resin. 
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Figure 141: The use of Rink amide resin and glutamic acid to generate C-terminal Michael acceptors with a P1 
glutamine. 
 
The peptide can then be built up on the N-terminus using Fmoc SPPS. Standard conditions will cleave 
the peptide from the resin with the acid now as an amide (i.e glutamic acid has become glutamine). 
The required glutamic acid Michael acceptor 195 can be synthesized from the commercially available 
Fmoc-protected amino acid in three steps. 
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Figure 142: General synthesis of peptidic Michael acceptors. Reagents and conditions: (a) HBTU, Weinreb base, DIPEA, 
DMF, rt, 12 hour, 79 %. (b) LiAlH4, THF, -78ºC, 1 h. (c) Wittig reagent 146, THF, rt, 24 h., 89% (d) 10% TFA in DCM, 2h 
(e) 20% piperidine in DMF, 88%. (f) HOAt, HATU, DIPEA, DMF, rt, 2 h. (g) Fmoc SPPS. (h) TFA/H2O/TIS, 95:2.5:2.5, rt, 
3 h, 37%. 
 
All inhibitors discussed in this section were synthesized by this route. 
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6.2.2 Methylation of Lysine 
 
Another potential solution to this problem is to substitute the primary amine for a tertiary one. The 
relationship between amine structure and pKa is complicated. Although basicity is generally improved 
by the addition of alkyl groups (secondary amines are invariably more basic than primary amines), for 
reasons of solubility and steric hindrance, tertiary amines are often less basic than primary, in spite of 
their alkyl group activation.229 
 
Figure 143: pKa of alkyl-substituted ammonium ion. pKa increases from ammonium to dimethylammonium due to 
electron donation by the alkyl substituents. This donation is compensated by less favourable solvation of the sterically 
hindered tertiary cation in trimethylammonium.229 
It was possible therefore that the dimethyl lysine analogue 202 of the P2 residue would remain 
deprotonated in biological conditions and so retain cell permeability. The tertiary amine would 
hopefully retain some affinity for the P2 pocket, leading to a decent compromise between cell 
permeability and enzyme potency.  
Fmoc dimethyl lysine is commercially available,141 and so this analogue could be easily synthesized 
using SPPS. 
 
Figure 144: Methylation of P2 lysine. The concept is that the alkylation of the amine would lower the pKa to the extent the 
compound is not protonated at biological pHs and so has greater permeability than the parent compound. 
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Compound 202 (IC50 = 1.30 µM) remained fairly potent against the enzyme (though less potent than 
15) but demonstrated no antiviral activity (tested by M. Windsor (Pirbright Institute)). 
 
6.2.3 Use of Neutral Residue. 
 
Although the use of a cationic P2 residue gave an excellent potency against the enzyme, it was an 
option was to use a neutral residue instead. This would involve a drastic reduction in enzyme 
inhibition, a price worth paying if cell permeability and antiviral activity are achieved. Therefore 
analogues of inhibitor 15 were synthesized with a different P2. These residues were leucine, 
norleucine (mimics a lysine without the ε-amine), phenylalanine and threoine (present in several of 
the polyprotein cleavage sites).These, and their enzyme activities are shown in Table 15. 
 
 
Table 15: Comparison of tetrapeptide Michael acceptors with different P2 residues. 
Compound P2 -R IC50 (µM) 
15 Lys  0.68 
203 Leu 
 
12 
204 nLeu  20 
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205 Phe 
 
23 
206 Thr 
 
80 
 
As suspected, the lack of positive charge resulted in reduced activity. The best compound was the P2 
Leu (203) with a moderate IC50 of 12 µM. Although this had considerably less potency than the parent 
compound (16) it was hoped that the cell permeability had improved such that some antiviral activity 
would be manifested. However none of these compounds demonstrated any activity against the virus 
(M. Windor). 
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6.2.4 Cell Penetrating Peptides 
 
Cell penetrating peptides (CPPs) are short peptides that facilitate cellular uptake of various molecular 
cargo (from nanosize particles to small chemical molecules and large fragments of DNA).230 The 
"cargo" is associated with the peptides either through chemical linkage via covalent bonds or through 
non-covalent interactions.231 The function of the CPPs are to deliver the cargo into cells, a process that 
commonly occurs through endocytosis with the cargo delivered to the endosomes of living 
mammalian cells. CPPs typically have an amino acid composition that either contains a high relative 
abundance of positively charged amino acids such as lysine or arginine. 
The precise mechanism of CPP cell entry is uncertain. Consensus seems to be that the polycationic 
structure of the CPPs is thought to manipulate the cellular endocytosis in some way.232,233 
 
Figure 145: Early-stage protease inhibitor design schematic for the use of CPPs to boost the cell permeability of 
protease inhibitors. 
 
The basic strategy was to use the developed chemistry to synthesize CPPs with a 3Cpro inhibitor on the 
C-terminus. Since CPPs consist of multiple basic residues, the P2 lysine should no longer be a barrier 
to cell penetration. 
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As there are many CPPs, it was decided to use two of the best-known and most effective: HIV Tat and 
Penetratin, both of which have demonstrated efficacy at improving the cellular activity of biologically 
active compounds.234,235 
 
Table 16: Activities of CPP-based inhibitors. 
Compound CPP -R IC50 (µM) 
15 - Ac-PAK 0.68 
207155 HIV-Tat GRKKRRQRRRPPQAPAK 0.85 
208155 Penetratin RQIKIWFQNRRMKWKKAPAK 0.90 
 
The first question was whether adding a vast sequence to the N-terminus would affect the activity of 
the binding sequence and warhead. Both CPP-based inhibitors demonstrated similar levels as 15. 
However neither peptide showed any effect in the cell-based assay (M. Windsor). 
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6.3 Peptide Backbone 
A possible interpretation of this continuing lack of success is that the four-residue (and the longer 
CPP-based) inhibitors are simply too long and peptide-like for success in a cellular system. As 
discussed in the introduction (section 1.5.3.2) peptides generally make poor drugs due to their easy 
hydrolysis by metabolic processes and the decreasing levels cell-permeability as the number of amide 
bonds increases.100 Thus it was decided to reduce the length in an attempt to make the inhibitors more 
druglike at the expense of enzyme potency. 
 The Z group was decided on as a capping group, as it had given effective results in previous 3Cpro 
studies,236,237 and indications were that bulkier capping groups were more effective than the acetyl 
group for shorter peptides.127 
 
Table 17: Activities of tri- and dipeptides. 
Compound Sequence IC50 (µM) 
209 Z-Ala-Lys 0.86 
210 Z-Ala-Lys(Me)2 10.5 
211 Z-Ala-Leu 60% @ 100µM 
212 Z-Lys 5.4 
213 Z-Lys(Me)2 16.8 
214 Z-Leu 37% @ 100µM 
 
As can be seen, the lysine containing compounds (209 and 212) retained excellent potency with three 
residues and a moderate amount with two. The dimethyl lysine analogues were less potent, and the 
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leucine analogues (211 and 214) were fairly inactive. The two residue dimethyl lysine analogue (213) 
was tested in the cell assay up to 500 μM but demonstrated no antiviral activity. 
 
6.4 Boosting the Activity 
 
The shorter peptides had lost so much potency against the enzyme that this lack of antiviral activity 
was felt to be inconclusive. If the potency of these compounds could be improved in some way and 
taken back up to the levels of 15, then the test for antiviral activity would be more decisive. 
 
6.4.1 Glutamine Analogue 
 
To improve the potency, we made use of the rupintrivir development against HRV (section 1.5.5.1).123 
Like FMDV 3Cpro, HRV 3Cpro favours a P1 glutamine. Upon examination of the binding of this P1 
glutamine it was noted that only one of the amide protons was involved in hydrogen bonding with the 
protease. It had further been observed that dimethyl and methyl glutamine analogues had a negative 
effect on activity. 
Therefore to fix the amide protein into the correct orientation for a favourable reaction, the lactam 
analogue (Figure 146) was developed. This proved to have an excellent effect on enzymatic and 
cellular potency.123 
 
Figure 146: Development of lactam-based glutamine analogue. 
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6.4.2 Synthesis 
 
It was therefore decided to employ this glutamine analogue in the P1 position against FMDV 3Cpro. 
This lactam analogue has been of some interest to antiviral researchers, and so the synthesis, while 
difficult, is also reasonably well established.238,239,236 The starting point is Boc-protected glutamic acid 
(215). After dimethylation, 216 is deprotonated by LiHMDS and reacted with a bromoacetonitrile 
electrophile. This reaction proceeds with excellent selectivity. 217 is then cyclized, normally with 
hydrogenation. 
With the lactam ring (218) constructed, the Michael acceptor warhead was added in. This was 
achieved by reduction with LiBH4 of the methyl ester. The resulting alcohol was subjected to one pot 
oxidation and Wittig reaction. 
 
 
Figure 147: Synthesis of 220. Reagents and conditions: (a) MeI, NaHCO3, DMF, 96 h, rt, 92%. (b) LiHMDS, THF, -78ºC. 
(c) Bromoacetonitrile, THF, -78ºC, 4 h, 90%. (d) NaBH4, CoCl2, MeOH, rt, 48 h, 41%. (e) LiBH4, THF, rt, 98%. (f) Py•SO3, 
DMSO, DCM, 35%. (g), Wittig reagent 146. (f) TFA. (g) EDCI, DIPEA,DMF.  
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Compound 219 consists of the new P1 residue and a Michael acceptor warhead. This compound was 
deprotected and coupled onto Z-protected lysine and leucine. The resulting compounds are shown in 
Table 18. Both compounds did indeed show enhanced potency against the enzyme, indicating the 
glutamine lactam was an improvement for FMDV 3Cpro as with HRV. The compounds were then 
tested for antiviral activity (M. Windsor). 
Compound 221 demonstrated no activity, but 222 did— showing an EC50 of 72 µM. 
 
Table 18: Activities of glutamine analogue based inhibitors with different P2 residues. 
Compound Structure IC50 (µM) EC50 (µM) 
221 
 
0.67 >100 
222 
 
3.7 72 
 
This was an enormous breakthrough and the first time antiviral activity had been achieved against 
FMDV using 3C protease inhibitors. This also confirmed our reservations about the P2 Lysine— 
although 221 demonstrates more enzyme activity than 222, it is ineffective against the virus; most 
likely due to the charged lysine residue preventing cell penetration. 
185 
 
6.4.3 Changing the Warhead 
6.4.3.1 Aldehyde  
Although the unsaturated ethyl ester is an effective warhead against 3Cpro, there was evidence that 
other warheads might provide more potency. 236,240 
Another advantage of using the lactam glutamine analogue is that it enables an aldehyde to be used as 
the warhead. An aldehyde cannot be used with the P1 glutamine as the primary amide will attack and 
cyclise (Figure 148).241 
 
Figure 148: Representation of the behaviour of glutamine with a C-terminal aldehyde. The cyclised form is favoured in 
aqueous solution and, it is presumed, has no efficacy as a warhead. This renders the aldehyde as unsuitable for use with a P1 
glutamine.241 
 
The aldehyde warhead has proved more effective against other cysteine proteases such as SARS236 
and HRV216 and so the aldehyde version of 222 (i.e 227) could be significantly more effective. 227 
was synthesized by coupling Z-Leu directly to the lactam methyl ester 218 to form 225 and then 
reducing with LiBH4 and oxidising with Dess-Martin Periiodane. 
 
Figure 149: Synthesis of 227. Reagents and conditions: (a) LiBH4, THF, rt, 4 h, quantitative. (b) Dess-Martin periiodane, 
DCM, rt, 3 h, 67 %. 
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6.4.3.2 α-Ketoamide 
  
There are some drawbacks to the use of aldehydes. Aldehydes are inherently unstable and an 
unrealistic option for a clinical drug. There are a number of electrophilic ketones which combine the 
potency of aldehydes with the stability of Michael acceptors. A particularly relevant example is α-
ketoamides. 
In recent years these have been used extensively against the HCV protease (a serine protease) and 
have resulted in a couple of highly effective clinical drugs (Figure 150).116,115 
 
Figure 150: Boceprevir 116, an anti-HCV protease inhibitor based around an α-ketoamide warhead. 
 
α-Ketoamides are also effective against cysteine proteases.242,106,243 
Another advantage of α-ketoamides compared with aldehyde is that more groups can be added to their 
terminal nitrogen in order to pick up more interactions on the P’ side of the scissile bond. Aldehydes 
can only ever be a terminal group. It was decided to use an isopropyl group on the amide to provide 
structural similarities to the P1’ leucine and also because this warhead has been seen to have efficacy 
against other viral proteases.237 Figure 151 displays the target compound 229. 
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Figure 151: Target compound with isopropyl α-ketoamide warhead. 
  
The compound in question was synthesized from the aldehyde 227. What followed was a reaction 
with an isocyanate in a Passieri-type reaction.244 The immediate product was the α-acetateamide 230 
which could be cleaved to form an α-hydroxideamide 231. This could be oxidised to give the target 
compound 229. 
 
Figure 152: Synthesis of 229. Reagents and conditions: (a) Isoproylisonitrile, acetic acid, ethyl acetate, 18h, rt. (b) K2CO3, 
MeOH, water, 2h, rt. (c) Dess-Martin, DCM, rt, 1h, 63%. 
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6.4.3.3 Warhead Results 
 
Compounds 227 and 229 were tested for activity against both enzyme and virus, and the results are 
shown in Table 19 together with Michael acceptor 222 for comparison. 
 
 
Table 19: Comparison of different warheads. 
Compound Warhead IC50 (µM) EC50 (µM) 
222 
 
3.7 72 
227 
 
0.66 27 
229 
 
30 >100 
 
As can be seen, the aldehyde proved more potent than the Michael acceptor both against the enzyme 
and the virus. The α-ketoamide on the other hand proved to be a modest inhibitor of the enzyme and 
demonstrated no antiviral activity. 
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6.5 Rupintrivir 
 
Rupintrivir (14) was also obtained commercially and tested. It proved highly potent against the 
enzyme (IC50 = 0.84 µM) and also demonstrated activity against the virus (EC50 = 47 µM). 
 
 
Figure 153: Rupintrivir 14. This compound possesses the lactam glutamine analogue P1 together with the unsaturated ethyl 
ester Michael acceptor warhead. P2 is a p-fluoro analogue of phenylalanine and the central amide bond is replaced by a 
ketone. The capping group is also unusual. 
  
A logical comparison here is with 222. Both inhibitors possess the same Warhead and P1 residue, but 
rupintrivir is more potent against both enzyme and virus. The possible reasons for this, relating to 
rupintrivir’s unusual remaining structure will be discussed in section 6.6. 
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6.6 Assessment 
The lessons learned thus far were as follows: 
 Warhead 
A comparison between 222 and 227 indicates that the aldehyde is more effective than the 
Michael acceptor. 
 P1 
The glutamine analogue appears to be far more effective than natural glutamine. 
 P2 
As had been suspected, the P2 lysine, while providing optimal potency against the enzyme, 
prevent cell-based activity; presumably by preventing cell permeability. Of the other residues 
tested, leucine appears to be the most effective; although there is no real comparison with the 
p-fluoro phenylalanine of rupintrivir. 
 Chain length 
Comparison between rupintrivir 14 and 222 indicate that the extra chain length improves 
antiviral activity. At the level of enzyme potency this would certainly be expected based on 
previous comparisons between different chain lengths (section 6.3). 
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6.7 Increasing the Chain Length 
And so a potential way of increasing the potency of 227 was to add in the P3 residue. The 
hypothetical molecule is shown in Figure 154. 
 
Figure 154: Target compound with P3 alanine residue. 
As has been discussed, making a peptide of this length in solution phase is a considerable challenge. 
The polar nature of the compounds makes isolating and purifying the compounds difficult. The 
eventual route is shown (Figure 155). Ultimately the same pathway as for the previous aldehyde 227 
was used, together with an initial synthesis of the Z-Ala-Leu-OH fragment 233. Because of the 
discussed difficulties of making peptides of this length, the overall yields were poor (4%). 
 
 
Figure 155: Synthesis of 232. Reagents and conditions: (a) HBTU, DIPEA, DMF, rt, 12 h. (b) LiOH, THF/H2O, rt, 12 h, 
72%. (c) 218, EDCI, DIPEA, DMF, rt, 14 h. (d) LiBH4, THF, rt, 8 h. (e) Dess-Martin periiodane, DCM, rt, 3 h, 4%. 
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Compound 232 is shown with 227 in Table 20 for easy comparison. 
 
Table 20: Activity of tripeptide as compared with dipeptide. 
Compound Structure IC50 (µM) 
EC50 
(µM) 
227 
 
0.66 27 
232 
 
0.055 54 
    
 
As expected, 232 proved highly potent against the enzyme. However the antiviral activity was not 
enhanced (EC50=54 µM).  
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6.8 Polio 
 
The relative ineffectiveness of 232 was a disappointment and possibly indicated a general intolerance 
of peptides in the cell based assay. 
To gain further insight into the antiviral effectiveness of these compounds, it was decided to test them 
against another picornavirus, in this case poliovirus (PV). The assays were carried out by T. Tuthill 
and M. Windsor (both Pirbright Institute, UK). The results are shown below: 
Table 21: Comparison of activities against PV and FMDV. 
Compound Structure 
PV EC50 
(µM) 
FMDV EC50 
(µM) 
222 
 
~90 72 
227 
 
~25 27 
232 
 
~15 54 
194 
 
14 
 
<1 47 
 
As can be seen, the inhibitors are generally more effective against PV than FMDV. This is 
particularly true for rupintrivir (14), which exhibited an EC50 well under the lower limit of the assay. 
This is expected in a sense as the PV 3Cpro is structurally very similar to the HRV 3Cpro (as discussed 
in section 1.4.6), the protease rupintrivir was designed to inhibit. 
Also of note is that the longer compound 232 is more effective than 227, an inversion of the situation 
in the FMDV assay. This supports our hypothesis that peptidyl compounds are disfavoured by the 
FMDV assay. 
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6.9 Rupintrivir and Picornaviruses 
 
With the protease inhibitors proving less effective against FMDV than PV, it was decided to compare 
the effect of rupintrivir (14) on different picornaviruses using data obtained in this project, and 
literature values. 
Table 22: The activity of rupintrivir against picornaviruses and their 3Cpros. 
Virus 
3Cpro IC50 
 (µM) 
EC50 
(µM) 
Rhinovirus 215 0.003 0.03 
Enterovirus 71245 2.3 0.001 
Poliovirus 237 1.83 <1 
Hepatitis A virus 237 >100 >100 
FMDV 0.88 47 
 
The sample size is admittedly small, however it appears that FMDV is an anomaly when it comes to 
protease inhibition, insofar as rupintrivir is highly effective against the protease, and comparatively 
ineffective against the virus. This is unlike the situation for HA which is doubly ineffective, or HRV, 
E-71 and PV which are highly potent against both enzyme and virus. 
Two possible explanations are as follows: 
1. The Renal Swine cells used for the FMDV assays are unfavourable towards 3Cpro inhibitors 
due to cell permeability, metabolism or a general intolerance of peptides. 
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2. More interestingly, it is possible that the differences between FMDV and other 
picornaviruses are being manifested. Some of these differences were discussed in the 
introduction (section 1.4.6). For example, potentially the more suspected greater efficiency 
of FMDV 3Cpro (due to “proper” triad 90) enables the replicating virus to perform all 
necessary cleavages with few active proteases. Another possibility is the FMDV Lpro 
(unique to FMDV and other apthoviruses) having a greater role than previously thought.  
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6.10 Depeptidisation and Future Work 
Since there was an indication that the peptidic nature of these inhibitors was proving detrimental to 
cellular activity, it was decided to attempt to depeptidise. One strategy is to replace the peptide chain 
beyond P1 with a small molecule. This has been tried with some success against rhinovirus.246 Two 
examples of effective small molecules are shown in Figure 156. 
 
Figure 156: Partial small molecule inhibitors of HRV.246 
 
Compound 237 was synthesised and tested against FMDV 3Cpro. The activity was poor (IC50= >50 
µM) and the compound demonstrated no antiviral activity. 
 
Figure 157: 237, an attempted partial small molecule inhibitor of FMDV 3Cpro. 
 
One potential strategy for the future is to use the Rink amide resin chemistry outlined in section 6.2.1 
to screen a multitude of potential small molecules for activity. The process is shown in Figure 158. 
SPPS techniques are used to generate large numbers of P1 glutamine, C-terminal Michael acceptor 
compounds with a small molecule attached to the N-terminus. 
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Figure 158: Identification of suitable small molecule mimics for P2-3 region. The bound glutamine-Michael acceptor can 
be coupled to a large number of small molecule carboxylic acids (represented by the green hexagon). The advantage of this 
is that large numbers of compounds could be obtained rapidly using SPPS techniques without the need for expensive/time 
consuming purification techniques. Once effective compounds were identified (238), the more effective P1 residue and 
warhead (239) could be incorporated using traditional solution-phase chemistry. 
 
If effective small molecules are found, the equivalent compound with the P1 lactam glutamine 
analogue and the aldehyde warhead could then be synthesized in order to further boost the activity. 
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Chapter 7: Conclusions and Future 
Work 
7.1 Peptidic Inhibitors 
Insofar as the prevention of viral replication in a cell-based assay was achieved, the project was a 
success. The best compound was 227 which was found to have an EC50 of 27 µM. 
 
Figure 159: Most successful inhibitor of FMDV. 
 
However this antiviral activity was less than might be expected (in comparison to other 
picornaviruses) and indications were that increasing it would be a challenge. It seemed (section 6.7) 
that peptidic compounds were disfavoured under the conditions of the cell-based assay, and so 
depeptidisation of the binding element appeared to be the logical way forward. One potential way of 
achieving this, by exploitation of the SPPS route used in section 6.2.1, was discussed (section 6.10). 
 
7.1.1 Potential Problems with C-terminal Aldehydes 
 
One potential problem with C-terminal aldehydes and ketones is the potential racemization of the α-
carbon stereocentre.247 
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Figure 160: Racemization of C-terminal α-carbon of peptide aldehyde. 
 
If this were to occur, it could be cause the activity to drop— assuming the D amino acid would have 
less affinity for the active site than the “natural” L stereoisomer. 
(This is not a concern for the glutamine compounds (section 6.2)— the reduction of Weinreb amides 
with LiAlH4 is well established to proceed with minimal epimerization and the intermediate aldehyde 
is quickly subjected to a Wittig reaction.248,92) 
One way of monitoring any loss of chirality would be to monitor the optical activity of a sample of 
227. This was not performed on any of the compounds in this thesis as the literature did not report this 
as being a problem for compounds employing the same P1 glutamine with an aldehyde 
warhead.236,237,249 Nonetheless, the potential problems here need to be fully investigated. 
 
7.2 SMW Inhibitors  
 
In light of the possible ineffectiveness of peptidyl inhibitors in the cell based assay, the small 
molecules developed in chapter 5 are of increased interest. Although 183 was a relatively modest 
inhibitor in comparison to the peptidyl compounds, it could potentially be improved, by extensive 
SAR studies, to boost potency. 
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Figure 161: Small molecule warhead compound. 
 
Although the approach is different to the previously discussed strategy, the target compounds are 
effectively of the same kind: small molecules binding components with warheads. 
 
7.3 Pseudo-irreversible Inhibitors 
The HTS strategy resulted in the development of highly potent small molecule inhibitors such as 22 
(Figure 162) (IC50 = 0.14µM). 
 
Figure 162: Pseudo-irreversible inhibitor discovered from HTS. 
 
The mode of inhibition was found to be the pseudo-irreversible mechanism based around catalytic 
hydrolysis of the ester together with an unusually stable acyl-enzyme resulting in very slow 
deacylation and thus very low turnover of the active enzyme. 
In spite of the high potency against the enzyme, the compounds proved completely ineffective when 
tested against FMDV and indications were that the activated ester nature of the compound lead to a 
poor survivability in a biological system (section 4.7.2). Since the ester was intrinsic to the activity of 
202 
 
the compounds, this indicated that pseudo-irreversibility was unlikely to provide a successful antiviral 
compound. 
Ultimately the investigation focussed on the development of compounds with anti-FMDV activity, 
and this emphasis left questions unanswered as regards the pseudo-irreversible inhibitors: 
 Why is the acyl-enzyme so stable? 
The pseudo-irreversible mechanism relies on the unusual stability of the acyl-enzyme. The 
orientation of the successful acyl groups in the FMDV 3Cpro active site remains unknown, in 
spite of speculation (section 4.5.3) based on the SARS 3CLpro acyl-enzyme structure. That 
this structure was obtained indicated that it is possible to grow crystals of a cysteine protease 
acyl-enzyme, and so this strategy could be employed to gain more structural information 
about the pseudo-irreversible inhibition of FMDV 3Cpro. 
 
 What is the role of the leaving group? 
The leaving group appears to be a vital component of a pseudo-irreversible VCP inhibitor. 
This is unlike the situation with serine digestive proteases where the leaving group is 
relatively unimportant. This can be rationalized by considering the high specificity required 
for viral polyprotein processing as compared with digestion. The exact role of the leaving 
group however remains unknown; and, unlike the acyl-enzyme, the interactions prior to 
cleavage are presumably too fleeting to allow X-ray crystallography to elucidate them.  
 
 Why does the high potency not translate to antiviral activity? 
As discussed, the compounds were ineffective in a cell based assay. The instability of 
compounds in water (section 4.7.2) and their rapid cleavage by trypsin indicated a low 
survivability in a biological environment, which could potentially preclude antiviral activity.  
This theory, however, remains unproven. 
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 What can be done to gain antiviral activity? 
If the activated ester nature of the compounds is indeed the barrier to antiviral activity then 
one potential strategy to overcome this was discussed in section 4.7.4. A consideration of the 
inverse substrates of trypsin lead to the hypothesis that an acyl group which performed both 
roles required for pseudo-irreversible inhibition by VCPs could potentially provide more 
successful inhibitors. The two roles in question are the formation of a stable acyl-enzyme, and 
the favourable binding allowing hydrolysis by the protease. According to our theory, the latter 
is normally performed by the leaving group and this has led to the relatively activated 
quinolone and bromopyridine leaving groups. If the acyl group performed the binding role, 
then the leaving group could be simpler, for example a simple ethyl ester. 
Attempts to develop such compounds consisted of the simple inversion of the successful 
leaving groups. These compounds however demonstrated no inhibition of the enzyme for 
reasons as yet unknown. 
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Chapter 8: Experimental 
8.1 Expression and Purification of FMDV 3Cpro 
 
The particular FMDV 3Cpro mutant used in this work corresponded to the viral strain A1061 and was 
expressed and purified using a previously established method.88 The particular mutant used had two 
mutations (C95K and C142L) which provided greater stability for long term storage. The enzyme also 
contained a non-cleavable histidine tag (6 × His) on the C-terminus.  
8.1.1 Transformation of E. coli 
The expression vector used to produce the 3Cpro mutants was based on a pETm11 vector and was 
further modified by Patricia Zunszain (Imperial College London). The cell line used was 
BL21(DE3)pLysS. The plasmid enabled resistance to kanamycin and the cell to chloramphenicol. 
Therefore these antibiotics were present in all LB broth and agar solutions (25 μg/mL for kanamycin 
and 35 μg/mL for chloramphenicol). All stages of the transformation were carried out under flame 
sterilised atmosphere. 0.6 µL (approximately 60 ng) of the plasmid stock was added to 50 µL of the 
thawed cell suspension on ice and the solutions were incubated on ice for 30 minutes. After this, the 
eppendorf was placed in a 42 °C water bath for 45 seconds to enhance the uptake of DNA up by the 
bacterial cells. Immediately after this, the solutions were placed back on ice for 5 minutes. 450 µL of 
warm LB broth (~37 °C) was subsequently added and the resulting cultures were incubated on a 
shaking plate at 37 °C for 1 hour. The cells were then pelleted at 13200 RPM for 1 minute using a 
bench top microcentrifuge (Centrifuge 5415, eppendorf, Cambridge, UK), and each pellet was re-
suspended in LB broth (approximately 100 μL). After this, the cells were spread on LB agar and 
incubated overnight at 37 °C. 
8.1.2 Expression of FMDV 3Cpro Mutants 
One of the resulting colonies was selected and used to inoculate 400 mL of LB broth. This broth was 
shaken and incubated overnight. It was then diluted with LB broth by a factor of 20 to obtain a total of 
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8 L of culture which was shaken at 37 °C for 3 hours. After this, protein expression was induced with 
IPTG (final concentration of 1 mM). After a further 3 hours of shaking at 37 °C, the cells were 
harvested by centrifugation at 4 °C (Beckman JS-4.2 centrifuge, 5000 g, 15 minutes) and the cell 
pellets obtained were stored at -80 °C until purification. 
8.1.3 Purification 
TALON immobilised metal affinity chromatography (IMAC) resin (Clontech, California, USA) was 
used in the purification of both FMDV 3Cpromutants. A buffer containing 50 mM HEPES, pH 7.1, 
400 mM NaCl, 1 mM β-mercaptoethanol and 0.01% sodium azide was used in all the purification 
steps and will be referred to as buffer A. The bacterial cell pellets were thawed on ice and 
resuspended in lysis buffer (~35mL of lysis buffer (buffer A plus 0.1% Triton X100) per 1 L of 
original E. coli culture). After this, the re-suspended pellets were transferred into a 500 mL metal 
container and sonicated (4 X 15 seconds) while being kept on ice. The sonicated mixture was 
centrifuged at 4 °C in pre-chilled centrifuge tubes (Beckman F0850 centrifuge, 23000 g, 20 minutes) 
to separate insoluble material from the supernatant. Then the nucleic acids were precipitated with 
protamine sulphate (at a final concentration of 1 mg/mL) and the mixtures centrifuged in the same 
way. Meanwhile, TALON resin (approximately 0.5 mL per 1 L of original culture) was equilibrated 
by repeated centrifugation and dilution in buffer A. The TALON was then added to the supernatant, 
and the mixture was incubated with the resin at 4 °C for 1 hour with rotation. After this, the 
suspension was centrifuged (Beckman J6-HC centrifuge, 4500 g, 4 minutes) to pellet the TALON 
beads, and the supernatant which contained the unbound material was removed. The washing of the 
resin and the elution of the bound proteins were achieved by repeated centrifugation (Beckman J6-HC 
centrifuge, 4500 g, 4 minutes) and dilution in the washing and elution buffers is described below.  
• Washing buffer W0: Buffer A (2 x 50 mL) 
• Washing buffer W5: Buffer A with 5 mM imidazole (2 × 50 mL) 
• Washing buffer W10: Buffer A with 10 mM imidazole (2 × 50 mL) 
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• Elution buffer E100: Buffer A with 100 mM imidazole (35 mL and 15 mL) 
• Elution buffer E250: Buffer A with 250 mM imidazole (20 mL) 
The eluted materials were analysed by SDS-PAGE (15% acrylamide gel, 240 V, 45 minutes) and the 
fractions containing the 3Cpro were combined and dialysed to remove imidazole. 10 kDa cut-off 
SnakeSkin dialysis tubing (Thermo Scientific, Waltham, MA, USA) was used, and the tubes 
containing the protein solution were left stirring overnight in 4 L of pre-chilled buffer A at 4 °C. The 
TALON-purified protein was concentrated using a 10,000 MW cut-off centrifugal concentrator 
(Vivaspin, Aubagne, France) to a concentration of approximately 10 mg/mL. The protein 
concentration was determined by absorbance at 280 nm, using E1% = 4.7 (absorbance of 4.7 
corresponds to 10 mg/mL of protein). This value was obtained using the ProtParam tool on the 
ExPASy Proteomics Server. [209] In the case of the catalytically active 3Cpro 
The purified protein was stored at -80 °C until use. The final yield of the purified active FMDV 3Cpro 
was approximately 4 mg per 1 litre of original E. coli culture. 
 
 
Figure 163: SDS-PAGE from purification elutions of FMDV 3Cpro. The ladder (L) indicates molecular weight in steps of 
10 kDa. The 3Cpro bands are found at approximately 23 kDa. The bulk of the protein was found to be in the W10, E100 and 
E250 elutions. 
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8.2 Solid Phase Peptide Synthesis 
 
All amino acid derivatives resin used in solid phase peptide synthesis were purchased from 
Novabiochem (Nottingham, UK), Synthesis was performed using an Intavis ResPep SL synthesiser. 
20 µmol of resin per synthesiser well was swelled with DMF (30 min) and the DMF was drained from 
the well. The Fmoc was then removed from the N-terminus of the lysine by treating the resin with 
20% piperidine in DMF for 25 minutes, before washing the resin with DMF (3-4 mL). The next 
amino acid (5 eq, 250 mM in N-methyl-2 pyrrolidone (NMP), 400 µL), pre-activated with HBTU (5 
eq) and N-methylmorpholine (NMM) (5 eq), was then coupled onto the N-terminus of the resin-bound 
lysine for 30-50 minutes, after which the amino acid solution was drained from the well. To cap any 
unreacted N-terminal amines, the resin was then treated with 5% Ac2O in DMF (400 µL), before 
washing the resin with DMF (3 mL). The Fmoc removal, amino acid activation and coupling / N-
terminal capping cycle was repeated until the desired peptide had been synthesised. Finally, the N-
terminal Fmoc was removed as described above. The free N-terminus could then be acetylated using 
the same conditions as the capping described above. 
In the case of the FRET substrate the free N terminus was reacted with 2.5 eq. of DABCYL- OSu. 
Peptides were purified using RP-HPLC/MS on a Waters 2767 system equipped with a photodiode 
array and an ESI mass spectrometer using a XBridge Prep C18 (5 µm, 19 mm × 100 mm) column, 
equipped with an XBridge Prep C18 guard column (5 µm, 19 mm × 10 mm). The following elution 
method was used: Gradient of solvent A (water) and solvent (methanol) B: 0-10 min 50-98% B, 10-12 
min 98% B, 12-13 min 98 to 50% B, 13-17 min 50% B. Flow rate: 20 mL/min. 
The fractions were then evaporated using a Genevac. 
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8.3 Fluorescence Assays 
 
8.3.1 General 
Ultrapure water was used to prepare all solutions. Initial FRET substrate hydrolysis rates were 
determined using a Cytofluor Series 4000 microplate reader (PerSeptive Biosystem), with Titertek 
microtitration 96-well plates. The samples were irradiated at 340 nm and fluorescence recorded at 460 
nm. All incubation and assays were performed at 37 °C and pH 7.4 using a twelve channel multi-
pipette (Finnpipette, from Labsystems). 
Assay buffer solution: All substrate and enzyme working solutions were made up for every set of 
experiments by dissolving stock solutions into a fresh pH 7.4 buffer solution with sodium phosphate 
(0.1 M), TCEP (0.1 mM), EDTA (1 mM) and glycerol (5% v/v), ensuring that the final working 
solution contained less than 5% by volume of DMSO. The stock solutions for the fluorophores, 
fluorogenic substrates and peptidyl inhibitors were kept at –20 °C. They were made by accurately 
weighing the dry mass of requisite compounds and adding the volume of DMSO required for the 
desired stock concentration. In general, inhibitors were used as 50 mM stock and the FRET substrate 
required a 5 mM stock solution. 
The stock solutions of FMDV 3Cpro mutants were kept at –80 °C straight after purification in small 
aliquots (generally 100 μL at 4 mg/mL, page 162).  
8.3.2 FMDV 3Cpro Inhibition Assays 
All inhibition assays required the determination of a relative rate, which was achieved by comparing 
the initial rate of the free enzyme [Mutant A (50 µL, 2 μM) plus FRET substrate (1) (100 µL, 100 
μM) and assay buffer (50 µL)] with the initial rate in the presence of the inhibitor at different 
concentrations and incubation times (depending on the experiment, see below) under the same 
conditions of time and temperature.  
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IC50 calculation 
Mutant A (50 µL, 2.0 µM) was incubated with the inhibitor (50 µL) at multiple concentrations 
(usually from 6 to 12) obtained by dilution (either double or triple) for 30 minutes at 37 °C. The 
fluorescence readings were obtained upon addition of substrate (100 µL, 100 µM) to the enzyme–
inhibitor mixture. The relative rates were plotted against inhibitor concentration on a log scale and the 
results were fitted to IC50 curves in GraFit (Leatherbarrow, 2003), the IC50 values and standard errors 
were obtained from the fit of the curves to the main values of the duplicates with a weighting based on 
their standard deviation. 
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8.3.3 Rapid Dilution Assay 
Inhibitors were tested at concentrations close to their IC50 value (22 (IC50=13.2 µM was tested at a 
concentration of 12.5 µM). The assay is based around a comparison between two experiments: 
 Constant dilution: The enzyme (50 µL, 2.0 µM) was incubated with the inhibitor (50 
µL, 50 µM) and additional buffer (98 µL) for 30 minutes at 37 °C. The fluorescence 
readings were obtained upon addition of substrate (2 µL, 5 mM DMSO stock) to the 
enzyme–inhibitor mixture. 
 Rapid dilution: The enzyme (10 µL, 10 µM) was incubated with the inhibitor (10 µL, 
250 µM). The fluorescence readings were obtained upon addition of the substrate (100 
µL, 100 µM) and additional buffer (80 µL). 
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8.3.4 Trypsin and Chymotrypsin Assays 
 
Chymotrypsin:250 
Substrate used: Suc-Ala-Ala-Pro-Phe-AMC. Excitation at 360nm and detection at 460nm. 
Enzyme: Bovine α-Chymotrypsin 
Buffer: 50 mM Tris-HCl, 150 mM NaCl, 0.01% v/v Triton X-100, 0.01% v/v NaN3, pH 7.6. 
The enzyme (50 µL, 2 nM) was incubated with the different concentrations of inhibitor (50 µL) for 30 
minutes at 37 °C. The fluorescence readings were obtained upon addition of substrate (100 µL, 10 
nM) to the enzyme–inhibitor mixture. 
 
Trypsin:251 
Substrate used: Z-L-Arg 7-AMC. Excitation at 360nm and detection at 460nm. 
Enzyme: Bovine Trypsin. 
Buffer: 50 mM Tris-HCl, 150 mM NaCl, 0.01% v/v Triton X-100, 0.01% v/v NaN3, pH 7.6. 
The enzyme (50 µL, 16 nM) was incubated with different concentrations of the inhibitor (50 µL) for 
30 minutes at 37 °C. The fluorescence readings were obtained upon addition of substrate (100 µL, 20 
nM) to the enzyme–inhibitor mixture. 
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8.4 Determination of Mass of Enzyme-inhibitor Complex 
In two spin columns with a 5 kDa cut-off (Vivaspin 500) a solution of bovine alpha chymotrypsin (25 
μL, 430 µM in water) was mixed with water (75 μL) and an excess of compound 22 in water (75 μL, 
3 mM, final E–I, 1:21). Both solutions were incubated at 37 °C for one hour. The solution containing 
inhibitor was washed with five cycles of buffer exchange with water and then purified further using 
ZipTip® Pipette Tips141. Both solutions were then analysed using ESI-TOF MS by the Mass 
Spectroscopy Service (Imperial College London). 
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8.5 Viral Assays 
Assays were performed by M. Windsor at Pirbright (Surrey, UK). 
Seed stocks of the wild-type isolate O1K (Kaufbeuren)-Cad2 were a kind gift from Dr Terry Jackson, 
Pirbright Laboratory. Aliquots of this seed virus were used to infect baby hamster kidney (BHK)-21 
cells (ATCC) to produce the working stock of virus. Virus was titrated at 8.95 TCID50/ml on BTY 
(bovine thyroid cells -primary cell culture, Pirbright laboratory). 
Inhibition tests for FMDV were carried out using the Renal Swine cell line (IBRS2 Pirbright 
laboratory) as these cells form a confluent monolayer which is highly susceptible to, and easily 
identifiable by, infection of FMDV. All cells were grown in Glasgow's Modified Eagle's Medium 
(GMEM) supplemented with 10% FCS, 100 U/ml penicillin, 100 µg/ml streptomycin. 
Cells were seeded at 1x105 cells per well of a flat bottomed 96 well plate and exposed to virus at the 
MOI of 0.05 for 30 minutes in 100ul/well. The virus inoculum was then removed and replaced by 
virus growth medium (GMEM 100U/ml penicillin, 100µg/ml streptomycin 2% FCS) 200ul/well, 
containing dilutions of the compounds (or control of medium alone). Cells were incubated for 3-5 
days before examination under a light microscope for signs of CPE, which was taken to show the 
presence of FMDV infection. EC50 was determined by calculating the dilution at which 50% of the 
wells still retained a confluent monolayer after 6 days 
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8.6 Chemistry 
8.6.1 General 
All chemicals were purchased from Sigma-Aldrich Ltd (Gillingham, UK), Acros Organics (Geel, 
Belgium), Alfa Aesar (Heysham, UK) and Tokyo Chemical Industry (Oxford, UK) and used without 
further purification. Moisture sensitive reactions were performed under nitrogen or argon atmosphere 
using dried glassware, anhydrous solvents and standard syringe/septa techniques.  
Silica gel normal phase column chromatography was performed either using Merck silica gel 60 
(0.015-0.040 mm) or where indicated, was performed on an Isolera (Biotage, UK) automated 
apparatus with SNAP silica cartridges (Biotage, UK). In this context CV refers to column volume. 
Preparative LC-MS: RP-HPLC/MS on a Waters 2767 system equipped with a photodiode array and 
an ESI mass spectrometer using a XBridge Prep C18 (5 µm, 19 mm × 100 mm) column, equipped 
with an XBridge Prep C18 guard column (5 µm, 19 mm × 10 mm). The following elution method was 
used: Gradient of solvent A (water) and solvent B (methanol): 0-10 min 50-98% B, 10-12 min 98% B, 
12-13 min 98 to 50% B, 13-17 min 50% B. Flow rate: 20 mL/min. 
1H and 13C NMR spectra were recorded on 400 MHz and 101 MHz respectively Bruker AV 
instruments at room temperature unless specified otherwise. Data are presented as follows: chemical 
shift in ppm, integration, multiplicity (br = broad, app = apparent, s = singlet, d = doublet, t = triplet, q 
= quartet, p = pentet, m = multiplet) and coupling constants in Hz. 
High resolution mass spectra were obtained from the Mass Spectrometry Service of Department of 
Chemistry, Imperial College London. 
Crystal structures were obtained by the Crystallography Service of Department of Chemistry, Imperial 
College London. 
 
215 
 
8.6.2 Synthesis and Characterisation of Compounds 
 
1-Methyl-2-oxo-1,2-dihydroquinolin-4-yl 2-methylbenzoate 22 To a stirred 
suspension of 4-hydroxy-N-methyl-2-quinolone (200 mg, 1.14 mmol) in 
DCM (20 mL) was added triethylamine (160 µL, 1.14 mmol) and o-toluoyl 
chloride (180 µL, 1.37 mmol). The reaction mixture was stirred at room 
temperature overnight. The reaction was quenched with water (30 mL), the phases separated and the 
organic layer was dried over magnesium sulfate and concentrated. The crude product was purified 
using flash column chromatography (50:50 ethyl acetate: hexane, Rf = 0.4) to yield the product as a 
white solid (298 mg, 89%). 1H NMR (CDCl3, ppm) 8.30 (d, J = 8.0 Hz, 1H), 7.75 (dd, J = 8.0, 1.3 
Hz, 1H), 7.65 (td J = 8.0, 1.0 Hz, 1H), 7.58 (td, J = 8.0, 1.3 Hz, 1H), 7.49 – 7.37 (m, 3H), 7.31 – 7.23 
(m, 1H), 6.74 (s, 1H), 3.78 (s, 3H), 2.71 (s, 3H). 13C NMR (CDCl3, ppm) 163.83, 162.87, 155.63, 
142.40, 140.32, 133.67, 132.45, 131.77, 131.43, 127.31, 126.35, 123.30, 122.42, 116.96, 114.67, 
112.40, 29.69, 22.17. ESI HRMS, found 294.1125 (C18H16NO3, [M + H]
+, requires 294.1130). 
4-Hydroxy-1-methyl-3-(2-methylbenzoyl)quinolin-2(1H)-one 16 To a 
solution of 22 (200 mg, 0.68 mmol) in DCM (15 mL) was added potassium 
cyanide (90 mg, 1.37 mmol), triethylamine (70 µL, 0.68 mmol) and a 
catalytic amount of 18-crown-6 ether (5 mg). The reaction mixture was stirred at room temperature 
for 72 hours, then quenched with saturated sodium thiosulfate (20 mL). The organic layers were 
separated, dried over magnesium sulfate and concentrated under reduced pressure. The crude product 
was purified using flash column chromatography (50:50 ethyl acetate: hexane Rf = 0.5) to yield the 
product as a light yellow solid (188 mg, 94%). 1H NMR (CDCl3, ppm) δ 16.45 (s, 1H), 8.33 – 8.26 
(m, 1H), 7.77 – 7.68 (m, 1H), 7.41 – 7.18 (m, 5H), 3.55 (s, 3H), 2.35 (s, 3H). 13C NMR (CDCl3, 
ppm) 204.77, 174.49, 160.77, 142.62, 141.44, 135.40, 133.73, 130.35, 129.53, 126.46, 125.58, 
125.22, 122.31, 115.60, 114.56, 106.76, 29.33, 19.50. ESI HRMS, found 294.1130 (C18H16NO3, [M + 
H]+, requires 294.1130). 
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1-Methyl-2-oxo-1,2-dihydroquinolin-4-yl acetate 49 Was prepared as in 22 
replacing o-toluoyl chloride with acetyl chloride (98 µL, 1.37 mmol). The crude 
product was purified using flash column chromatography (50:50 ethyl acetate: 
hexane, Rf = 0.5) to yield a white solid (216 mg, 87%). 
1H NMR (CDCl3, ppm) 
7.70 (dd, J = 7.8, 1.3 Hz, 1H), 7.66 (ddd, J = 8.5, 7.8, 1.4 Hz, 1H), 7.45 (d, J = 8.5 Hz, 1H), 7.28 (m, 
1H), 6.37 (s, 1H), 3.76 (s, 3H), 2.47 (s, 3H). 13C NMR (CDCl3, ppm) 162.81, 131.80, 123.15, 
122.35, 114.66, 112.17, 29.68, 21.23. 4 quaternary carbons were not observed. ESI, found 218.0828 
(C12H12NO3, [M + H]
+, requires 218.0817). 
1-Methyl-2-oxo-1,2-dihydroquinolin-4-yl benzoate 36 Was prepared as in 22 
replacing o-toluoyl chloride with benzoyl chloride (160 µL, 1.37 mmol). The 
crude product was purified using flash column chromatography (50:50 ethyl 
acetate: hexane, Rf = 0.5) to yield a white solid (294 mg, 92%). 
1H NMR 
(CDCl3, ppm) 8.20 (dd, J = 7.7, 1.5 Hz, 2H), 7.69 – 7.61 (m, 2H), 7.60 – 7.47 (m, 3H), 7.37 (d, J = 
8.7 Hz, 1H), 7.17 (d, J = 7.4 Hz, 1H), 6.68 (s, 1H), 3.69 (s, 3H). 13C NMR (CDCl3, ppm) 163.60, 
162.84, 155.52, 140.34, 134.53, 131.85, 130.61, 129.08, 128.55, 123.27, 122.46, 116.85, 114.71, 
112.37, 29.74. ESI HRMS, found 280.0977 (C17H14NO3, [M + H]
+, requires 280.0974). 
1-Methyl-2-oxo-1,2-dihydroquinolin-4-yl 2-phenylacetate 63 Was 
prepared as in 22 replacing o-toluoyl chloride with phenylacetyl chloride 
(181 µL, 1.37 mmol). The crude product was purified using flash column 
chromatography (50:50 ethyl acetate: hexane, Rf = 0.5). White solid (248 
mg, 74%). 1H NMR (CDCl3, ppm) 7.64 – 7.56 (m, 1H), 7.47 – 7.42 (m, 4H), 7.42 – 7.36 (m, 3H), 
7.16 (t, J = 7.6 Hz, 1H), 6.62 (s, 1H), 4.00 (s, 2H), 3.72 (s, 3H). 13C NMR (CDCl3, ppm) 131.75, 
129.56, 129.17, 127.97, 123.04, 122.36, 114.59, 112.05, 41.77, 29.69. 6 quaternary carbons not 
observed. ESI HRMS, found 294.1141 (C18H16NO3, [M + H]
+, requires 294.1130). 
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1-Methyl-2-oxo-1,2-dihydroquinolin-4-yl 3-chlorobenzoate 62 Was 
prepared as in 22 replacing o-toluoyl chloride with 3-chlorobenzoyl 
chloride (176 µL, 1.37 mmol). The crude product was purified using 
flash column chromatography (50:50 ethyl acetate: hexane, Rf = 0.5). 
White solid (304 mg, 85%). 1H NMR (CDCl3, ppm) 8.26 (m, 1H), 8.17 (m, 1H), 7.70 (m, 2H), 
7.67 (m, 1H), 7.55 (t, J = 7.9 Hz, 1H), 7.47 (d, J = 8.6 Hz, 1H), 7.28 (s, 1H), 6.75 (s, 1H), 3.78 (s, 
3H). 13C NMR (CDCl3, ppm) 162.68, 162.48, 155.21, 140.40, 135.32, 134.55, 131.95, 130.56, 
130.41, 130.32, 128.71, 123.12, 122.48, 116.59, 114.75, 112.49, 29.75. ESI HRMS, found 314.0586 
(C17H13
35ClNO3, [M + H]
+, requires 314.0584). 
1-Methyl-2-oxo-1,2-dihydroquinolin-4-yl cyclohexanecarboxylate 50 Was 
prepared as in 22 replacing o-toluoyl chloride with cyclohexanecarbonyl 
chloride ( 183 µL, 1.37 mmol). The crude product was purified using flash 
column chromatography (50:50 ethyl acetate: hexane, Rf = 0.7). White solid 
(240 mg, 74%). 1H NMR (CDCl3, ppm) 7.61 (dd, J = 8.2, 1.2 Hz, 1H), 7.59 – 7.53 (m, 1H), 7.34 
(d, J = 8.2 Hz, 1H), 7.21 (t, J = 7.6 Hz, 1H), 6.56 (s, 1H), 3.65 (s, 3H), 2.74 – 2.61 (m, 1H), 2.13 (m, 
2H), 1.84 (m, 2H), 1.73 – 1.56 (m, 3H), 1.45 – 1.21 (m, 3H). 13C NMR (CDCl3, ppm) 172.79, 
162.83, 155.29, 140.27, 131.69, 123.08, 122.30, 116.85, 114.60, 111.97, 43.58, 29.63, 29.14, 25.76, 
25.46. ESI HRMS, found 286.1447 (C17H20NO3, [M + H]
+, requires 286.1443). 
3-Acetyl-4-hydroxy-1-methylquinolin-2(1H)-one 25 252 Was prepared as in 16, 
using 49 as starting material. The crude product was purified using flash column 
chromatography (50:50 ethyl acetate: hexane, Rf = 0.55). White solid (56 mg, 
56%). 1H NMR (CDCl3, ppm) δ 16.93 (s, 1H), 8.24 (dd, J = 8.0, 1.4 Hz, 1H), 7.80 – 7.60 (m, 1H), 
7.32 (d, J = 8.0 Hz, 1H), 7.28 (m, 1H), 3.66 (s, 3H), 2.85 (s, 3H). ESI, found 218 (C12H12NO3, [M + 
H]+, requires 218). 
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3-Benzoyl-4-hydroxy-1-methylquinolin-2(1H)-one 35 156 Dimethyl 
anthranilate (2.3 mL, 15.7 mmol) was added to ethyl benzoylacetate (2.7 
ml, 15.7 mmol) and heated to 150 °C for 2 hours. 10 M potassium 
hydroxide (20 mL) was added to the mixture and stirred for 30 minutes and subsequently cooled in an 
ice bath. Conc. HCl was added dropwise to the chilled reaction mixture until a yellow precipitate was 
formed. The precipitate was filtered and washed with distilled water. 3-Benzoyl-4-hydroxy-1-methyl-
quinolone was obtained as a yellow solid (2.4 g, 55%). 1H NMR (CDCl3, ppm) 15.47 (s, 1H), 8.28 
(dd, J = 8.0, 1.4 Hz, 1H), 7.73 (ddd, J = 8.4, 7.2, 1.5 Hz, 1H), 7.65 (d, J = 7.1 Hz, 2H), 7.54 (app t, J = 
7.4 Hz, 1H), 7.46 (app t, J = 7.5 Hz, 2H), 7.38 – 7.25 (m, 2H), 3.61 (s, 3H). ESI, found 280 
(C17H14NO3, [M + H]
+, requires 280). 
4-Hydroxy-1-methyl-3-(2-phenylacetyl)quinolin-2(1H)-one 30 Was 
prepared as in 16, using 63 as starting material. The crude product was 
purified using flash column chromatography (50:50 ethyl acetate: 
hexane, Rf = 0.55). Light yellow-brown solid (63 mg, 63%). 
1H NMR (CDCl3, ppm) 16.70 (s, 1H), 
8.24 (dd, J = 8.1, 1.4 Hz, 1H), 7.85 – 7.57 (m, 1H), 7.49 – 7.04 (m, 7H), 4.70 (s, 2H), 3.70 (s, 3H). 13C 
NMR (CDCl3, ppm) 206.59, 174.39, 161.65, 141.91, 135.19, 135.03, 130.21, 128.57, 127.02, 
126.42, 122.30, 115.63, 114.39, 105.86, 48.92, 29.41. ESI HRMS, found 294.1134 (C18H16NO3, [M + 
H]+, requires 294.1130). 
3-(3-Chlorobenzoyl)-4-hydroxy-1-methylquinolin-2(1H)-one 29 Was 
prepared as in 16, using 62 as starting material. The crude product was 
purified using flash column chromatography (50:50 ethyl acetate: 
hexane, Rf = 0.55). Yellow solid (70 mg, 70%). 
1H NMR (CDCl3, ppm) 15.30 (s, 1H), 8.29 (dd, J 
= 8.1, 1.3 Hz, 1H), 8.10 (app t, J = 1.7 Hz, 1H), 8.03 – 7.99 (m, 1H), 7.79 – 7.72 (m, 1H), 7.60 (app t, 
J = 1.8 Hz, 1H), 7.52 – 7.29 (m, 5H), 3.62 (s, 3H). 13C NMR (CDCl3, ppm) 200.61, 173.48, 
161.02, 142.44, 141.94, 135.36, 134.03, 133.79, 131.43, 129.19, 127.76, 126.33, 125.90, 122.47, 
115.44, 114.63, 29.47. ESI HRMS, found 314.0577 (C18H12
35ClNO3, [M + H]
+, requires 314.0584). 
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3-(Cyclohexanecarbonyl)-4-hydroxy-1-methylquinolin-2(1H)-one 26 Was 
prepared as in 16, using 50 as starting material. The crude product was 
purified using flash column chromatography (50:50 ethyl acetate: hexane, 
Rf = 0.7). Yellow solid (71 mg, 71%). 
1H NMR (CDCl3, ppm) δ 17.32 (s, 1H), 8.21 (dd, J = 8.0, 
1.5 Hz, 1H), 7.77 – 7.54 (m, 1H), 7.30 – 7.26 (m, 1H), 7.26 – 7.21 (m, 1H), 4.06 (dd, J = 7.0, 3.9 Hz, 
1H), 3.64 (s, 3H), 2.07 – 1.08 (m, 10H). 13C NMR (CDCl3, ppm) 212.72, 175.00, 161.42, 141.74, 
134.87, 126.28, 122.12, 115.90, 114.25, 105.21, 48.28, 29.38, 29.29, 26.29, 26.13. ESI HRMS, found 
286.1441 (C17H20NO3, [M + H]
+, requires 286.1443). 
 1-Methyl-2-oxo-1,2-dihydroquinolin-4-yl furan-2-carboxylate 66 Was 
prepared as in 22 replacing furanoyl chloride with acetyl chloride. The crude 
product was purified using flash column chromatography (50:50 ethyl 
acetate: hexane, Rf = 0.45). White solid (90%). 
1H NMR (CDCl3, ppm) 
7.81 – 7.76 (m, 2H), 7.66 (ddd, J = 8.6, 7.3, 1.5 Hz, 1H), 7.54 (d, J = 3.3 Hz, 1H), 7.45 (d, J = 8.5 Hz, 
1H), 7.28 (m, 1H), 6.80 (s, 1H), 6.69 (dd, J = 3.6, 1.7 Hz, 1H), 3.77 (s, 3H). 13C NMR (CDCl3, 
ppm) 162.74, 155.13, 154.59, 148.17, 143.13, 140.35, 131.91, 123.27, 122.45, 120.90, 116.62, 
114.66, 112.75, 112.18, 29.73. ESI HRMS, found 270.0778 (C15H12NO4, [M + H]
+, requires 
270.0766). 
4-Hydroxyquinolin-2(1H)-one 78 191A mixture of aniline (0.93 g, 10.0 mmol) and 
Meldrum’s acid (1.44 g, 10.0 mmol) was stirred at 80 ºC for 1 hour. The reaction 
was then concentrated in order to remove produced acetone. Eaton’s reagent (3 
mL) was added and the mixture stirred at 70 ºC for 2 hours. Cold water (6 mL) was added to this 
mixture while stirring vigorously. The resulting precipitate was filtered, washed with cold water, and 
air dried to give a crude product as a brown solid. The pure product could be crystallised from ethanol 
to form brown-pink crystals (706 mg, 42%). 1H NMR (DMSO-d6, ppm) 11.58 (s br, 1H), 11.51 (s, 
1H), 7.81 (dd, J = 8.0, 1.2 Hz, 1H), 7.53 (ddd, J = 8.4, 7.3, 1.4 Hz, 1H), 7.31 (d, J = 8.1 Hz, 1H), 7.18 
(td, J = 7.6, 7.1, 0.9 Hz, 1H), 5.87 (s, 1H). ESI, found 163.15 (C9H8NO2, [M + H]
+, requires 162.05). 
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2-Oxo-1,2-dihydroquinolin-4-yl 2-methylbenzoate 88 Was prepared as in 22 
replacing 4-hydroxy-N-methyl-2-quinolone (23) with 78. The crude product 
was purified using flash column chromatography (5:95 methanol: DCM, Rf = 
0.4). White solid (144 mg, 45%) 1H NMR (CDCl3, ppm) 11.84 (s, 1H), 
8.31 (d, J = 7.9 Hz, 1H), 7.74 (d, J = 8.2 Hz, 1H), 7.64 – 7.54 (m, 2H), 7.52 – 7.37 (m, 4H), 7.31 – 
7.22 (m, 1H), 6.77 (s, 1H), 2.72 (s, 3H). ESI HRMS, found 280.0984 (C17H14NO3, [M + H]
+, requires 
280.0974). 
4-Hydroxy-1-methylpyridin-2(1H)-one 82 253 2,4-Dihydroxypyridine (1 g) was 
dissolved in 2N aqueous sodium hydroxide solution (10 mL) and dimethyl sulphate 
(1.13 g) was added dropwise over 30 minutes. The mixture was stirred at room 
temperature overnight, acidified with concentrated hydrochloric acid and the solvent removed under 
reduced pressure. The residue stirred in 5% methanol/dichloromethane and filtered. The filtrate was 
evaporated and the crude product purified using flash column chromatography (7:93 methanol: DCM, 
Rf = 0.2) to yield 1,2-dihydro-4-hydroxy-1-methyl-2-oxopyridine as an off-white solid (320 mg, 
28%). 1H NMR (DMSO-d6, ppm) 10.47 (s, 1H), 7.51 (d, J = 7.5 Hz, 1H), 5.83 (dd, J = 7.4, 2.6 Hz, 
1H), 5.58 (d, J = 2.6 Hz, 1H), 3.30 (s, 3H). ESI, found 126 (C6H8NO2, [M + H]
+, requires 126). 
1-Methyl-2-oxo-1,2-dihydropyridin-4-yl 2-methylbenzoate 92 Was prepared as in 
22 replacing 4-hydroxy-N-methyl-2-quinolone (23) with 82. The crude product 
was purified using flash column chromatography (30:70 ethyl acetate: hexane, Rf = 
0.5). White solid (170 mg, 61%) 1H NMR (CDCl3, ppm) 8.24 (dd, J = 7.8, 1.1 
Hz, 1H), 7.72 (dd, J = 7.9, 1.5 Hz, 1H), 7.65 – 7.55 (m, 2H), 7.49 – 7.25 (m, 5H), 6.60 (s, 2H), 2.70 
(s, 3H). ESI HRMS, found 244.0972 (C15H13NO3, [M + H]
+, requires 244.0974). 
4-Nitrophenyl 2-methylbenzoate 93 254 Was prepared as in 22 replacing 4-
hydroxy-N-methyl-2-quinolone (23) with nitrophenol 83. The crude product was 
purified using flash column chromatography (10:90 ethyl acetate: hexane, Rf = 
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0.6). Light yellow crystals (261 mg, 89%). 1H NMR (CDCl3, ppm) 8.35 (d, J = 9 Hz, 2H), 8.22 – 
8.20 (dd, J = 8.3, 1.4 Hz, 1H), 7.55 (app td, J = 7.5, 1.5 Hz, 1H), 7.43 (d, J = 9 Hz, 2H), 7.38 (m, 2H), 
2.70 (s, 3H). 
4-Quinolinyl 2-methylbenzoate 89 Was prepared as in 22 replacing 4-
hydroxy-N-methyl-2-quinolone (23) with 4-hydroxyquinoline 79. The crude 
product was purified using flash column chromatography (40:60 ethyl 
acetate: hexane, Rf = 0.7). Clear oil/white amorphous solid (289 mg, 96%). 
1H NMR (CDCl3, ppm) 9.00 (d, J = 4.9 Hz, 1H), 8.37 (d, J = 8.5 Hz, 1H), 8.21 (d, J = 8.5 Hz, 1H), 
8.06 (d, J = 8.1 Hz, 1H), 7.84 – 7.75 (m, 1H), 7.65 – 7.55 (m, 2H), 7.48 – 7.38 (m, 3H), 2.74 (s, 3H). 
13C NMR (CDCl3, ppm) 164.30, 155.10, 150.66, 149.66, 142.44, 133.74, 132.53, 131.54, 130.55, 
129.28, 127.36, 126.42, 125.88, 122.92, 121.63, 113.41, 22.24. ESI HRMS, found 264.1026 
(C17H14NO2, [M + H]
+, requires 264.1025). 
1-Napthyl 2-methylbenzoate 90 Was prepared as in 22 replacing 4-hydroxy-
N-methyl-2-quinolone (23) with 80. The crude product was purified using 
flash column chromatography (10:90 ethyl acetate: hexane, Rf = 0.6). White 
solid (263, 88%). 1H NMR (CDCl3, ppm) 8.43 (dd, J = 7.8, 1.3 Hz, 1H), 
8.02 – 7.91 (m, 2H), 7.83 (d, J = 8.3 Hz, 1H), 7.62 – 7.51 (m, 4H), 7.48 – 7.37 (m, 3H), 2.76 (s, 3H). 
13C NMR (CDCl3, ppm) 165.93, 147.09, 141.97, 134.93, 133.13, 132.34, 131.50, 128.45, 128.27, 
127.29, 126.69, 126.64, 126.26, 126.21, 125.68, 121.51, 118.53, 22.25. ESI HRMS, found 263.1077 
(C18H15O2, [M + H]
+, requires 263.1072). 
4-Nitrophenyl 2-methylbenzoate 91 Was prepared as in 22 replacing 4-
hydroxy-N-methyl-2-quinolone (23) with 81. The crude product was purified 
using flash column chromatography (50:50 ethyl acetate: hexane, Rf = 0.5). 
White crystals (291 mg, 91%). 1H NMR (CDCl3, ppm) δ 8.24 (dd, J = 7.8, 
1.1 Hz, 1H), 7.72 (dd, J = 7.9, 1.5 Hz, 1H), 7.65 – 7.55 (m, 2H), 7.41 (m, 3H), 7.36 – 7.30 (m, 1H), 
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6.60 (s, 1H), 2.70 (s, 3H). 13C NMR (CDCl3, ppm) 162.83, 161.68, 159.19, 153.93, 142.83, 134.13, 
132.96, 132.64, 131.44, 126.82, 126.50, 124.56, 123.06, 117.36, 116.06, 105.84, 22.21. ESI HRMS, 
found 281.0812 (C17H13O4, [M + H]
+, requires 281.0814). 
1-Methyl-2-oxo-1,2-dihydroquinolin-4-yl 4-
(dimethylamino)benzoate 55 Was prepared as in 22 using p- 
dimethylaminobenzoyl chloride. The crude product was purified 
using flash column chromatography (60:40 ethyl acetate: hexane, Rf 
= 0.3), yielding the desired product 55 as an white solid (280, 76%). 1H NMR (CDCl3, ppm) 1H 
NMR (400 MHz, Chloroform-d) δ 8.13 (d, J = 9.1 Hz, 2H), 7.78 (dd, J = 8.0, 1.3 Hz, 1H), 7.62 (ddd, J 
= 8.6, 7.3, 1.5 Hz, 1H), 7.43 (d, J = 8.5 Hz, 1H), 7.24 (app t, J = 7.6 Hz, 1H), 6.77 (d, J = 9.1 Hz, 2H), 
6.73 (s, 1H), 3.76 (s, 3H), 3.14 (s, 6H). 13C NMR (CDCl3, ppm) 163.82, 163.05, 155.97, 154.23, 
140.28, 132.51, 132.11, 131.54, 123.50, 122.24, 117.36, 114.53, 112.18, 111.12, 40.25, 29.62. ESI, 
found 323 (C19H19N2O3, [M + H]
+, requires 323). 
1-Methyl-2-oxo-1,2-dihydroquinolin-4-yl 4-(((tert-
butoxycarbonyl)amino)methyl)benzoate 76 To a solution of 4-N-
Boc-(Aminomethyl)benzoic acid (86 mg, 0.34 mmol) in DMF (5 
mL) was added EDCI (66 mg, 0.34 mmol), HOBt (46 mg, 0.34 
mmol) and DIPEA (60 µL, 0.34 mmol). The mixture was agitated then added to a solution of 4-
hydroxy-N-methyl-2-quinolone (50 mg, 0.29 mmol) in DMF (5 mL). The reaction was stirred 
overnight and then quenched with water (50 mL). The mixture was extracted with ethyl acetate (15 
mL) and the organic layers washed with 10% citric acid (50 mL) and brine (50 mL) and then 
concentrated. The crude product was chromatographed over silica (50:50 ethyl acetate: hexane, Rf = 
0.4) to give the title product as a white solid (88 mg, 76%) 1H NMR (CDCl3, ppm) 8.25 (d, J = 8.2 
Hz, 2H), 7.73 (d, J = 8.1 Hz, 1H), 7.65 (app t, J = 8.4 Hz, 1H), 7.50 (d, J = 8.0 Hz, 2H), 7.46 (d, J = 
8.6 Hz, 1H), 7.28 (m, 1H), 6.76 (s, 1H), 5.01 (s, 1H), 4.47 (m, 2H), 3.78 (s, 3H), 1.50 (s, 9H). ESI, 
found 409 (C23H25N2O5, [M + H]
+, requires 409). 
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1-Methyl-2-oxo-1,2-dihydroquinolin-4-yl 4-(aminomethyl)benzoate 
74. A solution of 10% TFA in DCM (6 mL) was added to 76 (30mg, 
0.073 mmol) and the mixture was stirred for 1 hour. The volatiles 
were removed under vacuum and the crude TFA salt was purified 
by LCMS to give 74 as an amorphous white solid (10 mg, 43%). 1H NMR (DMSO-d6, ppm) 8.25 
(d, J = 8.2 Hz, 2H), 7.73 (d, J = 8.1 Hz, 1H), 7.65 (t, J = 8.4 Hz, 1H), 7.50 (d, J = 8.0 Hz, 2H), 7.46 (d, 
J = 8.6 Hz, 1H), 7.28 (m, 1H), 6.76 (s, 1H), 4.47 (s, J = 5.8 Hz, 2H), 3.78 (s, 3H), 1.50 (s, 9H). 13C 
NMR (CDCl3, ppm) 163.47, 161.86, 155.27, 141.25, 140.27, 132.53, 130.89, 129.86, 128.33, 
123.12, 122.87, 116.11, 115.77, 112.41, 42.35, 29.71. ESI, found 309.1246 (C18H17N2O3, [M + H]
+, 
requires 309.1239). 
1-Methyl-2-oxo-1,2-dihydroquinolin-4-yl 4-
(acetamidomethyl)benzoate 77 To a solution of 74 (20 mg, 0.065 
mmol) in DCM (2 mL) was added triethylamine (20 µL, 0.14 
mmol) and acetyl chloride (20µL, 0.28 mmol). The mixture was 
stirred for 2 hours and then concentrated. The crude product was purified by LCMS to give the 
desired product as a white solid (4 mg, 18 %). 1H NMR (CDCl3, ppm) 8.25 (d, J = 8.2 Hz, 1H), 
7.72 (dd, J = 8.0, 1.1 Hz, 1H), 7.68 – 7.62 (m, 1H), 7.50 (d, J = 8.2 Hz, 1H), 7.46 (d, J = 8.5 Hz, 1H), 
7.25 (d, J = 7.5 Hz, 1H), 6.74 (s, 1H), 5.91 (s, 1H), 4.59 (d, J = 6.0 Hz, 2H), 3.77 (s, 3H), 2.12 (s, 3H). 
ESI HRMS, found 351.1165 (C20H19N2O4, [M + H]
+, requires 351.1134). 
 
4-Methyl-2-oxo-2H-chromen-7-yl 2-methylbenzoate 100 Was 
prepared in the same way as 22 using methylumbelliferone and o-
toluoyl chloride. The crude product was purified using flash column 
chromatography (50:50 ethyl acetate: hexane, Rf = 0.6). White crystals (54 mg, 94%). 
1H NMR 
(CDCl3, ppm) 8.20 (d, J = 7.6 Hz, 1H), 7.69 (d, J = 8.6 Hz, 1H), 7.54 (td, J = 7.7, 1.2 Hz, 1H), 7.37 
(m, 2H), 7.27 – 7.17 (m, 2H), 6.31 (d, J = 1.1 Hz, 1H), 2.70 (s, 3H), 2.48 (d, J = 1.1 Hz, 3H). 13C 
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NMR (CDCl3, ppm) 160.75, 153.61, 152.14, 141.98, 133.43, 132.32, 131.49, 126.24, 125.59, 
118.61, 114.73, 110.96, 22.18, 18.96. ESI HRMS, found 244.0969 (C14H14NO3, [M + H]
+, requires 
244.0974). 
4-Methyl-2-oxo-2H-chromen-7-yl acetate 99 255 Was prepared in the same 
way as 22 using methylumbelliferone and acetyl chloride. The crude product 
was purified using flash column chromatography (50:50 ethyl acetate: 
hexane, Rf = 0.7). White solid (23 mg, 92%). 
1H NMR (CDCl3, ppm) 7.63 (d, J = 8.6 Hz, 1H), 7.14 
(d, J = 2.3 Hz, 1H), 7.10 (dd, J = 8.6, 2.2 Hz, 1H), 6.29 (d, J = 1.2 Hz, 1H), 2.45 (d, J = 1.3 Hz, 3H), 
2.36 (s, 3H). 13C NMR (CDCl3, ppm) 168.97, 160.74, 154.35, 153.23, 152.14, 125.58, 118.30, 
118.03, 114.70, 110.67, 21.30, 18.91. ESI HRMS, found 244.0969 (C14H14NO3, [M + H]
+, requires 
244.0974). 
 
4,6-Dimethyl-3,4-dihydro-2H-pyrano[3,2-c]quinoline-2,5(6H)-dione 70 Was 
prepared using EDCI coupling in the same way 76 using crotonic acid as the 
carboxylic acid component. The crude product was purified using flash column 
chromatography (50:50 ethyl acetate: hexane, Rf = 0.4). Off white solid (233 
mg, 84%). 1H NMR (CDCl3, ppm 8.03 (dd, J = 8.0, 1.4 Hz, 1H), 7.65 (ddd, J = 8.7, 7.3, 1.5 Hz, 
1H), 7.42 (d, J = 8.5 Hz, 1H), 7.33 (app t, J = 7.5 Hz, 1H), 3.77 (s, 3H), 3.56 (m, 1H), 2.99 – 2.73 (m, 
2H), 1.30 (d, J = 7.2 Hz, 3H). 13C NMR (CDCl3, ppm) 166.57, 161.46, 153.14, 139.28, 131.55, 
122.97, 122.60, 114.34, 114.12, 113.77, 36.16, 29.85, 25.90, 19.32. ESI HRMS, found 244.0969 
(C14H14NO3, [M + H]
+, requires 244.0974). 
6-Methyl-2H-pyrano[3,2-c]quinoline-2,5(6H)-dione 71 Was prepared using EDCI 
coupling in the same way as 76 using propiolic acid as the carboxylic acid 
component. The crude product was purified using flash column chromatography 
(50:50 ethyl acetate: hexane, Rf = 0.3). Yellow crystals (214 mgs, 82%). 
1H NMR 
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(CDCl3, ppm) 8.28 (dd, J = 8.1, 1.4 Hz, 1H), 8.25 (d, J = 9.7 Hz, 1H), 7.74 (ddd, J = 8.6, 7.3, 1.5 
Hz, 1H), 7.45 (d, J = 8.6 Hz, 1H), 7.42 – 7.37 (m, 1H), 6.46 (d, J = 9.5 Hz, 1H), 3.79 (s, 3H). 13C 
NMR (CDCl3, ppm) 159.64, 158.91, 141.87, 140.27, 133.57, 124.19, 123.27, 115.16, 114.92, 
107.85, 33.83, 29.97, 24.98. ESI, found 228.01 (C13H10NO3, [M + H]
+, requires 228.07). 
(E)-1-Methyl-2-oxo-1,2-dihydroquinolin-4-yl 3-(4-
methoxyphenyl)acrylate 73 Was prepared using EDCI coupling 
in the same way as 74 using p-methoxycinnamic acid as the 
carboxylic acid component. The crude product was purified 
using flash column chromatography (50:50 ethyl acetate: hexane, Rf = 0.4). Off white solid (345, 
90%). 1H NMR (CDCl3, ppm) 7.94 (d, J = 15.9 Hz, 1H), 7.76 (d, J = 9.2 Hz, 1H), 7.62 (m, 3H), 
7.44 (d, J = 8.5 Hz, 1H), 7.28 (m, 1H), 6.99 (d, J = 8.8 Hz, 2H), 6.71 (s, 1H), 6.59 (d, J = 15.9 Hz, 
1H), 3.90 (s, 3H), 3.76 (s, 3H). 13C NMR (CDCl3, ppm) 164.16, 162.93, 162.35, 155.45, 148.22, 
140.34, 131.71, 130.54, 126.72, 123.41, 122.33, 116.94, 114.75, 113.32, 112.16, 55.65, 33.86, 29.67, 
25.00. ESI HRMS, found 336.1240 (C20H18NO3, [M + H]
+, requires 336.1236). 
5-Bromopyridin-3-yl 2-methylbenzoate 96 Was prepared as in 22 replacing 
4-hydroxy-N-methyl-2-quinolone with 94. The crude product was purified 
using flash column chromatography (50:50 ethyl acetate: hexane, Rf = 0.5). 
White crystals (319 mg, 96%). 1H NMR (CDCl3, ppm) 8.62 (d, J = 1.9 Hz, 1H), 8.51 (d, J = 2.4 
Hz, 1H), 8.18 (dd, J = 8.3, 1.4 Hz, 1H), 7.85 (m, 1H), 7.55 (m, 2H), 7.36 (m, 2H), 2.69 (s, 3H). ESI 
HRMS, found 291.9973 (C13H10
79BrNO2, [M + H]
+, requires 291.9973). 
(E)-5-bromopyridin-3-yl but-2-enoate 97 Was prepared as in 22. The 
crude product was purified using flash column chromatography (50:50 
ethyl acetate: hexane, Rf = 0.5). Clear oil (230 mg, 84%). 
1H NMR (CDCl3, ppm) 8.56 (s, 1H), 
8.41 (s, 1H), 7.74 (s, 1H), 7.40 – 7.10 (m, 1H), 6.05 (dd, J = 14.0, 1.6 Hz, 1H), 2.01 (dd, J = 7.0, 1.6 
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Hz, 3H). 13C NMR (CDCl3, ppm) 163.86, 149.07, 147.89, 141.81, 132.42, 121.11, 120.11, 38.94, 
18.53. ESI, found 241.9823 (C9H8
79BrNO2, [M + H]
+, requires 241.9817). 
5-Chloropyridin-3-yl 4-methylbenzoate 98 Was prepared as in 22. The 
crude product was purified using flash column chromatography (50:50 
ethyl acetate: hexane, Rf = 0.5). Orange crystals (275 mg, 97%). 
1H 
NMR (CDCl3, ppm) 8.54 (d, J = 2.1 Hz, 1H), 8.51 (d, J = 2.3 Hz, 1H), 8.10 (d, J = 8.2 Hz, 2H), 
7.79 – 7.75 (m, 1H), 7.36 (d, J = 7.9 Hz, 2H), 2.49 (s, 3H). ESI, found 248.15 (C13H10
35ClNO2, [M + 
H]+, requires 248.05). 
5-Chloropyridin-3-yl 1H-indole-4-carboxylate 102 Was prepared using 
EDCI coupling the same way as 74, yielding the desired product as a 
yellow oil (192 mg, 62%). The crude product was purified using flash 
column chromatography (Biotage Isolera, SNAP 5G, 20:80 – 70:30 
ethyl acetate:hexane, 10CV). 1H NMR (CDCl3, ppm) 8.72 (s, 1H), 8.54 (d, J = 2.1 Hz, 1H), 8.51 
(d, J = 2.3 Hz, 1H), 8.12 (dd, J = 7.4, 0.8 Hz, 1H), 7.82 – 7.76 (m, 1H), 7.73 (d, J = 8.2 Hz, 1H), 7.48 
– 7.42 (m, 1H), 7.34 (app t, J = 7.8 Hz, 1H), 7.24 (m, 1H). 13C NMR (CDCl3, ppm) 165.07, 148.02, 
145.57, 141.60, 136.83, 132.12, 130.39, 128.18, 127.36, 124.73, 121.47, 119.39, 117.61, 104.00. ESI 
HRMS, found 273.0435 (C14H10
35ClN2O2, [M + H]
+, requires 273.0431).  
 
2-Oxo-1,2-dihydroquinoline-4-carboxylic acid 110 197 A mixture of isatin (109) (1.0 
g, 6.8 mmol), and malonic acid (1.07 g, 10.3 mmol) in acetic acid (8 mL) was 
refluxed for 12 h. The precipitated solid was filtered, washed with acetone, ether, 
and dried to give the desired product as a yellow solid (1.05 g, 82 %). 1H NMR (DMSO-d6, ppm) 
13.95 (s, 1H), 12.07 (s, 1H), 8.15 (d, J = 8.2 Hz, 1H), 7.56 (t, J = 8.5 Hz, 1H), 7.38 (d, J = 8.2 Hz, 
1H), 7.24 (t, J = 7.1 Hz, 1H), 6.87 (s, 1H). ESI, found 190 (C10H8NO3, [M + H]
+, requires 190). 
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Ethyl 2-oxo-1,2-dihydroquinoline-4-carboxylate 111 256 110 (200 mg, 0.91 mmol) 
was refluxed for 16 hours in ethanol (10 ml) and catalytic H2SO4. The ethanol was 
evaporated, the residue neutralised with saturated NaHCO3 solution, and extracted 
with ethyl acetate. The organic extracts were dried (MgSO4) and concentrated to give the crude 
product which was purified using flash column chromatography (80:20 ethyl acetate: hexane, Rf = 
0.35). White solid (182 mg, 91%). 1H NMR (DMSO-d6, ppm) 12.13 (s, 1H), 8.06 (d, J = 7.3 Hz, 
1H), 7.58 (t, J = 8.3 Hz, 1H), 7.39 (d, J = 8.1 Hz, 1H), 7.25 (t, J = 8.3 Hz, 1H), 6.91 (m, 1H), 4.41 (q, J 
= 7.1 Hz, 2H), 1.36 (t, J = 7.1 Hz, 3H). ESI, found 218 (C13H12BrN2O, [M + H]
+, requires 218). 
p-Tolyl 2-oxo-1,2-dihydroquinoline-4-carboxylate 113 198 110 (1 g, 5.3 
mmol) was refluxed in POCl3 (8 ml) for 3 hours. The mixture was poured 
into ice water and extracted with chloroform. The organic extracts.were 
dried (MgSO4) and concentrated and then refluxed in thionyl chloride (10 mL) for 1 hour. The thionyl 
chloride was removed under a vacuum and the residue dissolved in benzene (10 mL). Triethylamine 
(0.93 ml, 6.8 mmol) and p-cresol (0.7 ml, 6.8 mmol) were added and the mixture refluxed for 1 hour. 
The benzene was removed under a vacuum and the residue treated with 10% NaHCO3 and the 
precipitate filtered and washed with water. This solid was dissolved in acetic acid (10 mL) together 
with sodium acetate (1.2 g, 15 mmol) and refluxed for 1 hour. The reaction mixture was cooled and 
diluted with water and filtered to give a yellow solid. This crude product was purified using flash 
column chromatography (5:95 MeOH: DCM, Rf = 0.4). White solid (720 mg, 48%). 
1H NMR (CDCl3, 
ppm) 12.51 (s, 1H), 8.48 (d, J = 8.3 Hz, 1H), 7.62 (t, J = 8.3 Hz, 1H), 7.53 (s, 1H), 7.51 (d, J = 7.6 
Hz, 1H), 7.35 (t, J = 7.8 Hz, 1H), 7.29 (d, J = 8.4 Hz, 2H), 7.18 (d, J = 8.4 Hz, 2H), 2.42 (s, 3H). ESI 
HRMS, found 280.0996 (C17H13NO3, [M + H]
+, requires 280.0974). 
 p-Tolyl 5-bromonicotinate 115 5-Bromonicotinic acid (50 mg, 0.25 
mmol) was dissolved in acetonitrile (6 ml) together with EDCI (60 mg, 
0.25 mmol) and Et3N (56 µL, 0.36 mmol). After 5 minutes p-cresol (26 
µL, 0.25 mmol) was added and the mixture stirred overnight. The acetonitrile was evaporated and the 
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residue partitioned between ethyl acetate and water. The organic layer was evaporated and the crude 
product was purified using flash column chromatography (50:50 ethyl acetate: hexane, Rf = 0.2). 
White solid (17 mg, 23%). 1H NMR (CDCl3, ppm) 9.31 (s, 1H), 8.94 (s, 1H), 8.60 (s, 1H), 7.26 (d, 
J = 8.4 Hz, 3H), 7.12 (d, J = 8.4 Hz, 2H), 2.41 (s, 3H). 13C NMR (CDCl3, ppm) 155.21, 149.46, 
140.14, 130.36, 121.23, 21.11. 5 quaternary carbons were not observed. ESI HRMS, found 291.9987 
(C13H10
79BrNO2, [M + H]
+, requires 291.9973). 
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N-(5-bromopyridin-3-yl)-2-methylbenzamide 126 Was prepared as in 22. 
The crude product was purified using flash column chromatography 
(50:50 ethyl acetate: hexane, Rf = 0.5). Clear oil (325 mg, 98%). 
1H NMR 
(CDCl3, ppm) 8.66 (s, 1H), 8.53 (d, J = 2.2 Hz, 1H), 8.37 (d, J = 2.0 Hz, 1H), 8.02 (s, 1H), 7.49 (d, 
J = 7.7 Hz, 2H), 7.41 (td, J = 7.6, 1.3 Hz, 1H), 7.34 – 7.24 (m, 2H), 2.51 (s, 3H). 13C NMR (CDCl3, 
ppm) 168.64, 146.02, 138.84, 137.01, 136.04, 135.24, 131.72, 131.14, 129.98, 126.83, 126.22, 
121.05, 20.07. ESI HRMS, found 291.0142 (C13H12
79BrN2O, [M + H]
+, requires 291.0133). 
 
1-Methylquinolin-2(1H)-one 131 257 A mixture of quinoline (525 mg, 4 mmol) 
and iodomethane (2.84 g, 20 mmol) was dissolved in DCM (10mL) and stirred 
overnight. The resulting solid was collected by filtration, washed with DCM and 
dried under vacuum to give an orange solid. The solid (100 mg, 0.37 mmol) was dissolved in MeCN 
and KMnO4 (116 mg, 0.74 mL) was added. The mixture was stirred for 20 minutes, then quenched 
with saturated sodium metabisulfate solution (10 mL). 2M HCl (20 mL) was added to the mixture, 
and the mixture extracted with chloroform. The organic phase was concentrated and purified to give 
the crude product which was not purified further. 1H NMR (DMSO-d6, ppm) 7.91 (d, J = 9.5 Hz, 
1H), 7.73 (dd, J = 7.7, 1.3 Hz, 1H), 7.64 (ddd, J = 8.6, 7.3, 1.5 Hz, 1H), 7.54 (d, J = 8.5 Hz, 1H), 7.28 
(app t, J = 7.6 Hz, 1H), 6.63 (d, J = 9.5 Hz, 1H), 3.36 (s, 3H). ESI, found 160 (C10H9NO, [M + H]
+, 
requires 160). 
1-Methyl-3,6,8-trinitroquinolin-2(1H)-one 127 201 To 131 (200 mg, 1.25 
mmol)) was added conc. H2SO4 (3 mL) and conc. HNO3 (3 mL) and the 
mixture heated at 100 ºC overnight. The mixture was cooled to room 
temperature and diluted with water (20 mL). The resulting precipitate was isolated by filtration and 
washed with cold water to afford the desired compound as a yellow solid (350 mg, 94%). 1H NMR 
(DMSO-d6, ppm) 1H NMR (400 MHz, DMSO-d6) δ 9.29 (s, 1H), 9.26 (d, J = 2.8 Hz, 1H), 9.10 (d, 
J = 2.8 Hz, 1H), 3.42 (s, 3H). ESI, found 295.03 (C10H6N4O7, [M + H]
+, requires 295.03). 
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1-Methyl-3,6-dinitroquinolin-2(1H)-one 132 To 131 was added conc. 
HNO3 (3 mL) and the mixture heated overnight at 100 ºC. The mixture 
was cooled to room temperature and diluted with water (20 mL). The 
resulting precipitate was isolated by filtration and washed with cold water to afford the desired 
compound as a yellow solid (268 mg, 86%). 1H NMR (DMSO-d6, ppm) δ 9.14 (s, 1H), 8.99 (d, J = 
2.7 Hz, 1H), 8.58 (dd, J = 9.4, 2.6 Hz, 1H), 7.87 (d, J = 9.5 Hz, 1H), 3.76 (s, 3H). ESI, found 249.98 
(C10H7N3O5, [M + H]
+, requires 249.04). 
1-(4-Methoxyphenyl)-2-(quinolin-4-yl)ethanone 135 204 To a solution 
of diisopropylamine (0.45 mL, 3.2 mmol) in THF (50 mL) at-78 ºC 
was added 1.6 M n-butyl lithium in THF (2 mL, 3.2 mmol). The 
mixture was warmed to 0 ºC and stirred for 10 minutes then cooled 
back to -78 ºC. A solution of lepidine (430 mg, 3 mmol) in THF (2 mL) was added dropwise over 20 
minutes. A solution of methyl p-methoxybenzoate (530 mg, 3.2 mmol) in THF (2 mL) was then added 
dropwise. The reaction was stirred for 2 hours at -78 ºC then allowed to warm to room temperature. 
The reaction was quenched with water (60 mL) and extracted with ethyl acetate (20 mL). The organic 
extracts were combined, dried over sodium sulfate, and concentrated in vacuo. The crude product was 
purified using flash column chromatography (70:30 ethyl acetate: hexane, Rf = 0.35) to give the 
desired product as a yellow oil (440 mg, 53%). 1H NMR (DMSO-d6, ppm) 8.85 (d, J = 4.4 Hz, 
1H), 8.15 (d, J = 8.3 Hz, 1H), 8.04 (d, J = 8.9 Hz, 2H), 7.89 (d, J = 8.9 Hz, 1H), 7.78 – 7.68 (m, 1H), 
7.55 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.31 – 7.24 (m, 1H), 6.97 (d, J = 8.9 Hz, 2H), 4.70 (s, 2H), 3.89 
(s, 3H). ESI, found 278.98 (C18H15NO2, [M + H]
+, requires 278.12). 
1,4-Dimethylquinolin-2(1H)-one 138 210 N-Methylaniline (2 mL, 1.9 mmol) and 
ethyl acetoacetate (4.67 mL, 3.8 mmol) were heated at reflux in acetic acid (10 
mL) for 48 h. The solvent was evaporated under reduced pressure and the residue 
was heated in 96% H2SO4 (8 mL) at 100 ºC for 1 h. After cooling to room temperature, the mixture 
was neutralised with aqueous 6 M NaOH. The resulting precipitate was filtered, washed with water 
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and dried. The desired compound was obtained as a white solid (187 mg, 57%). 1H NMR (CDCl3, 
ppm) 7.72 (d, J = 9.1 Hz, 1H), 7.63 – 7.54 (m, 1H), 7.39 (d, J = 8.5 Hz, 1H), 7.32 – 7.23 (m, 1H), 
6.61 (s, 1H), 3.72 (s, 3H), 2.48 (s, 3H). ESI, found 173.85 (C11H11NO, [M + H]
+, requires 174.09). 
4-(2-(4-Methoxyphenyl)-2-oxoethyl)-1-methylquinolin-2(1H)-one 137 
To a stirred suspension of 138 (50 mg, 0.29 mmol) in dry THF (5 mL) 
under an argon atmosphere at -78 ºC, was injected n-BuLi (140 µL of 
2.5 M solution in THF, 0.34 mmol). When the addition was complete, 
the reaction mixture was warmed to room temperature for 1 hour, treated with the methyl p-
methoxybenzoate (60 mg, 0.34 mmol) in THF( 2mL) at 0 ºC and stirred at room temperature for 15-
30 min. The mixture was cooled to 0 ºC, treated with 5 mL of 2N HCI, and extracted with CHC13 (3 x 
10 ml). The organic layer was separated and washed sequentially with aqueous sodium bicarbonate 
(10%, 30 mL) and saturated brine (30 mL), dried (sodium sulphate) and concentrated in vacuo. The 
crude product was purified by flash column chromatography (70:30 ethyl acetate:hexane, Rf = 0.25 ) 
to give the desired compound as a yellow oil (6 mg, 7%). 1H NMR (DMSO-d6, ppm) 8.05 (d, J = 
8.9 Hz, 2H), 7.60 (m, 2H), 7.43 (m, 1H), 7.23 (m, 1H), 7.00 (d, J = 8.9 Hz, 2H), 6.68 (s, 1H), 4.47 (s, 
2H), 3.91 (s, 3H), 3.75 (s, 3H). ESI, found 308.29 (C19H17NO3, [M + H]
+, requires 308.13). 
 
(E)-Ethyl 3-(2-oxo-1,2-dihydroquinolin-4-yl)acrylate 147 To a solution of 2-
hydroxy-4-methylquinoline (144) (200 mg, 1.26 mmol) in xylene (10 mL) was 
added selenium dioxide (490 mg, 4.40 mmol) and the reaction mixture was 
stirred at 150 °C for 48 hours. The reaction was cooled to around 60 °C and 
then filtered to remove solids and the filtrate concentrated to obtain the crude aldehyde which was 
used without further purification. The crude aldehyde (145) (100 mg, 0.58 mmol) was dissolved in 
THF (10 mL) and then (carbethoxymethylene)triphenylphosphorane (242 mg, 0.69 mmol) added. The 
mixture was stirred for 24 hours and then concentrated. The crude product was purified using flash 
column chromatography (Biotage Isolera, SNAP 5G, 40:60 – 80:20 ethyl acetate:hexane, 12 CV). 
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Yellow-brown solid (95 mg, 64%). 1H NMR (CDCl3, ppm) 12.3 (br s , 1H), 8.13 (d, J = 15.5 Hz, 
1H), 7.82 (d, J = 7.3 Hz, 1H), 7.59 (app td, J = 7.8, 7.4, 1.1 Hz, 1H), 7.49 (dd, J = 8.0, 1.2 Hz, 1H), 
7.31 (app td, J = 7.9, 1.2 Hz, 1H), 6.89 (s, 1H), 6.56 (d, J = 15.8 Hz, 1H), 4.34 (q, J = 7.1 Hz, 2H), 
1.40 (t, J = 7.1 Hz, 3H). 13C NMR (CDCl3, ppm) 165.87, 164.06, 146.16, 138.72, 138.63, 131.49, 
128.64, 126.17, 124.54, 123.36, 118.74, 117.13, 61.36, 14.44. ESI, found 244.0977 (C14H13NO3, [M + 
H]+, requires 244.0974). 
1-Methyl-2-oxo-1,2-dihydroquinoline-4-carbaldehyde 154 210 The aldehyde was 
obtained using the same method as in 147. In this case the crude intermediate 
aldehyde was purified by flash column chromatography (Biotage Isolera, SNAP 
12G, 20:80 – 50:50 ethyl acetate:hexane, 12 CV) to obtain the desired product as 
a grey-white solid (745 mg, 69%). 1H NMR (CDCl3, ppm) 10.16 (s, 1H), 8.84 (dd, J = 8.2, 1.4 Hz, 
1H), 7.67 (ddd, J = 8.6, 7.2, 1.5 Hz, 1H), 7.45 (d, J = 8.5 Hz, 1H), 7.40 – 7.31 (m, 1H), 7.18 (s, 1H), 
3.78 (s, 3H). 
4-(2-Methoxyvinyl)-1-methylquinolin-2(1H)-one 155 NaHMDS (1.3 mL of a 1.0 
M solution in THF, 1.3 mmol) was added dropwise to a suspension of 
MeOCH2PPh3Cl (480 mg, 1.40 mmol) in THF (5 mL) at 0 °C. The resulting deep 
orange solution was allowed to stir for 30 minutes at 0 °C before being cooled to 
−40 °C. Aldehyde 154 (60 mg, 0.64 mmol) was added dropwise as a solution in THF (2 mL) and the 
pale yellow solution was allowed to warm to room temperature over 2 hours. Saturated NH4Cl 
solution (10 mL) was added and the reaction mixture extracted into DCM (2 × 10 mL) and dried over 
Na2SO4. The solvent was removed under reduced pressure and the residue was purified by flash 
column chromatography (Biotage Isolera, SNAP 5G, 30:70 – 70:30 ethyl acetate:hexane, 12 CV) to 
give the title compound as a 10:9 mixture of trans:cis products (94 mg, 64%) with a PPh3(=O) 
impurity (~10% by LCMS). 1H NMR (CDCl3, ppm) Aromatic region obscured by PPh3(=O). 7.37 
(s, 0.9H), 7.13 (d, J = 12.4 Hz, 1H), 6.71 (s, 1H), 6.55 (d, J = 7.2 Hz, 0.9H), 6.12 (d, J = 12.4 Hz, 1H), 
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5.60 (d, J = 7.2 Hz, 0.9H), 3.86 (s, 2.7H), 3.81 (s, 3H), 3.74 (m, 5.7H). ESI, found 217 (C13H13NO3, 
[M + H]+, requires 216). 
 
(E)-ethyl 4-(1-methyl-2-oxo-1,2-dihydroquinolin-4-yl)but-2-enoate 143 and 
156 155 (90 mg, 0.42 mmol) was dissolved in THF (3 mL)and then 2 ml of 
4M HCl was added. The reaction was stirred and monitored by TLC to 
observe the formation of the aldehyde intermediate. After 3 hours, the 
reaction was neutralized with saturated NaHCO3 (20mL) and extracted with 
ethyl acetate (10 mL). The organic layer was dried (MgSO4) and then 
concentrated to provide the crude aldehyde. At this point the standard Wittig 
reaction as in 147 was followed. Two products (10: 7), whose spectra were consistent with the 
structures shown, were formed and proved inseparable. 1H NMR (CDCl3, ppm) δ 7.79 (dd, J = 8.0, 
1.3 Hz, 1H), 7.65 (dd, J = 8.0, 1.3 Hz, 0.7H), 7.62 – 7.55 (m, 1.7H), 7.40 (t, J = 7.5 Hz, 1.7H), 7.29 – 
7.22 (m, 1.7H), 7.13 (dt, J = 15.7, 6.5 Hz, 0.7H), 6.89 (d, J = 16.0 Hz, 1H), 6.79 (s, 1H), 6.62 (s, 
0.7H), 6.43 (dt, J = 15.7, 7.1 Hz, 1H), 5.88 (dt, J = 15.7, 1.6 Hz, 0.7H), 4.19 (m, 3.4 H), 3.72 (s, 
5.1H), 3.71 (m, 1.4H), 3.35 (dd, J = 7.1, 1.5 Hz, 2H), 1.29 (m, 5.1H). ESI HRMS, found 271.1280 
(C16H17NO3, [M + H]
+, requires 271.1287). 
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Ethyl 5-bromonicotinate 148 258 To a solution of 5-bromonicotinic acid (2 g, 
10 mmol) in ethanol (30 mL) was added conc. sulfuric acid (2 mL) and the 
mixture stirred at reflux overnight. The reaction mixture was concentrated and 
then neutralised with saturated sodium hydrogen carbonate. The mixture was extracted with ethyl 
acetate (15 mL)and the organic layer was dried (MgSO4) and concentrated to give the product as a 
white amorphous solid (2.12 g, 93%). 1H NMR (CDCl3, ppm) 9.14 (d, J = 1.8 Hz, 1H), 8.85 (d, J = 
2.3 Hz, 1H), 8.48 – 8.42 (m, 1H), 4.44 (q, J = 7.0 Hz, 2H), 1.43 (t, J = 7.0 Hz, 3H). ESI, found 230 
(C8H8
79BrNO2, [M + H]
+, requires 230). 
(5-Bromopyridin-3-yl)methanol 149 To a cold (0° C) solution of 148 (1.00 g, 4.3 
mmol) in MeOH (15 mL) was added sodium borohydride (650 mg, 17 mmol) 
portion wise. After 2 hours, the reaction was quenched by the addition of water 
(50 mL). The reaction was then extracted with DCM (10 mL). The extracts were combined and dried 
(MgSO4) and the filtrate was concentrated and purified by flash column chromatography (60:40 ethyl 
acetate:hexanes, Rf = 0.4) to produce the desired product as a clear oil (570 mg, 72 %). 
1H NMR 
(CDCl3, ppm) 8.61 (d, J = 1.6 Hz, 1H), 8.51 (s, 1H), 7.93 (d, J = 2.0 Hz, 1H), 4.76 (s, 2H), 2.31 (s, 
1H). ESI, found 188 (C6H6
79BrNO, [M + H]+, requires 188). 
5-Bromonicotinaldehyde 150 259 To a solution of 149 (200 mg, 1 mmol) in DCM 
(10 mL) was added Dess–Martin periodinane (640 mg, 1.5 mmol) and the reaction 
mixture was stirred for 1 hour. The reaction was quenched with 10% sodium 
thiosulphate solution (15 mL) and saturated sodium hydrogen carbonate solution (x mL). The mixture 
was extracted with DCM (10 mL) and the organic phase dried over magnesium sulphate and 
concentrated. The crude product was purified by flash column chromatography (Biotage Isolera, 
SNAP 25 G, 30:70 – 60:40 ethyl acetate:hexane, 12 CV) to obtain the desired product as a clear oil 
(190 mg, 96 %). 1H NMR (CDCl3, ppm) 10.10 (s, 1H), 9.01 (d, J = 1.7 Hz, 1H), 8.93 (d, J = 2.3 
Hz, 1H), 8.37 – 8.27 (m, 1H). ESI, found 186 (C6H4
79BrNO, [M + H]+, requires 186). 
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(E)-Ethyl 3-(5-bromopyridin-3-yl)acrylate 151 The Wittig reaction was 
carried out on 150 as in 147. The crude product was purified by flash 
column chromatography (Biotage Isolera, SNAP 12 G, 30:70 – 60:40 ethyl acetate:hexane, 12 CV), to 
obtain the desired product as an off white solid. (52 mg, 80%). 1H NMR (CDCl3, ppm) 8.67 (d, J = 
2.1 Hz, 1H), 8.66 (d, J = 1.8 Hz, 1H), 7.99 (app t, J = 2.0 Hz, 1H), 7.61 (d, J = 16.1 Hz, 1H), 6.52 (d, J 
= 16.1 Hz, 1H), 4.30 (q, J = 7.2 Hz, 2H), 1.36 (t, J = 7.2 Hz, 3H). 13C NMR (CDCl3, ppm) 166.01, 
151.89, 147.66, 139.28, 136.78, 132.07, 122.19, 121.29, 61.15, 14.42. ESI, found 255.77 
(C10H10
79BrNO2, [M + H]
+, requires 256.00). 
3-Bromo-5-(2-methoxyvinyl)pyridine 152 Using the same protocol as 
142/156 with 150 as the aldehyde substrate. The crude product was 
purified by flash column chromatography (Biotage Isolera, SNAP 25 G, 20:80 – 50:50 ethyl 
acetate:hexane, 12 CV). The title compound was isolated as a 10:7 mixture of trans:cis products (92 
mg, 76%) . 1H NMR (CDCl3, ppm) δ 8.50 (s, 0.7H), 8.36 (m, 2.7H), 8.14 (t, J = 2.0 Hz, 0.7H), 
7.64 (t, J = 2.1 Hz, 1H), 7.06 (d, J = 13.0 Hz, 1H), 6.26 (d, J = 6.9 Hz, 0.7H), 5.64 (d, J = 13.0 Hz, 
1H), 5.11 (d, J = 6.9 Hz, 0.7H), 3.80 (s, 2.1H), 3.68 (s, 3H). ESI, found 213.77 (C8H8
79BrNO, [M + 
H]+, requires 213.99). 
 (E)-Ethyl 4-(5-bromopyridin-3-yl)but-2-enoate 153 152 was 
subjected to acidic conditions as in 142/156 to obtain the crude 
aldehyde. This was subjected to the Wittig reaction as in 147. The crude product was purified by flash 
column chromatography (Biotage Isolera, SNAP 12 G, 30:70 – 60:40 ethyl acetate:hexane, 12 CV). 
Clear oil (49 mg, 42% from 152). 1H NMR (CDCl3, ppm) 8.52 (s, 1H), 8.48 (s, 1H), 7.85 (app t, J 
= 2.0 Hz, 1H), 6.45 – 6.38 (m, 2H), 4.19 (q, J = 7.2 Hz, 2H), 3.29 – 3.26 (m, 2H), 1.29 (t, J = 7.2 Hz, 
3H). 13C NMR (CDCl3, ppm) 171.01, 150.86, 149.43, 146.21, 135.49, 134.40, 128.52, 126.43, 
61.19, 38.46, 14.35. ESI HRMS, found 270.0142 (C11H12
79BrNO2, [M + H]
+, requires 270.0140). 
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3-Iodobenzamide 162 107 3-Iodobenzoic acid (0.29 g, 1.16 mmol) was stirred in 
DCM (10 mL) at room temperature under argon. Oxalyl chloride (0.3 mL, 3.5 
mmol) was added slowly, and slow gas evolution was observed. A catalytic 
amount of DMF was then added (causing extensive gas evolution) and the reaction was stirred for 2 h. 
The reaction was concentrated and the resulting brown oil dissolved in THF (10 mL)and added to a 
solution of 18% aqueous NH4OH (5 mL) at 0 °C. After the mixture was stirred for 15 min, the liquid 
was decanted off, and the remaining sludge was acidified with 1 N HCl. The white solid formed was 
collected by filtration, washed with water, and dried under vacuum to give the title compound as an 
off-white solid (0.24 g, 83%). 1H NMR (DMSO-d6, ppm 8.22 (t, J = 1.7 Hz, 1H), 8.10 (s, 1H), 7.89 
(app dt, J = 7.9, 1.6 Hz, 2H), 7.48 (s, 1H), 7.26 (t, J = 7.8 Hz, 1H). ESI, found 248 (C7H7INO, [M + 
H]+, requires 248). 
(E)-Ethyl 3-(3-carbamoylphenyl)acrylate 158 107 3-Iodo-benzamide 
(0.1 g, 0.47 mmol), methyl acrylate (53 µL, 0.59 mmol), a catalytic 
amount of palladium(II) acetate, and triethylamine (82 µL, 0.59 mmol) 
were stirred at reflux in acetonitrile (5 mL) under argon. The reaction was filtered to remove solid and 
the filtrate concentrated to give the crude product. This was purified by preparative LCMS to give the 
title product as a white solid (34 mg, 38%). 1H NMR (CDCl3, ppm) δ 8.00 (s, 1H), 7.81 (d, J = 7.8 
Hz, 1H), 7.73 (d, J = 15.9 Hz, 1H), 7.69 (s, 1H), 7.50 (app t, J = 7.7 Hz, 1H), 6.53 (d, J = 16.1 Hz, 
1H), 6.14 (br s, 1H), 5.74 (br s, 1H), 4.30 (q, J = 7.1 Hz, 2H), 1.36 (t, J = 7.1 Hz, 3H). ESI, found 220 
(C12H14NO3, [M + H]
+, requires 220). 
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N-(2-Acetylphenyl)benzamide 163 217 To a solution of benzoyl chloride (312 
mg, 2.22 mmol) in anhydrous CH2Cl2(12 mL) was added pyridine (0.23 mL, 
2.8 mmol) followed by 2'-aminoacetophenone (300 mg, 2.22 mmol). The 
resulting mixture was stirred at r.t. for 16 h. After complete consumption of the 
starting materials (as indicated by TLC) saturated aqueous NH4Cl solution (15 
mL) was added and the organic layer was separated. The aqueous layer was extracted with CH2Cl2 (3 
x 30 mL) and the combined organic layers were dried with Na2SO4, filtered and the solvent was 
removed under reduced pressure. The crude material was purified by flash column chromatography 
(20:80 ethyl acetate:hexane, Rf = 0.4) to afford the product as an orange-brown oil (525 mg, 99%). 
1H 
NMR (CDCl3, ppm) 12.73 (s, 1H), 9.01 (d, J = 9.5 Hz, 1H), 8.14 – 8.06 (m, 2H), 7.99 (dd, J = 8.0, 
1.5 Hz, 1H), 7.65 (ddd, J = 8.7, 7.5, 1.5 Hz, 1H), 7.61 – 7.51 (m, 3H), 7.22 – 7.16 (m, 1H), 2.75 (s, 
3H). ESI, found 240 (C15H13NO2, [M + H]
+, requires 240). 
2-Phenylquinolin-4(1H)-one 163 218 169 (0.5 g, 2.1 mmol) was combined 
with crushed NaOH (250 mg, 6.3 mmol). Anhydrous 1,4-dioxane (10 mL) 
was added and the reaction was then stirred for 2 hours at 110 °C and 
subsequently allowed to cool to room temperature, and then concentrated. 
Next, water (5mL) and hexane (40 mL) were added to the flask and the flask was sonicated for 
approximately two minutes. The biphasic mixture was neutralized to pH ~7 with 1M HCl and 
saturated NaHCO3 solutions. Once solid precipitated, the solid was isolated by filtration , and the 
precipitate was rinsed with copious amounts of hexane and minimal water to give the title product as a 
white solid (395 mg, 85%). 1H NMR (DMSO-d6, ppm) 11.72 (s, 1H), 8.10 (d, J = 9.4 Hz, 1H), 
7.84 (dd, J = 6.4, 2.6 Hz, 2H), 7.77 (d, J = 8.2 Hz, 1H), 7.68 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.60 (m, 
3H), 7.34 (app t, J = 7.3 Hz, 1H), 6.34 (s, 1H). ESI HRMS, found 222.0195 (C15H12NO, [M + H]
+, 
requires 222.0919). 
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2-Methyl-5-phenylpyrazolo[1,5-a]pyrimidin-7(4H)-one 164 219A solution 
of 3-amino-5-methylpyrazole (1.0 g, 48.14 mmol) and ethyl 
benzoylacetate (9.2 mL, 53.13 mmol) in AcOH (32 mL) was heated at 
reflux for 3h. The reaction mixture was cooled to room temperature and 
concentrated under vacuum. The resulting solid was resuspended in EtOAc and then filtered to give 
the desired product as a white solid (5.6 g, yield 55%). 1H NMR (DMSO-d6, ppm) 12.37 (s, 1H), 
8.10 – 7.48 (m, 5H), 6.06 (s, 1H), 6.01 (s, 1H), 2.33 (s, 3H). 13C NMR (DMSO-d6, ppm) 156.58, 
152.65, 149.70, 142.87, 132.85, 131.48, 129.54, 127.64, 94.09, 89.73, 14.61. ESI HRMS, found 
226.0969 (C13H12N3O, [M + H]
+, requires 226.0980). 
6-Bromo-2-phenylquinolin-4(1H)-one 182 260 4-bromoaniline (1.46 g, 
8.5 mmol) and ethyl benzoylacetate (1.5 mL, 8.5 mmol) were dissolved 
in cyclohexane (25 mL) together with molecular sieves and a catalytic 
amount of tosylic acid (10 mg). The reaction was stirred at reflux 
overnight and allowed to cool to room temperature. The reaction was filtered to remove solids and the 
filtrate concentrated to obtain a cloudy brown oil. Meanwhile, a solution of diphenylether was heated 
to 240 ºC. The oil was added to the stirred diphenylether and the mixture was maintained at 240 ºC for 
30 minutes, allowing any evolved gases to escape. At this point, the reaction was allowed to cool to 
room temperature with no stirring. A precipitate formed and was isolated by filtration to provide the 
product which was not purified further. Brown crystals (1.3 g, 51%). 1H NMR (DMSO-d6, ppm) 
11.91 (s, 1H), 8.19 (d, J = 2.3 Hz, 1H), 7.85 (dd, J = 6.2, 2.7 Hz, 2H), 7.75 (d, J = 8.9 Hz, 1H), 7.63 – 
7.59 (m, 2H), 7.45 (d, J = 5.0 Hz, 2H), 6.41 (d, J = 1.8 Hz, 1H). ESI, found 300 (C15H10
79BrNO, [M + 
H]+, requires 300). 
4-(Benzyloxy)-6-bromo-2-phenylquinoline 184 182 (1.2 g, 4.10 mmol) 
was dissolved in DMF (15 mL) and K2CO3 (2.8 g, 20 mmol) and benzyl 
bromide (1 mL, 8.2 mmol) were added. The reaction was heated at 60 
ºC overnight. The reaction was allowed to cool and then quenched with 
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water (x mL) and extracted with ethyl actetate (x mL). The organic layer was dried (magnesium 
sulfate) and concentrated and the pure product obtained after flash column chromatography (20:80 
ethyl acetate:hexane, Rf = 0.35) as a white solid (1.28 g, 80%). 
1H NMR (CDCl3, ppm) 9.27 (s, 
1H), 8.74 (d, J = 3.7 Hz, 1H), 8.57 (d, J = 8.0 Hz, 1H), 8.44 (d, J = 2.2 Hz, 1H), 8.04 (d, J = 8.9 Hz, 
1H), 7.84 (dd, J = 8.9, 2.2 Hz, 1H), 7.51 (m, 6H), 7.29 (m, 2H), 5.43 (s, 2H). ESI, found 390 
(C22H16
79BrNO, [M + H]+, requires 390). 
(E)-Ethyl 3-(4-(benzyloxy)-2-phenylquinolin-6-yl)acrylate 185 
The Heck reaction was carried out using the same method as 
158. The pure product obtained after flash column 
chromatography (Biotage Isolera, SNAP 12 G, 20:80 – 60:40 
ethyl acetate:hexane, 12 CV). The product was obtained as an off-white solid (490 mg, 93%). 1H 
NMR (CDCl3, ppm) 8.36 (d, J = 1.8 Hz, 1H), 8.15 – 8.07 (m, 2H), 7.96 – 7.85 (m, 2H), 7.61 – 7.38 
(m, 9H), 7.29 (m, 1H), 6.57 (d, J = 16.0 Hz, 1H), 5.42 (s, 2H), 4.31 (q, J = 7.2 Hz, 2H), 1.38 (t, J = 7.2 
Hz, 3H). ESI, found 410 (C27H23NO3, [M + H]
+, requires 410). 
(E)-Ethyl 3-(4-oxo-2-phenyl-1,4-dihydroquinolin-6-yl)acrylate 
183 185 (300 mg, 0.73 mmol) was dissolved in TFA (x mL) 
and stirred at reflux overnight. Once the reaction was shown to 
be complete by analytical LCMS, the reaction was 
concentrated to give the product as a grey-white solid (228 mg, 98%). The product was further 
purified by preparative LCMS to give the product as a white solid. 1H NMR (DMSO-d6, ppm) 
11.89 (s, 1H), 8.29 (s, 1H), 8.11 (dd, J = 8.8, 1.9 Hz, 1H), 7.85 (dd, J = 5.7, 3.6 Hz, 2H) , 7.78 (dd, J = 
12.3, 3.6 Hz, 2H), 7.64 – 7.57 (m, 3H), 6.67 (d, J = 16.0 Hz, 1H), 6.39 (s, 1H), 4.21 (q, J = 7.1 Hz, 
2H), 1.28 (t, J = 7.1 Hz, 3H). 13C NMR (DMSO-d6, ppm) 166.59, 158.99, 152.11, 143.95, 142.02, 
131.41, 130.74, 129.65, 128.26, 126.32, 123.78, 120.58, 119.08, 117.20, 114.32, 107.67, 60.57, 14.69. 
ESI HRMS, found 320.1276 (C20H17NO3, [M + H]
+, requires 320.1287). 
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Ethyl 4-oxo-2-phenyl-1,4-dihydroquinoline-6-carboxylate 186 
Prepared as in 182. Product contaminated with diephenyl ether (~ 
5% by LCMS) (1.2 g). 1H NMR (DMSO-d6, ppm) 12.02 (s, 1H), 
8.72 (m, 1H), 8.20 (m, 1H), 7.93 – 7.72 (m, 3H), 7.68 – 7.54 (m, 
3H), 6.44 (s, 1H), 4.37 (q, J = 7.1 Hz, 2H), 1.38 (t, J = 7.1 Hz, 3H). ESI, found 294 (C18H15NO3, [M + 
H]+, requires 294).  
Ethyl 4-(benzyloxy)-2-phenylquinoline-6-carboxylate 187 Prepared 
in the same way as 184. Purified by flash column chromatography 
(Biotage Isolera, SNAP 40 G, 20:80 – 70:30 ethyl acetate:hexane, 12 
CV). White solid (88%). 1H NMR (CDCl3, ppm) δ 9.02 (d, J = 
1.8 Hz, 1H), 8.33 (dd, J = 8.8, 1.9 Hz, 1H), 8.13 (m, 3H), 7.63 – 7.36 (m, 8H), 7.30 (m, 1H), 5.45 (s, 
2H), 4.47 (q, J = 7.1 Hz, 2H), 1.47 (t, J = 7.1 Hz, 3H). ESI, found 384.81 (C25H21NO3, [M + H]
+, 
requires 384.16. 
(4-(Benzyloxy)-2-phenylquinolin-6-yl)methanol 188 To a solution of 
187 (250 mg, 0.65 mmol) in THF (8 ml) was added LiALH4 . (76 
mg, 2 mmol). The reaction was stirred for 1 hour and quenched using 
Feiser conditions: 76 µL of water was added followed by 76 µL of 
15% aqueous NaOH and then 0.23 mL water. After 15 minutes stirring, MgSO4 was added and the 
mixture stirred for another 15 minutes. The reaction was then filtered and the filtrate concentrated to 
give the crude product. Purified by flash column chromatography (Biotage Isolera, SNAP 12 G, 60:40 
– 80:20 ethyl acetate:hexane, 14 CV). White solid (195 mg, 88%). 1H NMR (CDCl3, ppm) 8.23 (s, 
1H), 8.10 (d, J = 7.3 Hz, 2H), 7.75 (d, J = 9.9 Hz, 1H), 7.50 (m, 9H), 7.29 (s, 1H), 5.41 (s, 2H), 4.89 
(s, 2H). ESI, found 342.82 (C23H19NO2, [M + H]
+, requires 342.16). 
4-(Benzyloxy)-2-phenylquinoline-6-carbaldehyde 189 Using the same 
Dess-Martin periodine conditions as 150. Purified by flash column 
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chromatography (Biotage Isolera, SNAP 12 G, 40:60 – 70:30 ethyl acetate:hexane, 12 CV). White 
solid (184 mg, 95%). 1H NMR (CDCl3, ppm) 10.19 (s, 1H), 8.85 – 8.73 (m, 1H), 8.21– 8.10 (m, 
4H), 7.66 – 7.44 (m, 8H), 7.38 (s, 1H), 5.46 (s, 2H). ESI, found 341 (C23H17NO2, [M + H]
+, requires 
341). 
4-Oxo-2-phenyl-1,4-dihydroquinoline-6-carbaldehyde 190 Using the 
same method of deprotection with TFA as 183. Yellow solid (126 mg, 93 
%) some of which was further purified by LCMS to give a white solid. 
 1H NMR (CDCl3, ppm) 12.10 (s, 1H), 10.10 (s, 1H), 8.69 (d, J = 1.8 Hz, 1H), 8.12 (dd, J = 8.7, 
1.9 Hz, 1H), 7.99 – 7.76 (m, 3H), 7.68 – 7.52 (m, 3H), 6.48 (s, 1H). ESI HRMS, found 250.0886 
(C16H11NO2, [M + H]
+, requires 250.0886). 
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(S)-tert-Butyl 4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-
(methoxy(methyl)amino)-5-oxopentanoate 198 Fmoc-L-glutamic acid 5-
tert-butyl ester (5.0 g, 11.7 mmol) was dissolved in DMF (20 mL) together 
with HBTU (4.46 g, 11.7 mmol) and DIPEA (4.0 mL, 23 mmol). Weinreb 
base (1.14 g, 11.7 mmol) was then added and the reaction stirred overnight. The reaction was 
quenched with water (100 mL) and extracted with ethyl acetate (2 x 15 mL). The organic layer was 
washed with 10% citric acid (5 x 30 mL), saturated NaHCO3 (30 mL) and saturated brine (30 mL) and 
then dried over magnesium sulphate and concentrated to give the product as a clear oil (4.34 g, 79 %). 
1H NMR (CD3OD, ppm) 7.78 (d, J = 7.9 Hz, 2H), 7.62 (t, J = 6.8 Hz, 2H), 7.42 (t, J = 7.5 Hz, 2H), 
7.33 (tdd, J = 7.4, 2.5, 1.0 Hz, 2H), 5.63 (d, J = 8.8 Hz, 1H), 4.79 (s, 1H), 4.38 (d, J = 7.2 Hz, 2H), 
4.23 (t, J = 7.2 Hz, 1H), 3.80 (s, 3H), 3.24 (s, 3H), 2.35 (t, J = 7.4 Hz, 2H), 2.07 (m, 1H), 1.75 – 1.59 
(m, 1H), 1.46 (s, 9H). ESI, found 469.57 (C26H32N2O6, [M + H]
+, requires 469.24). 
(S,E)-7-tert-Butyl 1-ethyl 4-((((9H-fluoren-9-
yl)methoxy)carbonyl)amino)hept-2-enedioate 200 198 (4.34 g, 9.28 
mmol) was dissolved in dry THF (20 mL) under an argon atmosphere 
and cooled to -50 ºC. LiAlH4 (9.3 ml of 2M in THF) was added dropwise. The orange solution was 
stirred for 40 minutes and then quenched with ethyl acetate (5 mL). 10% potassium hydrogen sulphate 
(10 mL) was then added and the mixture extracted with ethyl acetate (20 mL). The organic extracts 
were dried over magnesium sulphate and concentrated. The crude aldehyde 199 (3.33 g, 8.14 mmol) 
was dissolved in THF (15 mL) and (carbethoxymethylene)triphenylphosphorane (5.67g, 16.28 mmol) 
added. The reaction was stirred for 24 hours and then concentrated. The product was purified by flash 
column chromatography (Biotage Isolera, SNAP 100G, 40:60 – 80:20 ethyl acetate:hexane, 16 CV). 
Clear oil (3.5 g, 89%). ESI, found 480 (C28H33NO6, [M + H]
+, requires 480). 
(S,E)-4-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-7-ethoxy-7-
oxohept-5-enoic acid 19592 200 ( 3 g, 6.25 mmol) was dissolved in a 
solution of 20% TFA in DCM (15 mL) and stirred for 2 hours. The 
reaction was concentrated to obtain an oil. This was triturated with a 1:1 mixture of Et2O and hexanes 
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(3 mL), and the resulting solid was collected by filtration and washed thoroughly with cold 
Et2O/hexane to afford 195 as a white solid (2.3 g, 88% yield) 
1H NMR (CD3OD, ppm) 7.81 (d, J = 
7.5 Hz, 2H), 7.67 (dd, J = 7.2, 3.2 Hz, 2H), 7.40 (t, J = 7.3 Hz, 2H), 7.33 (t, J = 7.4 Hz, 2H), 6.86 (dd, 
J = 15.7, 5.7 Hz, 1H), 5.91 (d, J = 16.8 Hz, 1H), 4.42 (d, J = 7.3 Hz, 2H), 4.29 (m, 1H), 4.21 (m, 3H), 
2.37 (m, 2H), 1.91 (m, 1H), 1.83 – 1.70 (m, 1H), 1.30 (t, J = 7.1 Hz, 3H). 13C NMR (CD3OD, ppm) 
δ 175.09, 166.45, 156.90, 147.90, 143.90, 141.25, 127.39, 126.77, 124.73, 120.56, 119.54, 66.24, 
60.25, 51.37, 29.86, 28.75, 26.94, 13.14. ESI, found 424 (C24H25NO6, [M + H]
+, requires 424). 
 
(S,E)-Ethyl 4-((S)-2-((S)-2-((R)-1-
acetylpyrrolidine-2-carboxamido)propanamido)-6-
aminohexanamido)-7-amino-7-oxohept-2-enoate 
1592 Was obtained using SPPS techniques and 
purified by preparative LCMS. 1H NMR (CD3OD, 
ppm) 6.88 (dd, J = 15.7, 5.4 Hz, 1H), 5.94 (dd, J 
= 15.7, 1.7 Hz, 1H), 4.54 (m, 1H), 4.40 – 4.25 (m, 3H), 4.20 (q, J = 7.2 Hz, 2H), 3.78 – 3.57 (m, 2H), 
2.95 (m, 2H), 2.32 (m, 3H), 2.14 (s, 3H), 2.02 (m, 3H), 1.88 (m, 4H), 1.76 – 1.64 (m, 2H), 1.49 (m, 
2H), 1.42 (d, J = 7.3 Hz, 3H), 1.29 (t, J = 7.2 Hz, 3H). ESI HRMS, found 539.3200 (C25H42N6O7, [M 
+ H]+, requires 539.3193). 
(S,E)-Ethyl 4-((S)-2-((S)-2-((R)-1-
acetylpyrrolidine-2-carboxamido)propanamido)-6-
(dimethylamino)hexanamido)-7-amino-7-oxohept-
2-enoate 202 was obtained in the same way as 15. 
1H NMR (CD3OD, ppm) 6.88 (dd, J = 15.7, 5.4 
Hz, 1H), 5.93 (dd, J = 15.7, 1.5 Hz, 1H), 4.54 (m, 1H), 4.39 – 4.25 (m, 3H), 4.19 (q, J = 7.2 Hz, 2H), 
3.75 – 3.56 (m, 2H), 3.20 – 3.06 (m, 2H), 2.90 (s, 6H), 2.30 (m, 3H), 2.13 (s, 3H), 2.05 – 1.68 (m, 
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8H), 1.47 (m, 2H), 1.42 (d, J = 7.3 Hz, 3H), 1.29 (t, J = 7.2 Hz, 3H). ESI HRMS HRMS, found 
567.3512 (C27H46N6O7, [M + H]
+, requires 567.3506). 
(S,E)-Ethyl 4-((S)-2-((S)-2-((R)-1-
acetylpyrrolidine-2-carboxamido)propanamido)-4-
methylpentanamido)-7-amino-7-oxohept-2-enoate 
203 was obtained in the same way as 15. 1H NMR 
(CD3OD, ppm) 6.88 (dd, J = 15.7, 5.1 Hz, 1H), 
5.93 (d, J = 15.7 Hz, 1H), 4.57 – 4.47 (m, 1H), 4.35 (m, 2H), 4.28 (m, 1H), 4.19 (q, J = 7.0 Hz, 2H), 
3.67 (m, 2H), 2.30 (m, 3H), 2.13 (s, 3H), 2.07 – 1.62 (m, 10H), 1.41 (d, J = 6.6 Hz, 3H), 1.29 (t, J = 
7.6 Hz, 3H), 0.96 (m, 6H). ESI HRMS, found 524.3063 (C25H41N5O7, [M + H]
+, requires 524.3084). 
 
(S,E)-Ethyl 4-((S)-2-((S)-2-((R)-1-
acetylpyrrolidine-2-
carboxamido)propanamido)hexanamido)-7-amino-
7-oxohept-2-enoate 204 was obtained in the same 
way as 15. 1H NMR (CD3OD, ppm) 6.88 (dd, J 
= 15.8, 5.4 Hz, 1H), 5.93 (d, J = 15.7 Hz, 1H), 4.52 (m, 1H), 4.43 – 4.22 (m, 3H), 4.19 (q, J = 7.0 Hz, 
2H), 3.76 – 3.55 (m, 3H), 2.38 – 2.23 (m, 3H), 2.12 (s, 3H), 2.10 – 1.68 (m, 10H), 1.41 (m, 4H), 1.28 
(t, J = 7.1 Hz, 3H), 0.94 (t, J = 6.8 Hz, 3H). ESI HRMS, found 524.3076 (C25H41N5O7, [M + H]
+, 
requires 524.3084). 
 
(S,E)-Ethyl 4-((S)-2-((S)-2-((R)-1-
acetylpyrrolidine-2-carboxamido)propanamido)-3-
phenylpropanamido)-7-amino-7-oxohept-2-enoate 
205 was obtained in the same way as 15. 1H NMR 
245 
 
(CD3OD, ppm) 7.35 – 7.15 (m, 5H), 6.76 (dd, J = 15.7, 5.4 Hz, 1H), 5.74 (d, J = 17.5 Hz, 1H), 
4.59 – 4.29 (m, 4H), 4.19 (q, J = 7.2 Hz, 3H), 3.76 – 3.56 (m, 2H), 3.29 – 2.97 (m, 2H), 2.36 – 2.20 
(m, 3H), 2.16 (s, 3H), 2.06 – 1.75 (m, 4H), 1.35 (m, 1H), 1.30 (t, J = 7.1 Hz, 3H), 1.24 (d, J = 7.3 Hz, 
3H). ESI HRMS, found 558.2929 (C28H39N5O7, [M + H]
+, requires 558.2928). 
 
(S,E)-Ethyl 4-((2S,3S)-2-((S)-2-((R)-1-
acetylpyrrolidine-2-carboxamido)propanamido)-3-
hydroxybutanamido)-7-amino-7-oxohept-2-enoate 
206 was obtained in the same way as 15. 1H NMR 
– 4.51 (m, 1H), 
4.39 – 4.22 (m, 3H), 4.18 (q, J = 7.2 Hz, 2H), 3.79 – 3.57 (m, 2H), 2.36 – 2.25 (m, 4H), 2.14 (s, 3H), 
2.09 – 1.96 (m, 3H), 1.93 – 1.79 (m, 1H), 1.45 (d, J = 7.3 Hz, 3H), 1.28 (t, J = 7.1 Hz, 3H), 1.23 (d, J 
= 6.4 Hz, 3H). ESI HRMS, found 512.2729 (C23H37N5O8, [M + H]
+, requires 512.2720). 
(5S,8S,11S,E)-Ethyl 11-(3-amino-3-
oxopropyl)-8-(4-aminobutyl)-5-methyl-3,6,9-
trioxo-1-phenyl-2-oxa-4,7,10-triazatetradec-
12-en-14-oate 209 was obtained in the same 
way as 15. 1H NMR (CD3OD, ppm) 7.44 – 
7.29 (m, 5H), 6.88 (dd, J = 15.7, 5.5 Hz, 1H), 5.93 (d, J = 17.0 Hz, 1H), 5.19 – 5.04 (m, 2H), 4.58 – 
4.49 (m, 2H), 4.39 – 4.29 (m, 1H), 4.20 (q, J = 7.2 Hz, 2H), 4.13 (m, 1H), 2.93 (t, J = 7.4 Hz, 2H), 
2.30 (m, 2H), 2.06 – 1.43 (m, 7H), 1.38 (d, J = 7.2 Hz, 3H), 1.28 (t, J = 7.1 Hz, 3H). ESI HRMS, 
found 534.2926 (C26H39N5O7, [M + H]
+, requires 534.2926). 
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(5S,8S,11S,E)-Ethyl 11-(3-amino-3-
oxopropyl)-8-(4-(dimethylamino)butyl)-5-
methyl-3,6,9-trioxo-1-phenyl-2-oxa-4,7,10-
triazatetradec-12-en-14-oate 210 was obtained 
in the same way as 15. 1H NMR (CD3OD, 
ppm) 7.42 – 7.28 (m, 5H), 6.88 (dd, J = 
15.7, 5.5 Hz, 1H), 5.93 (d, J = 15.7 Hz, 1H), 5.19 – 5.04 (m, 2H), 4.53 (m, 1H), 4.40 – 4.31 (m, 1H), 
4.20 (q, J = 7.2 Hz, 2H), 4.13 (m, 1H), 3.10 (m, 2H), 2.30 (m, 2H), 2.07 – 1.68 (m, 6H), 1.52 – 1.44 
(m, 2H), 1.38 (d, J = 7.2 Hz, 3H), 1.29 (t, J = 7.1 Hz, 3H). ESI HRMS, found 562.3243 (C28H43N5O7, 
[M + H]+, requires 562.3241). 
 
(5S,8S,11S,E)-Ethyl 11-(3-amino-3-
oxopropyl)-8-isobutyl-5-methyl-3,6,9-trioxo-
1-phenyl-2-oxa-4,7,10-triazatetradec-12-en-
14-oate 211 was obtained in the same way as 
15. 1H NMR (CD3OD, ppm) 1H NMR 
(400 MHz, Methanol-d4) δ 7.35 (dd, J = 14.0, 6.7 Hz, 5H), 6.88 (dd, J = 15.7, 5.4 Hz, 1H), 5.94 (d, J 
= 15.7 Hz, 1H), 5.11 (q, J = 12.5 Hz, 2H), 4.53 (dd, J = 9.2, 4.5 Hz, 1H), 4.37 (dd, J = 9.5, 5.0 Hz, 
1H), 4.20 (q, J = 7.0 Hz, 2H), 4.16 – 4.07 (m, 1H), 2.34 – 2.24 (m, 2H), 2.07 – 1.59 (m, 6H), 1.36 (d, 
J = 7.2 Hz, 3H), 1.29 (t, J = 7.1 Hz, 3H), 0.97 (dd, J = 19.5, 6.0 Hz, 7H). ESI HRMS, found 519.2811 
(C26H38N4O7, [M + H]
+, requires 519.2819). 
(S,E)-ethyl 7-amino-4-((S)-6-amino-2-
(((benzyloxy)carbonyl)amino)hexanamido)-7-
oxohept-2-enoate 212 was obtained in the same way 
as 15. 1H NMR (CD3OD, ppm) 7.42 – 7.29 (m, 
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5H), 6.87 (dd, J = 15.7, 5.5 Hz, 1H), 5.93 (d, J = 14.6 Hz, 1H), 5.13 (s, 2H), 4.55 (m 1H), 4.20 (q, J = 
7.1 Hz, 2H), 4.13 – 4.06 (m, 1H), 2.93 (m, 2H), 2.30 (m, 2H), 2.05 – 1.38 (m, 6H), 1.29 (t, J = 7.1 Hz, 
3H). ESI HRMS, found 463.2546 (C23H34N4O6, [M + H]
+, requires 463.2557). 
 
(S,E)-Ethyl 7-amino-4-((S)-2-
(((benzyloxy)carbonyl)amino)-6-
(dimethylamino)hexanamido)-7-oxohept-2-enoate 213 
was obtained in the same way as 15. 1H NMR 
(CD3OD, ppm) 7.46 – 7.28 (m, 5H), 6.87 (dd, J = 
15.7, 5.5 Hz, 1H), 5.93 (d, J = 15.6 Hz, 1H), 5.13 (s, 2H), 4.60 – 4.52 (m, 1H), 4.20 (q, J = 7.1 Hz, 
2H), 4.12 (m, 1H), 2.99 (m, 2H), 2.79 (s, 6H), 2.30 (m, 2H), 2.09 – 1.34 (m, 5H), 1.29 (t, J = 7.1 Hz, 
3H). ESI HRMS, found 491.2869 (C25H38N4O6, [M + H]
+, requires 491.2870). 
 
(S,E)-ethyl 7-amino-4-((S)-2-
(((benzyloxy)carbonyl)amino)-4-methylpentanamido)-
7-oxohept-2-enoate 214 was obtained in the same way 
as 15. 1H NMR (CD3OD, ppm) 7.35 (m , 5H), 6.88 
(dd, J = 15.7, 5.3 Hz, 1H), 5.91 (d, J = 15.7 Hz, 1H), 5.12 (s, 2H), 4.54 (m, 1H), 4.20 (q, J = 7.2 Hz, 
2H), 4.18 (m, 1H) 2.35 – 2.24 (m, 2H), 2.06 – 1.47 (m, 2H), 1.28 (t, J = 7.1 Hz, 3H), 0.96 (dd, J = 
14.8, 6.5 Hz, 6H).. ESI HRMS, found 448.2435 (C23H33N3O6, [M + H]
+, requires 448.2448). 
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(S)-Dimethyl 2-((tert-butoxycarbonyl)amino)pentanedioate 216 238,239,236 
To a stirred solution of N-Boc-(S)-glutamic acid (5 g, 20.2 mmol) in dry 
DMF (50 mL) were added NaHCO3 (10.2 g, 121 mmol) and CH3I (11.5 
g, 80 mmol) sequentially. After 5 days the mixture was quenched with water (100 mL). The residue 
was partitioned between ethyl acetate and water, and the organic phase was then washed sequentially 
with water, 10% Na2S03 and brine. Dried over with Na2SO4, filtered and concentrated in vacuo. The 
resulting thick oil was separated with silica gel chromatography (5:1 petroleum ether:ethyl acetate, Rf 
= 0.4) to give N-Boc-(S)-glutamic acid dimethyl ester as colourless oil (5.11 g, 92%). 1H NMR 
(CDCl3, ppm) 5.13 (d, J = 7.7 Hz, 1H), 4.36 (m, 1H), 3.76 (s, 3H), 3.70 (s, 3H), 2.50 – 2.35 (m, 
2H), 1.90-2.30 (m, 2H), 1.45 (s, 9H). 
(2S,4R)-Dimethyl 2-((tert-butoxycarbonyl)amino)-4-
(cyanomethyl)pentanedioate 217 238,239,236 To a solution of the ester 
(216) (5 g, 18 mmol) in THF (15 mL) was added dropwise a solution of 
LiHMDS (Prepared freshly:n- BuLi (16.6 ml of a 2.5 M solution, 38 mmol) was added dropwise to a 
solution of HMDS (8.4 ml, 40 mmol) in THF (15 mL) at 0 °C under argon. The mixture was stirred 
for 15 minutes before use.) at −78°C under an argon atmosphere. The resulting dark mixture was 
stirred at −78°C for 1 h. At the same time, bromoacetonitrile (1.95 g) was stirred with basic aluminum 
oxide (350 mg) for 2 h and then filtered. The freshly filtered bromoacetonitrile (1.4 ml, 20 mmol) was 
added dropwise to the dianion solution over a period of 1 h while maintaining the temperature below 
−70 °C. The reaction mixture was stirred at −78 °C for an additional 3–5 hours. The reaction was 
quenched with pre-cooled methanol (4 °C) (4 mL) in one portion and stirred for 30 min. The resulting 
methoxide was then quenched with a pre-cooled acetic acid in THF solution (4 ml HOAc/12 mL 
THF(4 °C)) in one portion. After stirring for 30 min, the cooling bath was removed and replaced with 
an ice water bath at 0 °C. The reaction mixture was allowed to warm up to room temperature and then 
poured into a saturated brine solution (50 mL). The layers were separated, and the organic layer was 
concentrated to afford a dark brown oil. The product was purified using flash column chromatography 
(Biotage Isolera, SNAP 100G, 40:60 – 80:20 ethyl acetate:hexane, 25 CV) to obtain the product as a 
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clear oil (5.1 g, 90%). 1H NMR (CDCl3, ppm) 5.13 (d, J = 8.4 Hz, 1H), 4.42 (m, 1H), 3.78 (m, 
6H), 2.96-2.86 (m, 1H), 2.82-2.65 (m, 2H), 2.18 (m, 2H), 1.46 (s, 9H). 13C NMR (CDCl3, ppm) 
172.60, 172.23, 155.75, 117.33, 80.76, 52.95, 51.17, 38.37, 34.10, 28.40, 19.15. ESI, found 315 
(C14H22N2O6, [M + H]
+, requires 315). 
 
(S)-Methyl 2-((tert-butoxycarbonyl)amino)-3-((S)-2-oxopyrrolidin-3-
yl)propanoate 218 238,239,236 A pink solution of CoCl2•6H2O (1.6 g, 7.5 mmol) 
and 217 (4.71 g, 15.0 mmol) in methanol (100 mL) was stirred vigorously and 
cooled to 0 °C while NaBH4 (2.28 g, 60 mmol) was added carefully over 30 
min. The reaction was exothermic, producing a black precipitate and copious quantities of hydrogen. 
After the reaction mixture was stirred for 36 hours at room temperature, the mixture was concentrated 
in vacuo and the condensed solution was poured into excess 1 M citric acid (80 mL) at 0 ºC. The 
mixture was extracted with ethyl acetate (3 x 20 mL), and the combined extracts were washed 
sequentially with saturated aqueous NaHCO3 (2 x 40 mL) and brine (40 mL). The organic layer was 
dried (MgSO4) and concentrated. The crude product was purified using silica gel chromatography 
(methanol:ethyl acetate:hexane 7:50:50, Rf =0.15) to obtain the product as a clear oil which 
crystallised on sitting (1.77g, 41 %). 1H NMR (CDCl3, ppm) 6.07 (d, J = 8.1 Hz, 1H), 5.73 (m, 
1H), 4.43 – 4.18 (m, 1H), 3.68 (s, 3H), 3.29 (m, 2H), 2.54 – 2.30 (m, 2H), 2.15 – 2.01 (m, 1H), 1.78 
(m, 2H), 1.38 (s, 9H). 13C NMR (CDCl3, ppm) 180.31, 173.04, 155.83, 79.77, 52.38, 52.21, 40.60, 
38.32, 33.86, 28.26, 27.88. ESI, found 287 (C13H23N2O5, [M + H]
+, requires 287). 
tert-Butyl ((S)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)carbamate 
240 238,239,236 218 (200 mg, 0.7 mmol) was dissolved in THF (8 mL) and LiBH4 
(61mg, 2.8 mmol) was added. The reaction was stirred overnight and then 
saturated ammonium chloride solution (12 mL) was added. The volatiles were removed under vacuum 
and the aqueous residue extracted with ethyl acetate (2 x 10 mL). This organic layer was washed with 
brine (20 mL) and then dried (MgSO4) and concentrated to give the product which did not require 
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further purification (177 mg, 98%). 1H NMR (CDCl3, ppm) 6.71 (s, 1H), 5.55 (d, J = 8.3 Hz, 1H), 
3.83 – 3.65 (m, 1H), 3.59 (s, 2H), 3.35 (d, J = 8.8 Hz, 2H), 2.62 – 2.30 (m, 2H), 1.97 (m, 1H), 1.88 – 
1.76 (m, 1H), 1.58 (m, 1H), 1.43 (s, 9H). 13C NMR (CDCl3, ppm) 181.33, 156.70, 79.52, 65.89, 
51.02, 40.71, 38.34, 32.75, 28.36.  
(S,E)-Ethyl 4-((tert-butoxycarbonyl)amino)-5-((S)-2-oxopyrrolidin-3-
yl)pent-2-enoate 219 238,239,236 A solution of Py•SO3 (336 mg, 2.1 mmol) 
in DMSO (30 mL) was poured into the solution of 240 (177 mg, 0.7 
mmol) and triethylamine (0.3 ml, 2.1 mmol) in DCM (10 mL) at –10 °C. The reaction mixture was 
stirred at room temperature for 30 min. The reaction was quenched by pouring into ice/brine (30 mL). 
The resulting slurry was extracted with ether (3 × 10 mL) and the combined organic layers were 
washed with 10% citric acid (20 mL), saturated NaHCO3 (20 mL) and brine (20 mL), dried over 
Na2SO4, filtered and concentrated in vacuo to afford a colourless oil. The oil was dissolved in toluene 
(10 mL) and Ph3P=CHCO2Et (245 mg, 0.7 mmol) was added and the reaction was stirred at 80 °C for 
1 h. After concentration, the resulting oil was purified by flash column chromatography (Biotage 
Isolera, SNAP 12 G, 20:80 – 80:20 ethyl acetate:hexane, 20CV)to give the product as clear oil (80 
mg, 35%). 1H NMR (CDCl3, ppm) 6.90 – 6.82 (dd, J= 15.7, 5.1 Hz, 1H), 6.80 (s, 1H), 5.94 (dd, J = 
15.7, 1.3 Hz, 1H), 5.39 (d, J = 8.3 Hz, 1H), 4.33 (s, 1H), 4.17 (q, J = 7.1 Hz, 2H), 3.42 – 3.29 (m, 2H), 
2.45 (m, 1H), 2.35 – 2.20 (m, 1H), 2.07 – 1.91 (m, 1H), 1.86 – 1.72 (m, 1H), 1.58 (m, 1H), 1.42 (s, 
9H), 1.27 (t, J = 7.1 Hz, 3H). 13C NMR (CDCl3, ppm) 180.33, 166.41, 155.70, 148.41, 120.89, 
79.78, 77.20, 60.60, 50.27, 40.59, 38.46, 35.98, 28.46, 14.34. 
(S,E)-Ethyl 4-((S)-2-(((benzyloxy)carbonyl)amino)-6-
((tert-butoxycarbonyl)amino)hexanamido)-5-((S)-2-
oxopyrrolidin-3-yl)pent-2-enoate 241 To a stirred 
solution of compound 219 (80mg, 0.24 mmol) in 
DCM (5 mL) was added TFA (3 mL). The resulting 
mixture was stirred for 1 h and then the solvents were 
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removed under reduced pressure. The residue was dissolved in DCM (5 mL), and treated with DIPEA 
(0.19 mL, 1.1mmol). Separately, Z-Lys(Boc)OH (91 mg, 0.24 mmol) was dissolved in DCM (5 mL), 
HOBt (36 mg, 0.27 mmol) and EDCI (51 mg, 0.27 mmol) were added respectively. The resulting 
mixture was stirred for 10 min, and then the unprotected amine solution derived from 219 was added 
dropwise. The resulting mixture was stirred overnight. The reaction was quenched with sat. aqueous 
NH4Cl (10 mL) solution. The layers were separated and the aqueous layer was washed by DCM (3 x 
10mL), and the combined organic layer was washed with sat. NaCl and dried by anhydrous Na2SO4. 
The crude product was purified by flash column chromatography (Biotage Isolera, SNAP 5 G, 3:97 – 
8:92 methanol:DCM, 16CV).(79 mg, 56 %) 1H NMR (CDCl3, ppm) 1H NMR (400 MHz, 
Chloroform-d) δ 7.31 (m, 5H), 6.84 (dd, J = 15.8, 5.0 Hz, 1H), 5.92 (d, J = 15.8 Hz, 1H), 5.09 (s, 2H), 
4.74 – 4.54 (m, 1H), 4.38 – 4.25 (m, 1H), 4.17 (q, J = 6.9 Hz, 2H), 3.34 – 3.02 (m, 4H), 2.55 – 2.24 
(m, 2H), 2.07 – 1.55 (m, 9H), 1.42 (s, 9H), 1.27 (t, J = 6.9 Hz, 3H). 13C NMR (CDCl3, ppm) 
180.98, 172.65, 166.34, 163.00, 156.42, 147.36, 136.41, 128.60, 126.83, 125.96, 121.24, 117.85, 
110.99, 79.28, 67.03, 60.67, 55.02, 48.98, 40.87, 40.19, 38.62, 36.79, 35.15, 32.72, 29.52, 28.53, 
22.74, 14.33. 
(S,E)-Ethyl 4-((S)-6-amino-2-
(((benzyloxy)carbonyl)amino)hexanamido)-5-((S)-2-
oxopyrrolidin-3-yl)pent-2-enoate 221 241 was 
subjected to boc-deprotection conditions as in 74. 
Further purification by LCMS to give product as a 
clear oil (31 mg, 47 %). 1H NMR (CD3OD, ppm) δ 
7.38 (s, 5H), 6.92 (dd, J = 15.7, 5.0 Hz, 1H), 5.95 (d, J = 15.5 Hz, 1H), 5.02 (s, 2H), 4.20 (q, J = 6.9 
Hz, 2H), 4.19 (m, 1H), 4.11 (m, 1H), 3.13 – 2.86 (m, 4H), 2.67 – 2.23 (m, 2H), 2.06 – 1.40 (m, 9H), 
1.37 – 1.21 (m, 3H). 13C NMR (CD3OD, ppm) 173.46, 166.37, 157.04, 147.78, 136.85, 128.11, 
127.66, 127.43, 120.47, 110.54, 72.16, 71.04, 66.75, 66.26, 60.33, 55.17, 39.13, 38.32, 34.59, 31.11, 
26.72, 22.67, 13.20. ESI HRMS, found 489.2703 (C25H37N4O6, [M + H]
+, requires 489.2713). 
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(S,E)-Ethyl 4-((S)-2-(((benzyloxy)carbonyl)amino)-4-
methylpentanamido)-5-((S)-2-oxopyrrolidin-3-yl)pent-
2-enoate 222 219 was coupled to Z-leucine using the 
same conditions as in 241. The crude product was 
purified by flash column chromatography (Biotage 
Isolera, SNAP 5 G, 3:97 – 8:92 methanol:DCM, 16CV). The product was isolated as a clear oil (65 
mg, 57%). 1H NMR (CDCl3, ppm) 7.35 (s, 5H), 6.84 (dd, J = 15.7, 5.4 Hz, 1H), 5.93 (d, J = 15.7 
Hz, 1H), 5.10 (s, 2H), 4.55 (m, 1H), 4.45 – 4.32 (m, 1H), 4.19 (q, J = 7.0 Hz, 2H), 3.35 – 3.19 (m, 
2H), 2.49 – 2.28 (m, 2H), 2.05 (m, 1H), 1.86 – 1.45 (m, 5H), 1.28 (t, J = 7.1 Hz, 3H), 1.00 – 0.90 (m, 
6H). 13C NMR (CDCl3, ppm) 180.36, 172.96, 166.44, 156.29, 147.55, 128.67, 128.30, 128.16, 
121.26, , 67.05, 60.63, 53.64, 49.25, 42.77, 40.68, 38.60, 35.14, 28.59, 24.94, 23.19, 22.07, 14.38. ESI 
HRMS, found 474.2598 (C25H36N3O6, [M + H]
+, requires 474.2604). 
(S)-methyl 2-((S)-2-(((benzyloxy)carbonyl)amino)-4-
methylpentanamido)-3-((S)-2-oxopyrrolidin-3-
yl)propanoate 225 218 was coupled to Z- Leucine using 
the same conditions as in 241. The crude product was 
purified by flash column chromatography (Biotage Isolera, 
SNAP 5 G, 3:97 – 8:92 methanol:DCM, 16CV). Clear oil (78 mg, 75%). 1H NMR (CDCl3, ppm) 
8.08 (d, J = 7.0 Hz, 1H), 7.29 (m, 5H), 7.13 (s, 1H), 5.84 (d, J = 8.8 Hz, 1H), 5.06 (s, 2H), 4.67 – 4.16 
(m, 2H), 3.69 (s, 3H), 3.23 (m, 2H), 2.56 – 2.03 (m, 3H), 1.95 – 1.42 (m, 4H), 0.94 (m, 6H). ESI, 
found 434 (C22H32N3O6, [M + H]
+, requires 434). 
Benzyl ((S)-1-(((S)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-
yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-
yl)carbamate 226 Reduction using the same conditions as 
240. The yield was quantitative (72 mg) with no 
purification necessary. 1H NMR (CDCl3, ppm) δ 7.74 
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(m, 1H), 7.30 (m, 5H), 6.87 (s, 1H), 5.92 (d, J = 8.4 Hz, 1H), 5.07 (s, 2H), 4.27 (d, J = 13.7 Hz, 1H), 
3.98 (s, 2H), 3.57 (s, 2H), 3.34 – 3.11 (m, 2H), 2.53 – 1.92 (m, 1H), 1.81 – 1.40 (m, 4H), 0.92 (t, J = 
5.4 Hz, 6H). ESI, found 406 (C21H32N3O5, [M + H]
+, requires 406).  
Benzyl ((S)-4-methyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-
oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-
yl)carbamate 227 Standard Dess Martin oxidation as in 150. 
The crude product was purified by flash column 
chromatography (Biotage Isolera, SNAP 12 G, 3:97 – 8:92 
methanol:DCM, 20CV). Clear oil (67%). 1H NMR (CDCl3, ppm) δ 9.48 (s, 1H), 8.39 (m, 1H), 
7.31 (m, 5H), 6.80 (s, 1H), 5.92 – 5.54 (m, 1H), 5.09 (s, 2H), 4.53 – 4.01 (m, 2H), 3.47 – 3.01 (m, 
3H), 2.58 – 1.39 (m, 5H), 1.07 – 0.69 (m, 6H). 13C NMR (CDCl3, ppm) 199.94, 180.29, 173.92, 
156.29, 136.43, 128.64, 128.27, 128.09, , 67.02, 57.77, 53.54, 42.49, 40.75, 38.31, 29.80, 28.57, 
24.88, 23.08, 22.09. ESI HRMS, found 404.2196 (C21H30N3O5, [M + H]
+, requires 404.2185). 
Benzyl ((S)-1-(((S)-4-(isopropylamino)-3,4-dioxo-1-((S)-
2-oxopyrrolidin-3-yl)butan-2-yl)amino)-4-methyl-1-
oxopentan-2-yl)carbamate 229 To a 0 ºC solution of 
aldehyde 227 (100 mg, 0.25 mmol) in EtOAc was added 
acetic acid (20 µL, 0.28 mmol) followed by 
isopropylisonitrile (20 µL, 26 mmol). The mixture was stirred at rt for 18 h then concentrated to 
dryness to provide crude 230. This was dissolved in a 1:1 mixture of MeOH and water (x mL). K2CO3 
(100 mg) was added and the reaction stirred for 2 hours with monitoring by TLC and LCMS. The 
reaction mixture was concentrated under vacuum to remove methanol then the aquous solution was 
extracted with EtOAc (x mL). The organic layer was washed with 1M HCl (x mL), then brine (x mL) 
and was dried (MgSO4), filtered and concentrated to yield crude 231. This was oxidised using 
standard Dess-Martin conditions (as in 150) and purified purified by flash column chromatography 
(Biotage Isolera, SNAP 5 G, 4:96 – 10:90 methanol:DCM, 20CV) to give the title compound as a 
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clear oil (65mg, 63%). 1H NMR (CDCl3, ppm) 8.39 (s, 1H), 7.31 (m, 5H), 6.81 (d, J = 7.9 Hz, 2H), 
6.59 (s, 1H), 5.51 (d, J = 8.6 Hz, 1H), 5.24 (d, J = 10.4 Hz, 1H), 5.10 (s, 2H), 4.40 (s, 1H), 4.05 (d, J = 
13.9 Hz, 1H), 3.44 – 3.18 (m, 2H), 2.62 – 1.44 (m, 6H), 1.21 (m, 6H), 0.96 (m, 6H). 13C NMR 
(CDCl3, ppm) 195.51, 180.17, 172.95, 158.65, 156.22, 136.49, 128.65, 128.26, 128.14, , 67.02, 
53.74, 53.22, 42.66, 41.91, 40.80, 39.18, 31.97, 28.43, 24.74, 23.06, 22.50, 22.42, 22.22. ESI HRMS, 
found 489.2729 (C25H37N4O6, [M + H]
+, requires 489.2713). 
 
(S)-2-((S)-2-(((benzyloxy)carbonyl)amino)propanamido)-4-
methylpentanoic acid 233 Z-alanine (5.0 g, 11.7 mmol) was 
dissolved in DMF (20 mL) together with HBTU (4.46 g, 11.7 
mmol) and DIPEA (4.0 mL, 23 mmol). Leucine methyl ester hydrochloride (1.14 g, 11.7 mmol) was 
then added and the reaction stirred overnight. The reaction was quenched with water (100 mL) and 
extracted with ethyl acetate (2 x 20 mL). The organic layer was washed with 10% citric acid (5 x 30 
mL), saturated NaHCO3 (50 mL) and saturated brine (30 mL) and then dried (MgSO4) and 
concentrated to give the ester intermediate as a clear oil. This oil was dissolved in 1:1 solution of THF 
and water and LiOH added. The reaction was stirred overnight and then concentrated to remove the 
THF. The aqueous mixture was neutralised with 2 M HCl and then extracted with ethyl acetate. The 
organic mixture was dried (MgSO4) and concentrated to give the title compound. Light yellow oil 
(2.83 g, 72%). 1H NMR (CDCl3, ppm) 7.35 (m, 5H), 6.77 (s, 1H), 5.70 (s, 1H), 5.11 (s, 2H), 4.59 
(m, 1H), 4.33 (m, 1H), 1.78 – 1.54 (m, 3H), 1.38 (d, J = 7.0 Hz, 3H), 1.01 – 0.87 (m, 6H). 13C NMR 
(CDCl3, ppm) 176.22, 172.95, 156.40, 128.73, 128.20, 67.33, 60.64, 51.04, 50.55, 41.17, 25.00, 
22.96, 21.95, 18.48, 14.36. ESI, found 337 (C17H25N2O5, [M + H]
+, requires 337). 
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Benzyl ((S)-1-(((S)-4-methyl-1-oxo-1-(((S)-1-oxo-
3-((S)-2-oxopyrrolidin-3-yl)propan-2-
yl)amino)pentan-2-yl)amino)-1-oxopropan-2-
yl)carbamate 232 Was synthesized the same way as 
227. The deprotected 218 (100 mg, 0.34 mmol) 
coupled with 233 (140 mg, 0.42 mmol) using EDCI. The intermediate alcohol was not isolated in this 
instance. Product was obtained as a clear oil (6 mg, 4%). 1H NMR (CD3OD, ppm 9.50 (s, 1H), 
8.41 (s, 1H), 7.51 – 7.19 (m, 5H), 7.01 (s, 1H), 6.42 (s, 1H), 5.61 (s, 1H), 5.11 (s, 2H), 4.73 – 4.10 (m, 
2H), 3.43 – 3.21 (m, 2H), 2.69 – 1.50 (m, 5H), 1.45 – 1.26 (m, 3H), 0.94 (m, 6H). 13C NMR (CDCl3, 
ppm) 199.90, 180.29, 173.45, 172.61, 156.27, 136.31, 128.75, 128.43, 128.23, , 67.27, 58.00, 
52.02, 50.98, 41.70, 40.81, 38.41, 29.95, 28.82, 25.06, 23.13, 22.06. ESI HRMS, found 475.2559 
(C24H35N4O6, [M + H]
+, requires 475.2557). 
N-((S)-1-Oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-
naphthamide 236 Was synthesized in the same way as 227. The 
deprotected 225 (50 mg, 0.17 mmol) was reacted with 2-naphthoyl 
chloride (40 mg, 0.21 mmol). The intermediate alcohol was not 
isolated in this instance. The product was obtained as a clear oil (21 mg, 39%). 1H NMR (CDCl3, 
ppm) δ 9.65 (s, 1H), 9.28 (s, 1H), 8.53 (s, 1H), 8.16 – 7.80 (m, 4H), 7.56 (m, 2H), 6.15 (m, 1H), 
4.53 (m, 1H), 3.64 – 3.27 (m, 2H), 2.78 – 2.37 (m, 3H), 2.21 – 1.80 (m, 2H). 13C NMR (CDCl3, 
ppm) δ 200.46, 180.79, 168.42, 135.16, 132.84, 130.47, 129.42, 128.57, 127.98, 127.89, 126.84, 
123.87, 77.20, 59.57, 41.06, 39.35, 29.89, 29.52. ESI HRMS, found 311.1407 (C18H19N2O3, [M + H]
+, 
requires 311.1396)  
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